Agents for treating pain and uses thereof

ABSTRACT

This invention relates to: (a) compounds and salts thereof that, inter alia, treat pain; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No.61/736,262 filed Dec. 12, 2012, and U.S. Provisional Application No.61/760,984 filed Feb. 5, 2013, which are incorporated herein byreference in their entirety.

FIELD OF THE INVENTION

This invention is directed to: (a) compounds and salts thereof that,inter alia, are useful to treat pain; (b) intermediates useful for thepreparation of such compounds and salts; (c) compositions comprisingsuch compounds and salts; (d) methods for preparing such intermediates,compounds, salts, and compositions; (e) methods of use of suchcompounds, salts, and compositions; and (f) kits comprising suchcompounds, salts, and compositions.

BACKGROUND OF THE INVENTION

Voltage-gated calcium channels have been implicated in regulation ofmembrane ion conductance, neurotransmitter release, and cellularexcitability, and can generally be classified into low-voltage activatedand high-voltage activated channels based on differences in structureand function. The N-type calcium channel in particular has beengenerally implicated in regulation of pain.

Inadequate pain management is a major public health problem. There is acontinuing need for the development of new therapeutic agents to treatpain including calcium channel blocker therapeutics with improvedsafety, potency, and/or other desirable pharmacological propertiesrelative to currently available therapeutic agents for the treatment ofpain. This invention provides compounds (including salts thereof),compositions, and methods of treatment that generally address such aneed.

BRIEF DESCRIPTION OF THE INVENTION

In one aspect, the invention is directed to compounds that correspond instructure to Formula (I):

wherein:

R¹ is selected from the group consisting of pyridinyl, pyrimidinyl,pyrazinyl, and pyridazinyl, wherein each such substituent is optionallysubstituted with one, two, or three substituents independently selectedfrom the group consisting of halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, andC₃-C₆-cycloalkyl;

R² is selected from the group consisting of phenyl, pyridinyl,pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each such substituentis optionally substituted with one, two, or three substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, andC₃-C₆-cycloalkyl;

as to X¹, X², X³, X⁴, and L:

X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selectedfrom the group consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and—S(O)₂—; or

X¹ is —CH₂—; one of X² and X³ is —C(O)— and the other one of X² and X³is —CH₂—; X⁴ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—; or

one of X¹ and X⁴ is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—; and

R³, R⁴, and R⁵ are independently selected from the group consisting ofhydrogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₆-alkyl.

In another aspect, the invention is directed to the salts (includingpharmaceutically acceptable salts) of the compounds of the invention.

In another aspect, the invention is directed to compositions (includingpharmaceutical compositions) that comprise one or more compounds and/orsalts of the invention, and, optionally, one or more additionaltherapeutic agents.

In another aspect, the invention is directed to kits that comprise oneor more compounds and/or salts of the invention, and, optionally, one ormore additional therapeutic agents.

In another aspect, the invention is directed to methods of using thecompounds, salts, compositions, and/or kits of the invention to treat,for example, an N-type calcium channel-mediated condition, such as pain.

In another aspect, the invention is directed to one or more compoundsand/or salts of the invention for use in the treatment of an N-typecalcium channel-mediated condition, such as pain.

In another aspect, the invention is directed to a use of one or morecompounds and/or salts of the invention to prepare a medicament. Themedicament optionally can comprise one or more additional therapeuticagents. In some embodiments, the medicament is useful for treating pain.

In another aspect, the invention is directed to methods for synthesizinga compound of Formula (I), or a salt thereof, and intermediates that areuseful in the synthesis of the compound.

Further benefits of Applicants' invention will be apparent to oneskilled in the art from reading this patent application. The embodimentsof the invention described in the following paragraphs are intended toillustrate the invention and should not be deemed to narrow the scope ofthe invention.

DETAILED DESCRIPTION OF THE INVENTION A. Definitions

With respect to the inventions disclosed in this application, thefollowing terms have the meanings set forth below:

The term “hydrogen” (alone or in combination with another term(s)) meansa hydrogen radical, and may be depicted as —H.

The term “halogen” or “halo” (alone or in combination with anotherterm(s)) means a fluorine radical (which may be depicted as —F),chlorine radical (which may be depicted as —Cl), bromine radical (whichmay be depicted as —Br), or iodine radical (which may be depicted as—I).

The term “hydroxy” (alone or in combination with another term(s)) means—OH.

The term “amino” (alone or in combination with another term(s)) means—NH₂.

The term “cyano” (alone or in combination with another term(s)) means—CN, which also may be depicted as —CN.

The term “alkyl” (alone or in combination with another term(s)) means astraight-or branched-chain saturated hydrocarbyl substituent, typicallya straight-or branched-chain saturated hydrocarbyl substituentcontaining from 1 to about 6 carbon atoms. Examples of such substituentsinclude methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-butyl, tert-butyl, pentyl, iso-amyl, and hexyl. As in thisdefinition, throughout this detailed description Applicants haveprovided illustrative examples. The provision of such illustrativeexamples should not be interpreted as if the provided illustrativeexamples are the only options available to one skilled in the art.

The term “cycloalkyl” (alone or in combination with another term(s))means a saturated cyclic hydrocarbyl substituent, typically a singlecarbon ring containing from 3 to 6 carbon ring atoms. Examples ofsingle-ring cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl,and cyclohexyl.

The term “alkoxy” (alone or in combination with another term(s)) meansan alkylether substituent, i.e., —O-alkyl. Examples of such asubstituent include methoxy (—O—CH₃), ethoxy, n-propoxy, isopropoxy,n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy.

The prefix “halo” indicates that the substituent to which the prefix isattached is substituted with one or more independently selected halogenradicals. For example, haloalkyl means an alkyl substituent in which atleast one hydrogen radical is replaced with a halogen radical. Examplesof haloalkyls include chloromethyl, 1-bromoethyl, fluoromethyl,difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should berecognized that if a substituent is substituted by more than one halogenradical, those halogen radicals may be identical or different (unlessotherwise stated).

In some instances, the number of carbon atoms in a hydrocarbylsubstituent (e.g., alkyl or cycloalkyl) is indicated by the prefix“C_(x)-C_(y)-”, wherein x is the minimum and y is the maximum number ofcarbon atoms in the substituent. Thus, for example, “C₁-C₆-alkyl” refersto an alkyl substituent containing from 1 to 6 carbon atoms.Illustrating further, C₃-C₆-cycloalkyl means a saturated hydrocarbylring containing from 3 to 6 carbon ring atoms.

A substituent is “substitutable” if it comprises at least one carbon ornitrogen atom that is bonded to one or more hydrogen atoms. Thus, forexample, hydrogen, halogen, hydroxy, and oxo do not fall within thisdefinition.

If a substituent is described as being “substituted”, a non-hydrogenradical is in the place of hydrogen radical on a carbon or nitrogen ofthe substituent. Thus, for example, a substituted alkyl substituent isan alkyl substituent in which at least one non-hydrogen radical is inthe place of a hydrogen radical on the alkyl substituent. To illustrate,monofluoroalkyl is alkyl substituted with a fluoro radical, anddifluoroalkyl is alkyl substituted with two fluoro radicals. It shouldbe recognized that if there is more than one substitution on asubstituent, each non-hydrogen radical may be identical or different(unless otherwise stated).

If a substituent is described as being “optionally substituted”, thesubstituent may be either (1) not substituted or (2) substituted. If asubstituent is described as being optionally substituted with up to aparticular number of non-hydrogen radicals, that substituent may beeither (1) not substituted; or (2) substituted by up to that particularnumber of non-hydrogen radicals or by up to the maximum number ofsubstitutable positions on the substituent, whichever is less.

If substituents are described as being “independently selected” from agroup, each substituent is selected independent of the other. Eachsubstituent therefore may be identical to or different from the othersubstituent(s).

When words are used to describe a substituent, the rightmost-describedcomponent of the substituent is the component that has the free valence.

When a chemical formula is used to describe a linking element betweentwo other elements of a depicted chemical structure, the leftmost dashof the substituent indicates the portion of the substituent that isbound to the left element in the depicted structure. The rightmost dash,on the other hand, indicates the portion of the substituent that isbound to the right element in the depicted structure. To illustrate, ifthe depicted chemical structure is X″-L-R² and L is described as—C(O)C(R³)(H)—, then the chemical structure would be X″—C(O)C(R³)(H)—R².

With reference to the use of the words “comprise” or “comprises” or“comprising” in this patent application (including the claims),Applicants note that unless the context requires otherwise, those wordsare used on the basis and clear understanding that they are to beinterpreted inclusively, rather than exclusively, and that Applicantsintend each of those words to be so interpreted in construing thispatent application, including the claims below.

As used herein, reference to “a” or “an” means “one or more.”Throughout, the plural and singular should be treated asinterchangeable, other than the indication of number. For example,reference to “a compound” includes a single compound as well as one ormore additional compounds, reference to “a pharmaceutically acceptablecarrier” includes a single pharmaceutically acceptable carrier as wellas one or more additional pharmaceutically acceptable carriers, and thelike.

Advanced Chemistry Development Name software has been used to generatethe compound names in this patent application.

B. Compounds

This invention is directed, in part, to compounds that correspond instructure to Formula (I):

wherein:

R¹ is selected from the group consisting of pyridinyl, pyrimidinyl,pyrazinyl, and pyridazinyl, wherein each such substituent is optionallysubstituted with one, two, or three substituents independently selectedfrom the group consisting of halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, andC₃-C₆-cycloalkyl;

R² is selected from the group consisting of phenyl, pyridinyl,pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each such substituentis optionally substituted with one, two, or three substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, andC₃-C₆-cycloalkyl;

as to X¹, X², X³, X⁴, and L:

X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selectedfrom the group consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and—S(O)₂—; or

X¹ is —CH₂—; one of X² and X³ is —C(O)— and the other one of X² and X³is —CH₂—; X⁴ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—; or

one of X¹ and X⁴ is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—; and

R³, R⁴, and R⁵ are independently selected from the group consisting ofhydrogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₆-alkyl.

B-1: Compound Stereochemistry

The compounds of Formula (I) can have the configuration of Formula(I-i), (I-ii), (I-iii), or (I-iv) as further discussed below.

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-i):

In another embodiment, the compounds of Formula (I) correspond instructure to Formula (I-ii):

In another embodiment, the compounds of Formula (I) correspond instructure to Formula (I-iii):

In another embodiment, the compounds of Formula (I) correspond instructure to Formula (I-iv):

B-2: Pyrrolo[1,2-a][1,4]-Diazepine Ring

In one embodiment of the compounds of Formula (I), X¹ is —CH₂—; X² is—CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selected from the groupconsisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and —S(O)₂—. Suchcompounds correspond in structure to Formula (I-A):

In another embodiment, X¹ is —CH₂—; one of X² and X³ is —C(O)— and theother one of X² and X³ is —CH₂—; X⁴ is —CH₂—; and L is selected from thegroup consisting of a bond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—. Suchcompounds correspond in structure to Formula (I-B):

In another embodiment, X¹ is —CH₂—; X² is —C(O)—; X³ is —CH₂—; X⁴ is—CH₂—; and L is selected from the group consisting of a bond, —CH₂—,—C(O)—, and —C(O)C(R⁴)(H)—. Such compounds correspond in structure toFormula (I-B-1):

In another embodiment, X¹ is —CH₂—; X² is —CH₂—; X³ is —C(O)—; X⁴ is—CH₂—; and L is selected from the group consisting of a bond, —CH₂—,—C(O)—, and —C(O)C(R⁴)(H)—. Such compounds correspond in structure toFormula (I-B-2):

In another embodiment, one of X¹ and X⁴ is —C(O)— and the other one ofX¹ and X⁴ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; and L is selected from thegroup consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—.Such compounds correspond in structure to Formula I-C:

In another embodiment, X¹—C(O)—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—;and L is selected from the group consisting of a bond, —CH₂—, —C(O)—,—C(O)C(R⁵)(H)—, and —S(O)₂—. Such compounds correspond in structure toFormula I-C-1:

In another embodiment, X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is—C(O)—; and L is selected from the group consisting of a bond, —CH₂—,—C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—. Such compounds correspond instructure to Formula I-C-2:

The compounds of Formulae (I-A), (I-B), (I-B-1), (I-B-2), (I-C),(I-C-1), and (I-C-2) can have configurations that correspond to any ofFormula (I-i), (I-ii), (I-iii), or (I-iv) discussed above. For example,the compounds of Formula (I-C-1) can correspond in structure to any ofFormulae (I-C-1-i), (I-C-1-ii), (I-C-1-iii), and (I-C-1-iv):

B-3: L Substituent

In one embodiment of the compounds of Formula (I), L is selected fromthe group consisting of a bond, —CH₂—, —C(O)—, and —S(O)₂—.

In another embodiment, L is selected from the group consisting of abond, —CH₂—, and —C(O)—.

In another embodiment, L is selected from the group consisting of abond, —CH₂—, and —S(O)₂—.

In another embodiment, L is selected from the group consisting of abond, —C(O)—, and —S(O)₂—.

In another embodiment, L is selected from the group consisting of —CH₂—,—C(O)—, and —S(O)₂—.

In another embodiment, L is selected from the group consisting of a bondand —CH₂.

In another embodiment, L is selected from the group consisting of a bondand —C(O)—.

In another embodiment, L is selected from the group consisting of a bondand —S(O)₂—.

In another embodiment, L is selected from the group consisting of —CH₂—and —C(O)—.

In another embodiment, L is selected from the group consisting of —CH₂—and —S(O)₂—.

In another embodiment, L is selected from the group consisting of —C(O)—and —S(O)₂—.

In another embodiment, L is a bond.

In another embodiment, L is —CH₂—.

In another embodiment, L is —C(O)—.

In another embodiment, L is —S(O)₂—.

In another embodiment, L is —C(O)C(R³)(H)—.

In another embodiment, L is —C(O)C(R⁴)(H)—.

In another embodiment, L is —C(O)C(R⁵)(H)—.

B-4: R³, R⁴, and R⁵ Substituents

In one embodiment of the compounds of Formula (I), R³, R⁴, and R⁵ areindependently selected from the group consisting of hydrogen, hydroxy,C₁-C₃-alkyl, C₁-C₃-alkoxy, and amino, wherein such amino is optionallysubstituted with one or two independently selected C₁-C₃-alkyl.

In another embodiment, R³, R⁴, and R⁵ are independently selected fromthe group consisting of hydrogen, hydroxy, C₁-C₃-alkyl, and amino,wherein such amino is optionally substituted with one or twoindependently selected C₁-C₃-alkyl.

In another embodiment, R³, R⁴, and R⁵ are independently selected fromthe group consisting of hydrogen, hydroxy, and amino

In another embodiment, R³ is selected from the group consisting ofhydrogen, hydroxy, C₁-C₃-alkyl, C₁-C₃-alkoxy, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R³ is independently selected from the groupconsisting of hydrogen, hydroxy, C₁-C₃-alkyl, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R³ is selected from the group consisting ofhydrogen, hydroxy, and amino

In another embodiment, R³ is hydrogen.

In another embodiment, R³ is hydroxy.

In another embodiment, R³ is C₁-C₃-alkyl.

In another embodiment, R³ is amino, wherein such amino is optionallysubstituted with one or two independently selected C₁-C₃-alkyl.

In another embodiment, R³ is selected from the group consisting ofamino, methylamino, and dimethylamino.

In another embodiment, R³ is amino

In another embodiment, R³ is methylamino.

In another embodiment, R³ is dimethylamino

In another embodiment, R⁴ is selected from the group consisting ofhydrogen, hydroxy, C₁-C₃-alkyl, C₁-C₃-alkoxy, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R⁴ is independently selected from the groupconsisting of hydrogen, hydroxy, C₁-C₃-alkyl, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R⁴ is selected from the group consisting ofhydrogen, hydroxy, and amino

In another embodiment, R⁴ is hydrogen.

In another embodiment, R⁴ is hydroxy.

In another embodiment, R⁴ is C₁-C₃-alkyl.

In another embodiment, R⁴ is amino, wherein such amino is optionallysubstituted with one or two independently selected C₁-C₃-alkyl.

In another embodiment, R⁴ is selected from the group consisting ofamino, methylamino, and dimethylamino.

In another embodiment, R⁴ is amino.

In another embodiment, R⁴ is methylamino.

In another embodiment, R⁴ is dimethylamino.

In another embodiment, R⁵ is selected from the group consisting ofhydrogen, hydroxy, C₁-C₃-alkyl, C₁-C₃-alkoxy, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R⁵ is independently selected from the groupconsisting of hydrogen, hydroxy, C₁-C₃-alkyl, and amino, wherein suchamino is optionally substituted with one or two independently selectedC₁-C₃-alkyl.

In another embodiment, R⁵ is selected from the group consisting ofhydrogen, hydroxy, and amino

In another embodiment, R⁵ is hydrogen.

In another embodiment, R⁵ is hydroxy.

In another embodiment, R⁵ is C₁-C₃-alkyl.

In another embodiment, R⁵ is amino, wherein such amino is optionallysubstituted with one or two independently selected C₁-C₃-alkyl.

In another embodiment, R⁵ is selected from the group consisting ofamino, methylamino, and dimethylamino.

In another embodiment, R⁵ is amino

In another embodiment, R⁵ is methylamino.

In another embodiment, R⁵ is dimethylamino

B-5: R¹ Substituent

In one embodiment of the compounds of Formula (I), R¹ is selected fromthe group consisting of pyridinyl, pyrimidinyl, pyrazinyl, andpyridazinyl, wherein each such substituent is optionally substitutedwith one, two, or three substituents independently selected from thegroup consisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one substituent selected fromthe group consisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one, two, or threesubstituents independently selected from the group consisting ofhalo-C₁-C₆-alkyl and C₃-C₆-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halo-C₁-C₆-alkyl andC₃-C₆-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halo-C₁-C₄-alkyl andC₃-C₄-cycloalkyl. In one embodiment, the optional substituent ishalo-C₁-C₄-alkyl. In one embodiment, the optional substituent isC₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one substituent selected fromthe group consisting of halomethyl and cyclopropyl. In one embodiment,the optional substituent is halomethyl. In one embodiment, the optionalsubstituent is trifluoromethyl. In one embodiment, the optionalsubstituent is cyclopropyl.

B-5(a): R¹ Pyridinyl or Pyrazinyl Substituent

In one embodiment of the compounds of Formula (I), R¹ is selected fromthe group consisting of pyridinyl and pyrazinyl, wherein each suchsubstituent is optionally substituted with one, two, or threesubstituents independently selected from the group consisting ofhalogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one or two substituents independently selected from thegroup consisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one substituent selected from the group consisting ofhalogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one, two, or three substituents independently selectedfrom the group consisting of halo-C₁-C₆-alkyl and C₃-C₆-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one or two substituents independently selected from thegroup consisting of halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl. In oneembodiment, the optional substituent is halo-C₁-C₄-alkyl. In oneembodiment, the optional substituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one substituent selected from the group consisting ofhalomethyl and cyclopropyl. In one embodiment, the optional substituentis halomethyl. In one embodiment, the optional substituent istrifluoromethyl. In one embodiment, the optional substituent iscyclopropyl.

In another embodiment, R¹ is selected from the group consisting of thesubstituents listed in Table 1.

TABLE 1

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ is selected from thegroup consisting of the substituents listed in Table 1.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ is selected from the group consisting of the substituents listed inTable 1.

In another embodiment, R¹ is selected from the group consisting of5-cyclopropyl-pyrazin-2-yl and 5-trifluoromethylpyridin-2-yl, i.e., thecompounds of Formula (I) correspond to one of the structures shown inTable 1A.

TABLE 1A

(Ia)

(Ib)

(I-Aa)

(I-Ab)

(I-Ba)

(I-Bb)

(I-Ba-1)

(I-Bb-1)

(I-Ba-2)

(I-Bb-2)

(I-Ca)

(I-Cb)

(I-Ca-1)

(I-Cb-1)

(I-Ca-2)

(I-Cb-2)

B-5(b): R¹ Pyrazinyl Substituent

In one embodiment of the compounds of Formula (I), R¹ is pyrazinyl,wherein such pyrazinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl. In oneembodiment, R¹ is optionally substituted pyrazin-2-yl.

In another embodiment, R¹ is pyrazinyl, wherein such pyrazinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyrazin-2-yl. In one embodiment, the optional substituent is halogen. Inone embodiment, the optional substituent is C₁-C₄-alkyl. In oneembodiment, the optional substituent is halo-C₁-C₄-alkyl. In oneembodiment, the optional substituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyrazinyl, wherein such pyrazinyl isoptionally substituted with one, two, or three substituentsindependently selected from the group consisting of halo-C₁-C₆-alkyl andC₃-C₆-cycloalkyl. In one embodiment, R¹ optionally substitutedpyrazin-2-yl.

In another embodiment, R¹ is pyrazinyl, wherein such pyrazinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halo-C₁-C₄-alkyl andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyrazin-2-yl.

In another embodiment, R¹ is pyrazinyl, wherein such pyrazinyl isoptionally substituted with one substituent selected from the groupconsisting of halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl. In one embodiment,R¹ is optionally substituted pyrazin-2-yl. In one embodiment, theoptional substituent is halo-C₁-C₄-alkyl. In one embodiment, theoptional substituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyrazinyl, wherein such pyrazinyl isoptionally substituted with one substituent selected from the groupconsisting of halomethyl and cyclopropyl.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ is pyrazinyl, whereinsuch pyrazinyl is optionally substituted with one substituent selectedfrom the group consisting of halomethyl and cyclopropyl.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl.

In another embodiment, R¹ is pyrazinyl that is substituted withtrifluoromethyl. In one embodiment, R¹ is pyrazin-2-yl that issubstituted with trifluoromethyl. In one embodiment, R¹ is5-trifluoromethylpyrazin-2-yl.

In another embodiment, R¹ is pyrazinyl that is substituted withcyclopropyl. In one embodiment, R¹ is pyrazin-2-yl that is substitutedwith cyclopropyl. In one embodiment, R¹ is 5-cyclopropylpyrazin-2-yl.

B-5(c): R¹ Pyridinyl Substituent

In one embodiment of the compounds of Formula (I), R¹ is pyridinyl,wherein such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl. In oneembodiment, R¹ is optionally substituted pyridin-2-yl. In oneembodiment, R¹ is optionally substituted pyridin-3-yl. In oneembodiment, R¹ is optionally substituted pyridin-4-yl.

In another embodiment, R¹ is pyridinyl, wherein such pyridinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyridin-2-yl. In one embodiment, R¹ is optionally substitutedpyridin-3-yl. In one embodiment, R¹ is optionally substitutedpyridin-4-yl. In one embodiment, the optional substituent is halogen. Inone embodiment, the optional substituent is C₁-C₄-alkyl. In oneembodiment, the optional substituent is halo-C₁-C₄-alkyl. In oneembodiment, the optional substituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyridinyl, wherein such pyridinyl isoptionally substituted with one, two, or three substituentsindependently selected from the group consisting of halo-C₁-C₆-alkyl andC₃-C₆-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyridin-2-yl. In one embodiment, R¹ is optionally substitutedpyridin-3-yl. In one embodiment, R¹ is optionally substitutedpyridin-4-yl.

In another embodiment, R¹ is pyridinyl, wherein such pyridinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halo-C₁-C₄-alkyl andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyridin-2-yl. In one embodiment, R¹ is optionally substitutedpyridin-3-yl. In one embodiment, R¹ is optionally substitutedpyridin-4-yl.

In another embodiment, R¹ is pyridinyl, wherein such pyridinyl isoptionally substituted with one substituent selected from the groupconsisting of halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl. In one embodiment,R¹ is optionally substituted pyridin-2-yl. In one embodiment, R¹ isoptionally substituted pyridin-3-yl. In one embodiment, R¹ is optionallysubstituted pyridin-4-yl. In one embodiment, the optional substituent ishalo-C₁-C₄-alkyl. In one embodiment, the optional substituent isC₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyridinyl, wherein such pyridinyl isoptionally substituted with one substituent selected from the groupconsisting of halomethyl and cyclopropyl. In one embodiment, R¹ isoptionally substituted pyridin-2-yl. In one embodiment, R¹ is optionallysubstituted pyridin-3-yl. In one embodiment, R¹ is optionallysubstituted pyridin-4-yl.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ is pyridinyl, whereinsuch pyridinyl is optionally substituted with one substituent selectedfrom the group consisting of halomethyl and cyclopropyl.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl.

In another embodiment, R¹ is pyridinyl that is substituted withtrifluoromethyl. In one embodiment, R¹ is pyridin-2-yl that issubstituted with trifluoromethyl. In one embodiment, R¹ is5-trifluoromethylpyridin-2-yl. In one embodiment, R¹ is pyridin-3-ylthat is substituted with trifluoromethyl. In one embodiment, R¹ is6-trifluoromethylpyridin-3-yl.

In another embodiment, R¹ is pyridinyl that is substituted withcyclopropyl. In one embodiment, R¹ is pyridin-2-yl that is substitutedwith cyclopropyl. In one embodiment, R¹ is 5-cyclopropylpyridin-2-yl. Inone embodiment, R¹ is pyridin-3-yl that is substituted with cyclopropyl.In one embodiment, R¹ is 6-cyclopropylpyridin-3-yl.

In another embodiment, R¹ is selected from the group consisting of thesubstituents listed in Table 1B:

TABLE 1B

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ is pyridinyl, whereinsuch pyridinyl is optionally substituted with one substituent selectedfrom the group consisting the substituents listed in Table 1B.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone substituent selected from the group consisting of the substituentslisted in Table 1B.

B-5(d): R¹ Pyrimidinyl Substituent

In one embodiment of the compounds of Formula (I), R¹ is pyrimidinyl,wherein such pyrimidinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl. In oneembodiment, R¹ is optionally substituted pyrimidin-2-yl. In oneembodiment, R¹ is pyrimidin-3-yl.

In another embodiment, R¹ is pyrimidinyl, wherein such pyrimidinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyrimidin-2-yl. In one embodiment, R¹ is pyrimidin-3-yl. In oneembodiment, the optional substituent is halogen. In one embodiment, theoptional substituent is C₁-C₄-alkyl. In one embodiment, the optionalsubstituent is halo-C₁-C₄-alkyl. In one embodiment, the optionalsubstituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyrimidinyl, wherein such pyrimidinyl isoptionally substituted with one, two, or three substituentsindependently selected from the group consisting of halo-C₁-C₆-alkyl andC₃-C₆-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyrimidin-2-yl. In one embodiment, R¹ is pyrimidin-3-yl.

In another embodiment, R¹ is pyrimidinyl, wherein such pyrimidinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halo-C₁-C₄-alkyl andC₃-C₄-cycloalkyl. In one embodiment, R¹ is optionally substitutedpyrimidin-2-yl. In one embodiment, R¹ is pyrimidin-3-yl.

In another embodiment, R¹ is pyrimidinyl, wherein such pyrimidinyl isoptionally substituted with one substituent selected from the groupconsisting of halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl. In one embodiment,In one embodiment, R¹ is optionally substituted pyrimidin-2-yl. In oneembodiment, R¹ is pyrimidin-3-yl. In one embodiment, the optionalsubstituent is halo-C₁-C₄-alkyl. In one embodiment, the optionalsubstituent is C₃-C₄-cycloalkyl.

In another embodiment, R¹ is pyrimidinyl, wherein such pyrimidinyl isoptionally substituted with one substituent selected from the groupconsisting of halomethyl and cyclopropyl. In one embodiment, R¹ isoptionally substituted pyrimidin-2-yl. In one embodiment, R¹ ispyrimidin-3-yl.

In another embodiment, R¹ is pyrimidinyl that is substituted withtrifluoromethyl. In one embodiment, R¹ is pyrimidin-2-yl that issubstituted with trifluoromethyl. In one embodiment, R¹ is5-trifluoromethylpyrimidin-2-yl. In one embodiment, R¹ is pyrimidin-3-ylthat is substituted with trifluoromethyl. In one embodiment, R¹ is6-trifluoromethylpyrimidin-3-yl.

In another embodiment, R¹ is pyrimidinyl that is substituted withcyclopropyl. In one embodiment, R¹ is pyrimidin-2-yl that is substitutedwith cyclopropyl. In one embodiment, R¹ is 5-cyclopropylpyrimidin-2-yl.In one embodiment, R¹ is pyrimidin-3-yl that is substituted withcyclopropyl. In one embodiment, R¹ is 6-cyclopropylpyrimidin-3-yl.

B-6: R² Substituent

In one embodiment of the compounds of Formula (I), R² is selected fromthe group consisting of phenyl, pyridinyl, pyrimidinyl, pyrazinyl, andpyridazinyl, wherein each such substituent is optionally substitutedwith one or two substituents independently selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein eachsuch substituent is optionally substituted with one substituent selectedfrom the group consisting of halogen, cyano, C₁-C₆-alkyl,halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.In one embodiment, the optional substituent is halogen. In oneembodiment, the optional substituent is cyano. In one embodiment, theoptional substituent is C₁-C₆-alkyl. In one embodiment, the optionalsubstituent is halo-C₁-C₆-alkyl. In one embodiment, the optionalsubstituent is C₁-C₆-alkoxy. In one embodiment, the optional substituentis halo-C₁-C₆-alkoxy. In one embodiment, the optional substituent isC₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein eachsuch substituent is optionally substituted with two substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, andC₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein eachsuch substituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In one embodiment, the optionalsubstituents are independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment, R² is selected from the group consisting ofphenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein eachsuch substituent is optionally substituted with one substituent selectedfrom the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituent isselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy. In one embodiment, the optional substituent ishalogen. In one embodiment, the optional substituent ishalo-C₁-C₃-alkyl. In one embodiment, the optional substituent ishalo-C₁-C₃-alkoxy. In one embodiment, the optional substituent isfluoro. In one embodiment, the optional substituent is trifluoromethyl.In one embodiment, the optional substituent is trifluoromethoxy.

In another embodiment, R² is selected from the group consisting ofphenyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein eachsuch substituent is optionally substituted with two substituentsindependently selected from the group consisting of halogen,halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In one embodiment, the optionalsubstituents are independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy. In one embodiment, theoptional substituents are independently halogen. In one embodiment, theoptional substituents are chloro and fluoro. In one embodiment, oneoptional substituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2.

TABLE 2

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is selected from thegroup consisting of the substituents listed in Table 2.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2A.

TABLE 2A

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is selected from thegroup consisting of the substituents listed in Table 2A.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2A.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2A.

B-6(a): R² Phenyl or Pyridinyl Substituent

In one embodiment of the compounds of Formula (I), R² is selected fromthe group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, andC₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl and pyridinyl, wherein each such substituent is optionallysubstituted with one substituent selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl. In one embodiment, the optionalsubstituent is halogen. In one embodiment, the optional substituent iscyano. In one embodiment, the optional substituent is C₁-C₆-alkyl. Inone embodiment, the optional substituent is halo-C₁-C₆-alkyl. In oneembodiment, the optional substituent is C₁-C₆-alkoxy. In one embodiment,the optional substituent is halo-C₁-C₆-alkoxy. In one embodiment, theoptional substituent is C₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl and pyridinyl, wherein each such substituent is optionallysubstituted with two substituents independently selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is selected from the group consisting ofphenyl and pyridinyl, wherein each such substituent is optionallysubstituted with one or two substituents independently selected from thegroup consisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. Inone embodiment, the optional substituents are independently selectedfrom the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment, R² is selected from the group consisting ofphenyl and pyridinyl, wherein each such substituent is optionallysubstituted with one substituent selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In one embodiment, theoptional substituent is selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituent is halogen. In one embodiment, the optional substituent ishalo-C₁-C₃-alkyl. In one embodiment, the optional substituent ishalo-C₁-C₃-alkoxy. In one embodiment, the optional substituent isfluoro. In one embodiment, the optional substituent is trifluoromethyl.In one embodiment, the optional substituent is trifluoromethoxy.

In another embodiment, R² is selected from the group consisting ofphenyl and pyridinyl, wherein each such substituent is optionallysubstituted with two substituents independently selected from the groupconsisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In oneembodiment, the optional substituents are independently selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.In one embodiment, the optional substituents are fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituents are independently halogen. In one embodiment, the optionalsubstituents are chloro and fluoro. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

B-6(b): R² Phenyl Substituent

In one embodiment of the compounds of Formula (I), R² is phenyl, whereineach such phenyl is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, andC₃-C₆-cycloalkyl.

In another embodiment, R² is phenyl, wherein each such phenyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is phenyl, wherein each such phenyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is phenyl, wherein each such phenyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is phenyl substitutedwith one or two substituents independently selected from the groupconsisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is phenyl substituted with one or two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment, R² is phenyl, wherein each such phenyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In oneembodiment, the optional substituent is selected from the groupconsisting of fluoro, trifluoromethyl, and trifluoromethoxy. In oneembodiment, the optional substituent is halogen. In one embodiment, theoptional substituent is halo-C₁-C₃-alkyl. In one embodiment, theoptional substituent is halo-C₁-C₃-alkoxy. In one embodiment, theoptional substituent is fluoro. In one embodiment, the optionalsubstituent is trifluoromethyl. In one embodiment, the optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is phenyl, wherein each such phenyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituents are independently halogen. In one embodiment, the optionalsubstituents are chloro and fluoro. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is phenyl substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy. In one embodiment, R² is phenyl substituted withfluoro (e.g., 2-fluorophenyl, 3-fluorophenyl, or 4-fluorophenyl). In oneembodiment, R² is phenyl substituted with trifluoromethyl (e.g.,2-trifluoromethylphenyl, 3-trifluoromethylphenyl, or4-trifluoromethylphenyl). In one embodiment, R² is phenyl substitutedwith trifluoromethoxy (e.g., 2-trifluoromethoxyphenyl,3-trifluoromethoxyphenyl, or 4-trifluoromethoxyphenyl).

In another embodiment, R² is phenyl substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² is phenylsubstituted with one fluoro substituent and one trifluoromethylsubstituent (e.g., 2-fluoro-3-trifluoro-phenyl,3-fluoro-4-trifluoro-phenyl, 2-trifluoro-3-fluoro-phenyl,3-trifluoro-4-fluoro-phenyl).

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2B.

TABLE 2B

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2B.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2B.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2C.

TABLE 2C

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2C.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2C.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2D.

TABLE 2D

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2D.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2D.

B-6(c): R² Pyridinyl Substituent

In one embodiment of the compounds of Formula (I), R² is pyridinyl,wherein each such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl. In one embodiment, R² isoptionally substituted pyridin-2-yl.

In another embodiment, R² is pyridinyl, wherein each such pyridinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl. In oneembodiment, R² is optionally substituted pyridin-2-yl.

In another embodiment, R² is pyridinyl, wherein each such pyridinyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl. In oneembodiment, R² is optionally substituted pyridin-2-yl.

In another embodiment, R² is pyridinyl, wherein each such pyridinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, R² is optionally substitutedpyridin-2-yl. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is pyridinylsubstituted with one or two substituents independently selected from thegroup consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is pyridinyl substituted with one or two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment, R² is pyridinyl, wherein each such pyridinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In oneembodiment, R² is optionally substituted pyridin-2-yl. In oneembodiment, the optional substituent is selected from the groupconsisting of fluoro, trifluoromethyl, and trifluoromethoxy. In oneembodiment, the optional substituent is halogen. In one embodiment, theoptional substituent is halo-C₁-C₃-alkyl. In one embodiment, theoptional substituent is halo-C₁-C₃-alkoxy. In one embodiment, theoptional substituent is fluoro. In one embodiment, the optionalsubstituent is trifluoromethyl. In one embodiment, the optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is pyridinyl, wherein each such pyridinyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, R² is optionally substitutedpyridin-2-yl. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituents are independently halogen. In one embodiment, the optionalsubstituents are chloro and fluoro. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is pyridin-2-yl substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² ispyridin-2-yl substituted with fluoro (e.g., 3-fluoropyridin-2-yl,4-fluoropyridin-2-yl, 5-fluoropyridin-2-yl, or 6-fluoropyridin-2-yl). Inone embodiment, R² is pyridin-2-yl substituted with trifluoromethyl(e.g., 3-trifluoromethylpyridin-2-yl, 4-trifluoromethylpyridin-2-yl,5-trifluoromethylpyridin-2-yl, or 6-trifluoromethylpyridin-2-yl). In oneembodiment, R² is pyridin-2-yl substituted with trifluoromethoxy (e.g.,3-trifluoromethoxypyridin-2-yl, 4-trifluoromethoxypyridin-2-yl,5-trifluoromethoxypyridin-2-yl, or 6-trifluoromethoxypyridin-2-yl).

In another embodiment, R² is pyridinyl substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² issubstituted pyridin-2-yl.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2E.

TABLE 2E

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2E.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2E.

In another embodiment, R² is selected from the group consisting of thesubstituents listed in Table 2F.

TABLE 2F

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is selected from the group consisting of the substituents listed inTable 2F.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is selected from the groupconsisting of the substituents listed in Table 2F.

B-6(d): R² Pyrimidinyl Substituent

In one embodiment of the compounds of Formula (I), R² is pyrimidinyl,wherein each such pyrimidinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrimidinyl, wherein each such pyrimidinylis optionally substituted with one substituent selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrimidinyl, wherein each such pyrimidinylis optionally substituted with two substituents independently selectedfrom the group consisting of halogen, cyano, C₁-C₆-alkyl,halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrimidinyl, wherein each such pyrimidinylis optionally substituted with one or two substituents independentlyselected from the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is pyrimidinylsubstituted with one or two substituents independently selected from thegroup consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is pyrimidinyl substituted with one or two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment, R² is pyrimidinyl, wherein each such pyrimidinylis optionally substituted with one substituent selected from the groupconsisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In oneembodiment, the optional substituent is selected from the groupconsisting of fluoro, trifluoromethyl, and trifluoromethoxy. In oneembodiment, the optional substituent is halogen. In one embodiment, theoptional substituent is halo-C₁-C₃-alkyl. In one embodiment, theoptional substituent is halo-C₁-C₃-alkoxy. In one embodiment, theoptional substituent is fluoro. In one embodiment, the optionalsubstituent is trifluoromethyl. In one embodiment, the optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is pyrimidinyl, wherein each such pyrimidinylis optionally substituted with two substituents independently selectedfrom the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituents are independently halogen. In one embodiment, the optionalsubstituents are chloro and fluoro. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

B-6(e): R² Pyrazinyl Substituent

In one embodiment of the compounds of Formula (I), R² is pyrazinyl,wherein each such pyrazinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrazinyl, wherein each such pyrazinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrazinyl, wherein each such pyrazinyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment, R² is pyrazinyl, wherein each such pyrazinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R² is pyrazinylsubstituted with one or two substituents independently selected from thegroup consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR² is pyrazinyl substituted with one or two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment, R² is pyrazinyl, wherein each such pyrazinyl isoptionally substituted with one substituent selected from the groupconsisting of halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy. In oneembodiment, the optional substituent is selected from the groupconsisting of fluoro, trifluoromethyl, and trifluoromethoxy. In oneembodiment, the optional substituent is halogen. In one embodiment, theoptional substituent is halo-C₁-C₃-alkyl. In one embodiment, theoptional substituent is halo-C₁-C₃-alkoxy. In one embodiment, theoptional substituent is fluoro. In one embodiment, the optionalsubstituent is trifluoromethyl. In one embodiment, the optionalsubstituent is trifluoromethoxy.

In another embodiment, R² is pyrazinyl, wherein each such pyrazinyl isoptionally substituted with two substituents independently selected fromthe group consisting of halogen, halo-C₁-C₃-alkyl, andhalo-C₁-C₃-alkoxy. In one embodiment, the optional substituents areindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, the optionalsubstituents are independently halogen. In one embodiment, the optionalsubstituents are chloro and fluoro. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethyl. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethyl. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethyl. In one embodiment, one optionalsubstituent is halogen and the other optional substituent istrifluoromethoxy. In one embodiment, one optional substituent is chloroand the other optional substituent is trifluoromethoxy. In oneembodiment, one optional substituent is fluoro and the other optionalsubstituent is trifluoromethoxy.

In another embodiment, the compounds of Formula (I) correspond to astructure shown in Table 1A, and R² is pyrazinyl substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment, R² is 5-cyclopropylpyridazin-2-yl.

Various embodiments of the pyrrolo[1,2-a][1,4]diazepine ring of thepresent invention and substituents R¹, R², R³, R⁴, R⁵, and L have beendiscussed above. These individual embodiments can be combined to formvarious additional embodiments of the compounds of Formula (I), (I-i),(I-ii), (I-iii), (I-iv), (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1),or (I-C-2). All embodiments of the compounds of Formula (I), (I-i),(I-ii), (I-iii), (I-iv), (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1),or (I-C-2) formed by combining the substituent embodiments discussedabove are within the scope of applicant's invention, and severalrepresentative embodiments of these compounds are provided below.

B-7: R¹/R² Substituents

In one embodiment of the compounds of Formula (I):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment:

R² is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, C₁-C₄-alkoxy,halo-C₁-C₄-alkoxy, and C₃-C₄-cycloalkyl.

In another embodiment:

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment:

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In additional embodiments, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ and R² are as definedin the various substituent embodiments discussed above.

In additional embodiments, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

B-7(a): R¹ Pyrazinyl/R² Phenyl Substituents

In one embodiment of the compounds of Formula (I):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, cyano, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, C₁-C₄-alkoxy,halo-C₁-C₄-alkoxy, and C₃-C₄-cycloalkyl.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of trifluoromethyland cyclopropyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In additional embodiments, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ and R² are as definedin the various substituent embodiments discussed above.

In additional embodiments, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

B-7(b): R¹ Pyrazinyl/R² Pyridinyl Substituents

In one embodiment of the compounds of Formula (I):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, cyano, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, C₁-C₄-alkoxy,halo-C₁-C₄-alkoxy, and C₃-C₄-cycloalkyl.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of trifluoromethyland cyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In additional embodiments, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ and R² are as definedin the various substituent embodiments discussed above.

In additional embodiments, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

B-7(c): R¹ Pyridinyl/R² Phenyl Substituents

In one embodiment of the compounds of Formula (I):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, cyano, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, C₁-C₄-alkoxy,halo-C₁-C₄-alkoxy, and C₃-C₄-cycloalkyl.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyrazinyl is optionally substituted withone substituent selected from the group consisting of trifluoromethyland cyclopropyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting offluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In additional embodiments, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ and R² are as definedin the various substituent embodiments discussed above.

In additional embodiments, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

B-7(d): R¹ Pyridinyl/R² Pyridinyl Substituents

In one embodiment of the compounds of Formula (I):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, cyano, C₁-C₄-alkyl, halo-C₁-C₄-alkyl, C₁-C₄-alkoxy,halo-C₁-C₄-alkoxy, and C₃-C₄-cycloalkyl.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone substituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone substituent selected from the group consisting of trifluoromethyland cyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment:

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In additional embodiments, the compounds correspond to a structure ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹ and R² are as definedin the various substituent embodiments discussed above.

In additional embodiments, the compounds correspond to a structure ofFormula (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2), andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

B-7(e): Representative R¹/R² Substituents

In one embodiment of the compounds of Formula (I):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In one embodiment, R² is phenyl that is substituted with one substituentindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² is phenylthat is substituted with two substituents independently selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.In one embodiment, R² is pyridinyl that is substituted with onesubstituent independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² ispyridinyl that is substituted with two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment:

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is substituted with one substituentselected from the group consisting of halomethyl and cyclopropyl; and

R² is selected from the group consisting of:

In one embodiment, R¹ is pyridinyl that is substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl. In one embodiment, R¹ is pyridinyl that is substituted withone halomethyl substituent. In one embodiment, R¹ is pyridinyl that issubstituted with one trifluoromethyl substituent. In one embodiment, R¹is pyridinyl that is substituted with one cyclopropyl substituent. Inone embodiment, R¹ is pyrazinyl that is substituted with one substituentselected from the group consisting of halomethyl and cyclopropyl. In oneembodiment, R¹ is pyrazinyl that is substituted with one halomethylsubstituent. In one embodiment, R¹ is pyrazinyl that is substituted withone trifluoromethyl substituent. In one embodiment, R¹ is pyrazinyl thatis substituted with one cyclopropyl substituent.

In another embodiment:

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment:

R¹ is

and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In one embodiment, R² is phenyl that is substituted with one substituentindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² is phenylthat is substituted with two substituents independently selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.In one embodiment, R² is pyridinyl that is substituted with onesubstituent independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy. In one embodiment, R² ispyridinyl that is substituted with two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment:

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is substituted with one substituentselected from the group consisting of halomethyl and cyclopropyl; and

R² is selected from the group consisting of:

In one embodiment, R¹ is pyridinyl that is substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl. In one embodiment, R¹ is pyridinyl that is substituted withone halomethyl substituent. In one embodiment, R¹ is pyridinyl that issubstituted with one trifluoromethyl substituent. In one embodiment, R¹is pyridinyl that is substituted with one cyclopropyl substituent. Inone embodiment, R¹ is pyrazinyl that is substituted with one substituentselected from the group consisting of halomethyl and cyclopropyl. In oneembodiment, R¹ is pyrazinyl that is substituted with one halomethylsubstituent. In one embodiment, R¹ is pyrazinyl that is substituted withone trifluoromethyl substituent. In one embodiment, R¹ is pyrazinyl thatis substituted with one cyclopropyl substituent.

In another embodiment:

R¹ is

and

R² is selected from the group consisting of:

B-8: Formula (I-A)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-A):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

L is selected from the group consisting of a bond, —CH₂—, —C(O)—,—C(O)C(R³)(H)—, and —S(O)₂—; and

R³ is selected from the group consisting of hydrogen, hydroxy, amino,methylamino, and dimethylamino.

In another embodiment of the compounds of Formula (I-A):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-A):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-A):

R¹ is

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-A), L is a bond;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-A), L is —CH₂—; andR¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-A), L is —C(O)—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-A), L is —S(O)₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-A), L is—C(O)C(R³)(H)—; and R¹ and R² are as defined in the various substituentembodiments discussed above.

In another embodiment of the compounds of Formula (I-A), L is—C(O)C(R³)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R³ is hydrogen.

In another embodiment of the compounds of Formula (I-A), L is—C(O)C(R³)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R³ is hydroxy.

In another embodiment of the compounds of Formula (I-A), L is—C(O)C(R³)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R³ is selected from the groupconsisting of amino, methylamino, and dimethylamino

In additional embodiments, the compounds of Formula (I-A) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R³, and L are asdefined in the various substituent embodiments discussed above.

B-9: Formula (I-B-1)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-B-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

L is selected from the group consisting of a bond, —CH₂—, —C(O)—, and—C(O)C(R⁴)(H)—; and

R⁴ is selected from the group consisting of hydrogen, hydroxy, amino,methylamino, and dimethylamino

In another embodiment of the compounds of Formula (I-B-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-1):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-B-1):

R¹ is

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-B-1), L is a bond;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-1), L is —CH₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-1), L is —C(O)—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-1), L is—C(O)C(R⁴)(H)—; and R¹ and R² are as defined in the various substituentembodiments discussed above.

In another embodiment of the compounds of Formula (I-B-1), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is hydrogen.

In another embodiment of the compounds of Formula (I-B-1), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is hydroxy.

In another embodiment of the compounds of Formula (I-B-1), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is selected from the groupconsisting of amino, methylamino, and dimethylamino

In additional embodiments, the compounds of Formula (I-B-1) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R⁴, and L are asdefined in the various substituent embodiments discussed above.

B-10: Formula (I-B-2)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-B-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

L is selected from the group consisting of a bond, —CH₂—, —C(O)—, and—C(O)C(R⁴)(H)—; and

R⁴ is selected from the group consisting of hydrogen, hydroxy, amino,methylamino, and dimethylamino

In another embodiment of the compounds of Formula (I-B-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-B-2):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-B-2):

R¹ is

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-B-2), L is a bond;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-2), L is —CH₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-2), L is —C(O)—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-B-2), L is—C(O)C(R⁴)(H)—; and R¹ and R² are as defined in the various substituentembodiments discussed above.

In another embodiment of the compounds of Formula (I-B-2), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is hydrogen.

In another embodiment of the compounds of Formula (I-B-2), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is hydroxy.

In another embodiment of the compounds of Formula (I-B-2), L is—C(O)C(R⁴)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁴ is selected from the groupconsisting of amino, methylamino, and dimethylamino

In additional embodiments, the compounds of Formula (I-B-2) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R⁴, and L are asdefined in the various substituent embodiments discussed above.

B-11: Formula (I-C-1)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-C-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

L is selected from the group consisting of a bond, —CH₂—, —C(O)—,—C(O)C(R⁵)(H)—, and —S(O)₂—; and

R⁵ is selected from the group consisting of hydrogen, hydroxy, amino,methylamino, and dimethylamino.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-1):

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-1):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-C-1):

R¹ is

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-C-1), L is a bond;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-1), L is —CH₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-1), L is —C(O)—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-1), L is —S(O)₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-1), L is—C(O)C(R⁵)(H)—; and R¹ and R² are as defined in the various substituentembodiments discussed above.

In another embodiment of the compounds of Formula (I-C-1), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is hydrogen.

In another embodiment of the compounds of Formula (I-C-1), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is hydroxy.

In another embodiment of the compounds of Formula (I-C-1), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is selected from the groupconsisting of amino, methylamino, and dimethylamino

In additional embodiments, the compounds of Formula (I-C-1) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R⁵, and L are asdefined in the various substituent embodiments discussed above.

B-12: Formula (I-C-2)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (I-C-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy;

L is selected from the group consisting of a bond, —CH₂—, —C(O)—,—C(O)C(R⁵)(H)—, and —S(O)₂—; and

R⁵ is selected from the group consisting of hydrogen, hydroxy, amino,methylamino, and dimethylamino

In another embodiment of the compounds of Formula (I-C-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is selected from the group consisting of pyridinyl and pyrazinyl,wherein each such substituent is optionally substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyrazinyl, wherein such pyrazinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is phenyl, wherein such phenyl is optionally substituted with one ortwo substituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with one substituentselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is phenyl, wherein such phenyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halo-C₁-C₄-alkyl and C₃-C₄-cycloalkyl; and

R² is pyridinyl, wherein such pyridinyl is optionally substituted withone or two substituents independently selected from the group consistingof halogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is pyridinyl, wherein such pyridinyl is substituted with onesubstituent selected from the group consisting of trifluoromethyl andcyclopropyl; and

R² is pyridinyl, wherein such pyridinyl is substituted with twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (I-C-2):

R¹ is selected from the group consisting of:

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-C-2):

R¹ is

and

R² is selected from the group consisting of:

In another embodiment of the compounds of Formula (I-C-2), L is a bond;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-2), L is —CH₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-2), L is —C(O)—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-2), L is —S(O)₂—;and R¹ and R² are as defined in the various substituent embodimentsdiscussed above.

In another embodiment of the compounds of Formula (I-C-2), L is—C(O)C(R⁵)(H)—; and R¹ and R² are as defined in the various substituentembodiments discussed above.

In another embodiment of the compounds of Formula (I-C-2), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is hydrogen.

In another embodiment of the compounds of Formula (I-C-2), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is hydroxy.

In another embodiment of the compounds of Formula (I-C-2), L is—C(O)C(R⁵)(H)—; R¹ and R² are as defined in the various substituentembodiments discussed above; and R⁵ is selected from the groupconsisting of amino, methylamino, and dimethylamino.

In additional embodiments, the compounds of Formula (I-C-2) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R⁴, and L are asdefined in the various substituent embodiments discussed above.

B-13: Formula (Ia)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (Ia):

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy;

as to X¹, X², X³, X⁴, and L:

X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selectedfrom the group consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and—S(O)₂—; or

X¹ is —CH₂—; one of X² and X³ is —C(O)— and the other one of X² and X³is —CH₂—; X⁴ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—; or

one of X¹ and X⁴ is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—; and

R³, R⁴, and R⁵ are independently selected from the group consisting ofhydrogen, hydroxy, amino, methylamino, and dimethylamino

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is phenyl,wherein such phenyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ia), R² is phenyl,wherein such phenyl is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is phenyl,wherein such phenyl is substituted with one substituent selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is phenyl,wherein such phenyl is substituted with two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is pyridinyl,wherein such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ia), R² is pyridinyl,wherein such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is pyridinyl,wherein such pyridinyl is substituted with one substituent selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is pyridinyl,wherein such pyridinyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ia), X¹ is —CH₂—; X²is —CH—; X³ is —CH—; X⁴ is —CH—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R³)(H)—.In one embodiment, L is —C(O)C(R³)(H)—; and R³ is hydrogen. In oneembodiment, L is —C(O)C(R³)(H)—; and R³ is hydroxy. In one embodiment, Lis —C(O)C(R³)(H)—; and R³ is selected from the group consisting ofamino, methylamino, and dimethylamine

In another embodiment of the compounds of Formula (Ia), X¹ is —CH₂—; oneof X² and X³ is —C(O)— and the other one of X² and X³ is —CH—; X⁴ is—CH—; and R¹ and R² are as defined in the various substituentembodiments discussed above. In one embodiment, L is a bond. In oneembodiment, L is —CH₂—. In one embodiment, L is —C(O)—. In oneembodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is —C(O)C(R⁴)(H)—;and R⁴ is hydrogen. In one embodiment, L is —C(O)C(R⁴)(H)—; and R⁴ ishydroxy. In one embodiment, L is —C(O)C(R⁴)(H)—; and R⁴ is selected fromthe group consisting of amino, methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ia), X¹ is —CH₂—; X²is —C(O)—; X³ is —CH₂—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydrogen. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydroxy. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ia), X¹ is —CH₂—; X²is —CH₂—; X³ is —C(O)—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydrogen. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydroxy. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ia), one of X¹ and X⁴is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X² is —CH₂—; X³ is—CH₂—; and R¹ and R² are as defined in the various substituentembodiments discussed above. In one embodiment, L is a bond. In oneembodiment, L is —CH₂—. In one embodiment, L is —C(O)—. In oneembodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In one embodiment,L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, L is—C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ia), X¹—C(O)—; X² is—CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—.In one embodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, Lis —C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting ofamino, methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ia), X¹ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; X⁴ is —C(O)—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—.In one embodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, Lis —C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting ofamino, methylamino, and dimethylamine.

In additional embodiments, the compounds of Formula (Ia) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R³, R⁴, R⁵, and Lare as defined in the various substituent embodiments discussed above.

B-14: Formula (Ib)

In one embodiment, the compounds of Formula (I) correspond in structureto Formula (Ib):

R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy;

as to X¹, X², X³, X⁴, and L:

X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selectedfrom the group consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and—S(O)₂—; or

X¹ is —CH₂—; one of X² and X³ is —C(O)— and the other one of X² and X³is —CH₂—; X⁴ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—; or

one of X¹ and X⁴ is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; and L is selected from the group consisting of abond, —CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—; and

R³, R⁴, and R⁵ are independently selected from the group consisting ofhydrogen, hydroxy, amino, methylamino, and dimethylamino

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is phenyl,wherein such phenyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ib), R² is phenyl,wherein such phenyl is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is phenyl,wherein such phenyl is substituted with one substituent selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is phenyl,wherein such phenyl is substituted with two substituents independentlyselected from the group consisting of fluoro, trifluoromethyl, andtrifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is pyridinyl,wherein such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, halo-C₁-C₃-alkyl, and halo-C₁-C₃-alkoxy.

In another embodiment of the compounds of Formula (Ib), R² is pyridinyl,wherein such pyridinyl is optionally substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is pyridinyl,wherein such pyridinyl is substituted with one substituent selected fromthe group consisting of fluoro, trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is pyridinyl,wherein such pyridinyl is substituted with two substituentsindependently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), R² is selectedfrom the group consisting of:

In another embodiment of the compounds of Formula (Ib), X¹ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R³)(H)—.In one embodiment, L is —C(O)C(R³)(H)—; and R³ is hydrogen. In oneembodiment, L is —C(O)C(R³)(H)—; and R³ is hydroxy. In one embodiment, Lis —C(O)C(R³)(H)—; and R³ is selected from the group consisting ofamino, methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), X¹ is —CH₂—; oneof X² and X³ is —C(O)— and the other one of X² and X³ is —CH₂—; X⁴ is—CH₂—; and R¹ and R² are as defined in the various substituentembodiments discussed above. In one embodiment, L is a bond. In oneembodiment, L is —CH₂—. In one embodiment, L is —C(O)—. In oneembodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is —C(O)C(R⁴)(H)—;and R⁴ is hydrogen. In one embodiment, L is —C(O)C(R⁴)(H)—; and R⁴ ishydroxy. In one embodiment, L is —C(O)C(R⁴)(H)—; and R⁴ is selected fromthe group consisting of amino, methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), X¹ is —CH₂—; X²is —C(O)—; X³ is —CH₂—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydrogen. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydroxy. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), X¹ is —CH₂—; X²is —CH₂—; X³ is —C(O)—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —C(O)C(R⁴)(H)—. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydrogen. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is hydroxy. In one embodiment, L is—C(O)C(R⁴)(H)—; and R⁴ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), one of X¹ and X⁴is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X² is —CH₂—; X³ is—CH₂—; and R¹ and R² are as defined in the various substituentembodiments discussed above. In one embodiment, L is a bond. In oneembodiment, L is —CH₂—. In one embodiment, L is —C(O)—. In oneembodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In one embodiment,L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, L is—C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting of amino,methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), X¹—C(O)—; X² is—CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—.In one embodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, Lis —C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting ofamino, methylamino, and dimethylamine.

In another embodiment of the compounds of Formula (Ib), X¹ is —CH₂—; X²is —CH₂—; X³ is —CH₂—; X⁴ is —C(O)—; and R¹ and R² are as defined in thevarious substituent embodiments discussed above. In one embodiment, L isa bond. In one embodiment, L is —CH₂—. In one embodiment, L is —C(O)—.In one embodiment, L is —S(O)₂—. In one embodiment, L is —C(O)C(R⁵)(H)—.In one embodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydrogen. In oneembodiment, L is —C(O)C(R⁵)(H)—; and R⁵ is hydroxy. In one embodiment, Lis —C(O)C(R⁵)(H)—; and R⁵ is selected from the group consisting ofamino, methylamino, and dimethylamine.

In additional embodiments, the compounds of Formula (Ib) have aconfiguration that corresponds to a configuration of a compound ofFormula (I-i), (I-ii), (I-iii), or (I-iv), and R¹, R², R³, R⁴, R⁵, and Lare as defined in the various substituent embodiments discussed above.

Specific compounds of Formula (I) include the compounds of Examples 1through 208 discussed below.

In one embodiment, the compounds are selected from the group consistingof the compounds of Examples 1 through 55.

In one embodiment, the compounds are selected from the group consistingof the compounds of Examples 1 through 21.

In another embodiment, the compounds are selected from the groupconsisting of consisting of the compounds of Examples 22 through 27.

In another embodiment, the compounds are selected from the groupconsisting of the compounds of Examples 28 through 55.

(i) Isomers

This invention also is directed, in part, to all isomers of thecompounds of Formula (I) and salts thereof (e.g., structural andstereoisomers). Structural isomers include chain and position isomers.Stereoisomers include E/Z isomers (i.e., isomers with regard to one ormore double bonds), enantiomers (i.e., stereoisomers that have oppositeconfigurations at all stereogenic centers), and diastereoisomers (i.e.,stereoisomers that have the same configuration at one or morestereogenic centers, but differ at other stereogenic centers).

As previously discussed, the stereoisomers of the compounds of Formula(I) include those depicted below as Formulae (I-i), (I-ii), (I-iii), and(I-iv):

Further, as previously discussed, the stereoisomers of the compounds ofFormulae (I-A), (I-B), (I-B-1), (I-B-2), (I-C), (I-C-1), or (I-C-2) canbe depicted in a similar manner. For example, the stereoisomers of thecompounds of Formula (I-A) include those depicted below as Formulae(I-C-1-i), (I-C-1-ii), (I-C-1-iii), and (I-C-1-iv):

Stereoisomeric mixtures, e.g., mixtures of diastereomers, can beseparated into their corresponding isomers using conventional separationmethods. For example, diastereomeric mixtures can be separated intotheir individual diastereomers by means of fractional crystallization,chromatography, solvent distribution, and similar procedures. Thisseparation can take place at any appropriate step of the compoundsynthesis or purification, e.g., through use of a chiral startingcompound or chiral intermediate compound, or purification of the finalcompound itself. Enantiomers can be separated, for example, through theformation of diastereomeric salts (e.g., by salt formation with anenantiomerically pure chiral acid), or by means of chromatography (e.g.,high performance liquid chromatography) using chiral chromatographicmedia.

In one embodiment, the compound is present as a substantially puresingle isomer. In another embodiment, the compound is present as amixture of two or more isomers. Mixtures of the compounds within thisembodiment include racemic or equimolar mixtures as well as mixtures ofthe compounds where one isomeric form is enriched relative to the otherisomeric forms of the compound. In additional embodiments, any form ofthe compound, such as an isomeric form of a compound disclosed in one ofthe Examples of this application, can make up about 60, 70, 80, 85, 90,95, 97, 99, 99.5, 99.7, 99.9 percent or more of the mixture of theisomeric forms of that compound on a molar or weight basis. In oneillustrative embodiment, a specific isomeric form of the compound canmake up about 90 percent or more of the mixture of the isomeric forms ofthat compound on a molar or weight basis. In another illustrativeembodiment, a specific form of the compound can make up about 95 percentor more of the mixture of the isomeric forms of that compound on a molaror weight basis. In yet another illustrative embodiment, a specific formof the compound can make up about 99 percent or more of the mixture ofthe isomeric forms of that compound on a molar or weight basis.

(ii) Salts

Those skilled in the art will recognize that the compounds described inthis application, including those set forth in the Examples, can occurin the free form (i.e., non-salt form) or in the salt form. In additionto encompassing the free form of the compounds of Formula (I), thisinvention is directed, in part, to all salts of the compounds of Formula(I). Depending upon the specific compound, a salt form may beadvantageous relative to the non-salt form due to one or more physicalproperties of the salt, such as stability, solubility, or ease ofisolation, purification, and/or resolution of the compound. Where a saltis intended to be administered to a patient (as opposed to, for example,being in use in an in vitro context), the salt preferably ispharmaceutically acceptable and/or physiologically compatible. Salts canbe prepared in situ during the final isolation and purification of thecompounds of the invention or separately, e.g., by reacting a free basefunction with a suitable organic acid.

The term “pharmaceutically acceptable” is used adjectivally in thispatent application to mean that the modified noun is appropriate for useas a pharmaceutical product or as a part of a pharmaceutical product.Pharmaceutically acceptable salts include salts commonly used to formalkali metal salts and to form addition salts of free acids or freebases. In general, these salts typically may be prepared by conventionalmeans by reacting, for example, the appropriate acid or base with acompound of the invention.

Pharmaceutically acceptable acid addition salts of the compounds ofFormula (I) can be prepared from an inorganic or organic acid. Examplesof often suitable inorganic acids include hydrochloric, hydrobromic,hydroiodic, nitric, carbonic, sulfuric, and phosphoric acid. Suitableorganic acids generally include, for example, aliphatic, cycloaliphatic,aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes oforganic acids. Specific examples of often suitable organic acids includeacetate, trifluoroacetate, formate, propionate, succinate, glycolate,gluconate, digluconate, lactate, malate, tartaric acid, citrate,ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate,glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate,p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate),ethanesulfonate, benzenesulfonate, pantothenate,2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenicacid, beta-hydroxybutyric acid, galactarate, galacturonate, adipate,alginate, bisulfate, butyrate, camphorate, camphorsulfonate,cyclopentanepropionate, dodecylsulfate, glycoheptanoate,glycerophosphate, heptanoate, hexanoate, nicotinate, oxalate, palmoate,pectinate, 2-naphthalesulfonate, 3-phenylpropionate, picrate, pivalate,thiocyanate, tosylate, and undecanoate.

Pharmaceutically acceptable base addition salts of the compounds ofFormula (I) include, for example, metallic salts and organic salts.Preferred metallic salts include alkali metal (group Ia) salts, alkalineearth metal (group IIa) salts, and other physiologically acceptablemetal salts. Such salts may be made from aluminum, calcium, lithium,magnesium, potassium, sodium, and zinc. Preferred organic salts can bemade from amines, such as tromethamine, diethylamine,N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine (N-methylglucamine), and procaine. Basicnitrogen-containing groups can be quaternized with agents such as loweralkyl (C₁-C₆) halides (e.g., methyl, ethyl, propyl, and butyl chlorides,bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl,dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl,myristyl, and stearyl chlorides, bromides, and iodides), arylalkylhalides (e.g., benzyl and phenethyl bromides), and others.

Additional examples of pharmaceutically acceptable salts are describedin “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” byStahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

(iii) Additional Forms

The compounds of the invention also can exist in unsolvated or solvatedform. Solvents can include, for example, pharmaceutically acceptablesolvents such as water (resulting in hydrates of the compound), ethanol,and the like. For the purposes of the present invention, solvated formsof the compounds are considered equivalent to unsolvated forms of thecompounds and both are included within the scope of the compounds of theinvention.

C. Compositions

This invention also is directed, in part, to compositions comprising oneor more compounds and/or salts of the invention. Although the compoundmay be administered alone or in the form of a pharmaceuticalcomposition, administration generally will be in the form of apharmaceutical composition. In some embodiments, the compositioncomprises a compound of Formula (I), or a pharmaceutically acceptablesalt thereof, in association with a pharmaceutically acceptable carrier.The preferred composition depends on the method of administration, andtypically comprises one or more conventional pharmaceutically acceptablecarriers, adjuvants, and/or vehicles (together referred to as“excipients”). Such compositions can be formulated for various routes ofsystemic or local delivery for example, by oral administration, topicaladministration, transmucosal administration, rectal administration,intravaginal administration, or administration by subcutaneous,intrathecal, intravenous, intramuscular, intraperitoneal, intranasal,intraocular or intraventricular injection.

Solid dosage forms for oral administration include, for example,capsules, tablets, pills, powders, and granules. In such solid dosageforms, the compounds or salts are ordinarily combined with one or moreexcipients. If administered per os, the compounds or salts can be mixedwith, for example, lactose, sucrose, starch powder, cellulose esters ofalkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesiumstearate, magnesium oxide, sodium and calcium salts of phosphoric andsulfuric acids, gelatin, acacia gum, sodium alginate,polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted orencapsulated for convenient administration. Such capsules or tablets cancontain a controlled-release formulation, as can be provided in, forexample, a dispersion of the compound or salt in hydroxypropylmethylcellulose. In the case of capsules, tablets, and pills, the dosage formsalso can comprise buffering agents, such as sodium citrate, or magnesiumor calcium carbonate or bicarbonate. Tablets and pills additionally canbe prepared with enteric coatings.

Liquid dosage forms for oral administration include, for example,pharmaceutically acceptable emulsions (including both oil-in-water andwater-in-oil emulsions), solutions (including both aqueous andnon-aqueous solutions), suspensions (including both aqueous andnon-aqueous suspensions), syrups, and elixirs containing inert diluentscommonly used in the art (e.g., water). Such compositions also cancomprise, for example, wetting, emulsifying, suspending, flavoring(e.g., sweetening), and/or perfuming agents.

Parenteral administration includes subcutaneous injections, intravenousinjections, intramuscular injections, intrasternal injections, andinfusion. Injectable preparations (e.g., sterile injectable aqueous oroleaginous suspensions) can be formulated according to the known artusing suitable dispersing, wetting agents, and/or suspending agents.Acceptable vehicles and solvents include, for example, water,1,3-butanediol, Ringer's solution, isotonic sodium chloride solution,bland fixed oils (e.g., synthetic mono- or diglycerides), fatty acids(e.g., oleic acid), dimethyl acetamide, surfactants (e.g., ionic andnon-ionic detergents), and/or polyethylene glycols.

Formulations for parenteral administration may, for example, be preparedfrom sterile powders or granules having one or more of the excipientsmentioned for use in the formulations for oral administration. Acompound or salt of the invention can be dissolved in water,polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseedoil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/orvarious buffers. The pH may be adjusted, if necessary, with a suitableacid, base, or buffer.

Suppositories for rectal administration can be prepared by, for example,mixing a compound or salt of the invention with a suitable nonirritatingexcipient that is solid at ordinary temperatures, but liquid at therectal temperature, and will therefore melt in the rectum to release thedrug. Suitable excipients include, for example, cocoa butter; syntheticmono-, di-, or triglycerides, fatty acids, and/or polyethylene glycols.

The compounds of the present invention can be formulated foradministration topically to the skin or mucosa, i.e., dermally ortransdermally. Such administration can include the use, e.g., oftransdermal patches or iontophoresis devices.

In some embodiments, the compositions further comprise one or moreadditional therapeutic agents. Such therapeutic agents can, but need notbe, additional therapeutic agents for treating pain. In one embodiment,the additional therapeutic agent is selected from the group consistingof acetaminophen, NSAIDs (such aspirin, ibuprofen, and naproxen), andopioid analgesics. In another embodiment, the additional therapeuticagent is acetaminophen. In another embodiment, the additionaltherapeutic agent is an NSAID. In another embodiment, the additionaltherapeutic agent is an opioid analgesic.

Besides those representative dosage forms described above,pharmaceutically acceptable excipients and carriers are generally knownto those skilled in the art and are thus included in the instantinvention. Formulation of drugs is generally discussed in, for example,Hoover, J., Remington's Pharmaceutical Sciences (Mack Publishing Co.,1975) and Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems(Lippincott Williams & Wilkins, 2005).

The therapeutically effective dose level for any particular patient willdepend upon the specific situation and can depend upon a variety offactors including the type, age, weight, sex, diet, and condition of thepatient being treated; the severity of the pathological condition;activity of the specific compound employed; the specific compositionemployed; the age, body weight, general health, sex and diet of thepatient; the route of administration; the duration of the treatment;pharmacological considerations, such as the activity, efficacy,pharmacokinetic, and toxicology profiles of the particular compound orsalt used; whether a drug delivery system is utilized; drugs used incombination or coincidental with the specific compound employed; andlike factors well-known in the medical arts. An ordinarily skilledphysician provided with the disclosure of the present application willbe able to determine appropriate dosages and regimens for administrationof the therapeutic agent to the subject, and to adjust such dosages andregimens as necessary during the course of treatment, in accordance withmethods well-known in the therapeutic arts. It is well within the skillof the art to start doses of the compound at levels lower than requiredto achieve the desired therapeutic effect and to gradually increase thedosage until the desired effect is achieved. Thus, the dosage regimenactually employed can vary widely, and therefore, can derive from thepreferred dosage regimen set forth below.

The preferred total daily dose of the compound or salt (administered insingle or divided doses) typically is from about 0.001 to about 100mg/kg, more preferably from about 0.001 to about 30 mg/kg, and even morepreferably from about 0.01 to about 10 mg/kg (i.e., mg of the compoundor salt per kg body weight). Dosage unit compositions can contain suchamounts or submultiples thereof to make up the daily dose. In manyinstances, the administration of the compound or salt will be repeated aplurality of times. Multiple doses per day typically may be used toincrease the total daily dose, if desired.

Depending upon the route and frequency of administration, thepharmaceutical compositions of the present invention can contain, forexample, from about 0.1 percent by weight to about 99 percent or more byweight of the active ingredient. Depending upon the compoundadministered, the amount of active ingredient contained in the dosageunit composition employed for adult human treatment generally can range,for example, from about 0.01 mg to about 3000 mg. For the therapeuticuses described in this application, the amount of active ingredientcontained in the dosage unit composition generally will be in the range,for example, from about 0.1 mg to about 1000 mg. In one embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 1 mg to about 500 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 1 mg to about 250 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 1 mg to about 25 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 25 mg to about 50 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 50 mg to about 100 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 100 mg to about 150 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 150 mg to about 200 mg. In another embodiment, theamount of active ingredient contained in the dosage unit composition isin a range from about 200 mg to about 250 mg.

D. Kits

This invention also is directed, in part, to a kit comprising one ormore compounds and/or salts of the invention. The kit can optionallycontain one or more additional therapeutic agents and/or instructionsfor, for example, using the kit. In one embodiment, the kit includes aunit dosage form comprising a compound of Formula (I), or apharmaceutically acceptable salt thereof, contained within a packagingmaterial and a label or package insert which indicates that the unitdosage form can be used for treating pain. In another embodiment, thekit includes a unit dosage form comprising a compound of Formula (I), ora pharmaceutically acceptable salt thereof contained within a packagingmaterial; a second therapeutic agent; and a label or package insertwhich indicates that the unit dosage form and second therapeutic agentcan be used for treating pain.

E. Methods of Use

This invention also is directed, in part, to a method for blockingcalcium channel activation, particularly N-type calcium channelactivation. In one embodiment, the invention is directed, in part, to amethod for blocking calcium channel activation in vitro. In anotherembodiment, the invention is directed, in part, to a method for blockingcalcium channel activation in vivo.

In one embodiment, the invention is directed to methods for treating acondition in a subject that can be treated by blocking N-Type calciumchannel activation in the subject. These methods comprise administeringto the subject one or more compounds and/or salts of the invention, and,optionally, one or more additional therapeutic agents. In someembodiments, a therapeutically effective amount of the compound(s)and/or salt(s) is administered to the subject.

The terms “treat,” “treating,” and “treatment” are readily understood bya physician of ordinary skill and, with respect to treatment of aparticular condition, can include ameliorating, suppressing,eradicating, preventing, reducing the risk of, and/or delaying the onsetof the disease being treated.

A “therapeutically-effective amount” or “effective amount” is an amountthat will achieve the goal of treating the targeted condition. Where thecompound or composition is being administered to treat pain, forexample, a therapeutically effective amount of the compound orcomposition is an amount that is sufficient, either alone or incombination with additional therapies, to provide an anti-pain effect ina subject as compared to the response obtained without administration ofthe compound or composition.

The term “subject” includes animals such as mammals, including primates(e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats,mice and the like. The methods of treatment are particularly suitablefor use with a human subject, but may be used with other animalsubjects, particularly mammals.

One embodiment of the present invention provides a method of treatingpain in a subject in need thereof. The method comprises administering tothe subject, including a mammal, such as a human, a therapeuticallyeffective amount of a compound of Formula (I), or a pharmaceuticallyacceptable salt thereof. Conditions related to pain include, forexample, acute pain, chronic pain, neuropathic pain, nociceptive pain,allodynia, inflammatory pain, inflammatory hyperalgesia, post herpeticneuralgia, post-operative pain, post-stroke pain, neuropathies,neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury,rheumatoid arthritic pain, osteoarthritic pain, burns, back pain, eyepain, visceral pain, cancer pain, dental pain, headache, migraine,carpal tunnel syndrome, fibromyalgia, neuritis, sciatica, pelvichypersensitivity, pelvic pain, menstrual pain.

Pain generally can be classified as acute or chronic. Acute pain beginssuddenly and is short-lived (usually twelve weeks or less). It isusually associated with a specific cause such as a specific injury andis often sharp and severe. It is the kind of pain that can occur afterspecific injuries resulting from surgery, dental work, a strain or asprain. Acute pain does not generally result in any persistentpsychological response. In contrast, chronic pain is long-term pain,typically persisting for more than three months and leading tosignificant psychological and emotional problems. Common examples ofchronic pain include neuropathic pain (e.g., painful diabeticneuropathy, postherpetic neuralgia), carpal tunnel syndrome, back pain,headache, cancer pain, arthritic pain and chronic post-surgical pain. Inone embodiment, the condition related to pain is chronic pain. Inanother embodiment, the condition related to pain is acute pain.

Pain also can be divided into a number of different subtypes accordingto differing pathophysiology, including neuropathic, nociceptive, andinflammatory pain. Some types of pain have multiple etiologies and canbe classified in more than one area, e.g., back pain and cancer painhave both nociceptive and neuropathic components.

In one embodiment, the condition related to pain is selected from thegroup consisting of neuropathic pain, nociceptive pain, and inflammatorypain.

In another embodiment, the condition related to pain is neuropathicpain. Neuropathic pain generally is defined as pain initiated or causedby a primary lesion or dysfunction in the nervous system and can result,for example, from trauma or disease. The term neuropathic painencompasses many conditions with diverse etiologies including peripheralneuropathy, diabetic neuropathy, post-herpetic neuralgia, trigeminalneuralgia, back pain, cancer neuropathy, HIV-neuropathy, phantom limbpain, carpal tunnel syndrome, central post-stroke pain, and painassociated with chronic alcoholism, hypothyroidism, uremia, multiplesclerosis, spinal cord injury, Parkinson's disease, epilepsy and vitamindeficiency.

In another embodiment, the condition related to pain is nociceptivepain. Nociceptive pain is induced by tissue injury or by intense stimuliwith the potential to cause injury. When a substantial injury occurs tobody tissue through trauma or disease, the characteristics of nociceptoractivation are altered and there is sensitization in the peripheryleading to a heightened sensation of pain in the subject. Moderate tosevere acute nociceptive pain is a prominent feature of pain fromcentral nervous system trauma, strains/sprains, burns, myocardialinfarction and acute pancreatitis, post-operative pain (pain followingany type of surgical procedure), post-traumatic pain, renal colic,cancer pain and back pain. Cancer pain can be chronic pain such as tumorrelated pain (e.g., bone pain, headache, facial pain or visceral pain)or pain associated with cancer therapy (e.g., post-chemotherapysyndrome, chronic postsurgical pain syndrome or post radiationsyndrome). Cancer pain can also occur in response to chemotherapy,immunotherapy, hormonal therapy or radiotherapy. Back pain can be due toherniated or ruptured intervertebral discs or abnormalities of thelumber facet joints, sacroiliac joints, paraspinal muscles or theposterior longitudinal ligament.

In another embodiment, the condition related to pain is inflammatorypain. A common type of inflammatory pain is arthritic pain arising fromrheumatoid disease (such as ankylosing spondylitis) or symptomaticosteoarthritis or degenerative joint disease. Another type ofinflammatory pain is visceral pain. Visceral pain is pain associatedwith the viscera, which encompass the organs of the abdominal cavityincluding the sex organs, spleen and part of the digestive system. Painassociated with the viscera can be divided into digestive visceral painand non-digestive visceral pain. Commonly encountered gastrointestinaldisorders that cause pain include functional bowel disorder andinflammatory bowel disease. These gastrointestinal disorders include awide range of disease states that are currently only moderatelycontrolled, including, with respect to functional bowel disorder,gastro-esophageal reflux, dyspepsia, irritable bowel syndrome, andfunctional abdominal pain syndrome, and, in respect of inflammatorybowel disease, Crohn's disease, ileitis and ulcerative colitis, all ofwhich regularly produce visceral pain. Other types of visceral paininclude the pain associated with dysmenorrhea, cystitis and pancreatitisand pelvic pain.

In another embodiment, the condition related to pain results from amusculo-skeletal condition such as myalgia, fibromyalgia, spondylitis,sero-negative (non-rheumatoid) arthropathies, non-articular rheumatism,dystrophinopathy, glycogenolysis, polymyositis and pyomyositis; heartand vascular pain, including pain caused by angina, myocardicalinfarction, mitral stenosis, pericarditis, Raynaud's phenomenon,scleredoma and skeletal muscle ischemia; head pain, such as migraine(including migraine with aura and migraine without aura), clusterheadache, tension-type headache mixed headache and headache associatedwith vascular disorders; and orofacial pain, including dental pain, oticpain, burning mouth syndrome and temporomandibular myofascial pain.

In some embodiments, the methods comprise combination therapy, whereinthe compound(s) and/or salt(s) of the invention is/are co-administeredwith a second (or even a third, fourth, etc.) compound, such as, forexample, another therapeutic agent used to treat pain. The compound(s)and/or salt(s) of this invention can also be co-administered withtherapeutic agents other than therapeutic agents used to treat pain. Inthese co-administration embodiments, the compound(s) and/or salt(s) ofthe invention and the second, etc. therapeutic agent(s) may beadministered in a substantially simultaneous manner (e.g., or withinabout five minutes of each other), in a sequential manner, or both. Itis contemplated that such combination therapies may includeadministering one therapeutic agent multiple times between theadministrations of the other. The time period between the administrationof each agent may range from a few seconds (or less) to several hours ordays, and will depend on, for example, the properties of eachcomposition and active ingredient (e.g., potency, solubility,bioavailability, half-life, and kinetic profile), as well as thecondition of the patient. The compound(s) and/or salt(s) of thisinvention and the second, etc. therapeutic agent may also beadministered in a single formulation.

In certain embodiments, the method comprises co-administering to thesubject the compound(s) and/or salt(s) of the invention with one or morecompounds selected from the group consisting of nonsteroidalanti-inflammatory drugs (NSAIDs), opioid analgesics, barbiturates,benzodiazapines, histamine antagonists, sedatives, skeletal musclerelaxants, transient receptor potential ion channel antagonists,α-adrenergics, tricyclic antidepressants, anticonvulsants, tachykininantagonists, muscarinic antagonists, cyclooxygenase-2 selectiveinhibitors, neuroleptics, vanilloid receptor agonists, vanilloidreceptor antagonists, β-adrenergics, local anesthetics, corticosteroids,5-HT receptor agonists, 5-HT receptor antagonists, 5-HT_(2A) receptorantagonists, cholinergic analgesics, α₂δ ligands (such as gabapentin orpregabalin), cannabinoid receptor ligands, metabotropic glutamatesubtype 1 receptor antagonists, serotonin reuptake inhibitors,norepinephrine reuptake inhibitors, dual serotonin-noradrenalinereuptake inhibitors, Rho kinase inhibitors, inducible nitric oxidesynthase inhibitors, acetylcholinesterase inhibitors, prostaglandin E₂subtype 4 antagonists, leukotriene B4 antagonists, 5-lipoxygenaseinhibitors, sodium channel blockers, 5-HT₃ antagonists,N-methyl-D-aspartic acid receptor antagonists, and phosphodiesterase Vinhibitors.

In one embodiment, the method comprises administering to the subject atherapeutically effective amount of a compound described herein, or apharmaceutically acceptable salt, with or without a pharmaceuticallyacceptable carrier, in combination with a second therapeutic agentselected from the group consisting of acetaminophen, NSAIDs, opioidanalgesics, and combinations thereof.

In one embodiment, the method comprises administering to the subject atherapeutically effective amount of a compound described herein, or apharmaceutically acceptable salt, with or without a pharmaceuticallyacceptable carrier, in combination with one or more additionaltherapeutic agents for treating pain. In one embodiment, the additionaltherapeutic agent is selected from the group consisting ofacetaminophen, NSAIDs (such aspirin, ibuprofen, and naproxen), andopioid analgesics. In another embodiment, the additional therapeuticagent is acetaminophen. In another embodiment, the additionaltherapeutic agent is an NSAID. In another embodiment, the additionaltherapeutic agent is an opioid analgesic.

The present invention also is directed, in part, to one or morecompounds and/or salts of the invention for use in the treatment of anN-type calcium channel-mediated condition, such as pain.

The present invention also is directed, in part, to one or morecompounds and/or salts of the invention, and, optionally one or moreadditional therapeutic agents, for use as a medicament. In someembodiments, the medicament is for treating pain. In another embodiment,the medicament is for treating neuropathic pain. In another embodiment,the medicament is for treating nociceptive pain. In another embodiment,the medicament is for treating inflammatory pain.

The present invention is further directed, in part, to a use of one ormore compounds and/or salts of the invention, and, optionally one ormore additional therapeutic agents to prepare a medicament. In someembodiments, the medicament is for co-administration with one or moreadditional therapeutic agents. In some embodiments, the medicament isfor treating pain. In some embodiments, the medicament is for treatingneuropathic pain. In some embodiments, the medicament is for treatingnociceptive pain. In some embodiments, the medicament is for treatinginflammatory pain.

F. Intermediate Compounds

This invention also is directed, in part, to novel intermediates thatcan be used to prepare the compounds of Formula (I), and theircorresponding salts, as shown in Schemes 1-13 and as described in theExamples below.

G. Methods for Preparation

This invention also is directed, in part, to a process for preparing acompound of Formula (I), or a pharmaceutically acceptable salt thereof,e.g., as described in any one of the reaction schemes or Examples of thepresent application. This invention also encompasses compounds of theinvention when prepared by metabolic processes. Preparation of thecompounds by metabolic processes includes those occurring in the humanor animal body (in vivo) or processes occurring in vitro.

Unless otherwise noted, the compounds of the invention wherein thegroups R¹, R², and L have the meanings as set forth in the BriefDescription of the Invention and Detailed Description of the Inventionsections can be synthesized as shown in Schemes 1-13. One of skill inthe art will appreciate that the compounds of the invention can beprepared by a variety of processes known for the preparation ofcompounds of this class and that the methods below are representativeand not inclusive of all possible methods for preparing compounds of thepresent invention.

Abbreviations which have been used in the descriptions of the Schemesand the Examples that follow are: APCI for atmospheric pressure chemicalionization; Bn for benzyl; Boc for tert-butoxycarbonyl; Bu for butyl;i-Bu for isobutyl; DIAD for diisopropyl azodicarboxylate; DMSO fordimethyl sulfoxide; ESI for electrospray ionization; Et for ethyl; LCMSfor liquid chromatography-mass spectrometry; HPLC for high performanceliquid chromatography; Me for methyl; MeOH for methanol; Ms formethanesulfonyl; Ph for phenyl; PPh₃ for triphenylphosphine; and psi forpounds per square inch.

As shown in Scheme 1, compounds of Formula (1-7), wherein R¹ and R² areas described in the various embodiments of the invention, can beprepared from a compound of Formula (1-1). A compound of Formula (1-1)can be treated with acrylonitrile in the presence of a base such aspotassium hydroxide in optionally heated water to give compounds ofFormula (1-2). A compound of Formula (1-2) can then be hydrogenated inthe presence of a catalyst such as Raney®-nickel with optional heatingto give the cyclized compound of Formula (1-3). The carbonyl of acompound of Formula (1-3) can then be reduced with lithium aluminumhydride, and the secondary amine thus formed can be protected usingreagents and conditions known to one of skill in the art to givecompounds of Formula (1-4), wherein PG¹ is a nitrogen protecting group.Compounds of Formula (1-4) can be reacted with R¹-Hal¹ (wherein Hal¹ isa halogen such as chlorine, bromine or iodine) with a base such aspotassium tert-butoxide under nucleophilic heteroaromatic substitutionreaction conditions known to one of skill in the art to give compoundsof Formula (1-5). Removal of the protecting group, PG¹, from compoundsof Formula (1-5) provides compounds of Formula (1-6). Reaction ofcompounds of Formula (1-6) with a sulfonyl chloride, R²SO₂Cl, in thepresence of a base such as a tertiary amine gives compounds of Formula(1-7). Compounds of Formula (1-7) are representative of compounds ofFormula (I), including compounds of Formula (I-A).

As shown in Scheme 2, compounds of Formula (2-9), wherein R¹ and R² areas described in the various embodiments of the invention, can beprepared from a compound of Formula (2-1). A compound of Formula (2-1)wherein LG¹ is a leaving group (such as a sulfonate, chlorine, bromineor iodine) can be treated with a compound of Formula (2-2) with optionalheating to give a compound of Formula (2-3). The primary hydroxy moietyin compounds of Formula (2-3) can be converted to a leaving group, LG²(wherein LG² is a leaving group such as a sulfonate, chlorine, bromineor iodine), using conditions known to one of skill in the art to providea compound of Formula (2-4). A compound of Formula (2-4) can be treatedwith a base such as sodium hydride to form a seven-membered ringcompound. Subsequent hydrogenation of the seven-membered ring compoundin the presence of di-tert-butyl dicarbonate removes the benzyl groupand introduces the tert-butoxycarbonyl moiety to give a compound ofFormula (2-5). Treatment of a compound of Formula (2-5) with a base suchas a lithium amide base and a compound of Formula (2-6) results inhydroxylation adjacent to the lactam carbonyl giving a compound ofFormula (2-7). A compound of Formula (2-7) can be reacted with R¹-Hal¹(wherein Hal¹ is a halogen such as chlorine, bromine or iodine) with abase such as sodium hydride under nucleophilic heteroaromaticsubstitution reaction conditions known to one of skill in the art togive compounds of Formula (2-8). The tert-butoxycarbonyl moiety ofcompounds of Formula (2-8) can be removed under acidic conditions andthe exposed secondary amine can be reacted with R²-Hal¹ in the presenceof base such as a tertiary amine base and optional heating to givecompounds of Formula (2-9). Compounds of Formula (2-9) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-C-2).

As shown in Scheme 3, compounds of Formula (3-7) wherein R¹ and R² areas described in the various embodiments of the invention, can beprepared from a compound of Formula (3-1). A compound of Formula (3-1)can be converted to a compound of Formula (3-2) in a three-step process.The first step is conversion of the carboxylic acid to an anhydride bytreatment with a chloroformate in the presence of a base. The mixedanhydride is then reduced to the corresponding primary alcohol with areductant such as sodium borohydride. The sequence is completed withoxidation of the primary alcohol with such reagents as sulfur trioxidepyridine complex or under Swern oxidation conditions to give a compoundof Formula (3-2). A compound of Formula (3-2) can then be reductivelyaminated with ethyl 3-(benzylamino)propanoate to give a compound ofFormula (3-3). The reductive amination can be achieved in the presenceof acetic acid and sodium cyanoborohydride or resin-boundcyanoborohydride. Alternatively, sodium triacetoxyborohydride can beused as the reductant. Removal of the tert-butoxycarbonyl moiety in acompound of Formula (3-3) followed by treatment with a base, such as atertiary amine base, and optional heating results in cyclization to acompound of Formula (3-4). Alternatively, after tert-butoxycarbonylmoiety removal, the intermediate acid salt can be free based with a basesuch as sodium carbonate, and then the free base can be heated in asolvent such as toluene to give the cyclized compound of Formula (3-4).Hydrogenation of a compound of Formula (3-4) in the presence ofdi-tert-butyl dicarbonate removes both benzyl groups and introduces thetert-butoxycarbonyl moiety selectively to give a compound of Formula(3-5). Introduction of R¹ under the heteroaromatic nucleophilicsubstitution reaction conditions described in Schemes 1 and 2 followedby acid removal of the tert-butoxycarbonyl protecting group givescompounds of Formula (3-6). Reaction of compounds of Formula (3-6) witha sulfonyl chloride, R²SO₂Cl, in the presence of a base such as atertiary amine gives compounds of Formula (3-7). Compounds of Formula(3-7) are representative of compounds of Formula (I), includingcompounds of Formula (I-C-1).

As shown in Scheme 4, the stereochemistry of many intermediates can bemanipulated to give diastereomers. For example, the chiral compound ofFormula (4-1) (which can be prepared as described in Scheme 3 for thepreparation of a compound of Formula (3-2) starting from(2S,4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylicacid) can be epimerized with a base such as1,8-diazabicyclo[5.4.0]undec-7-ene in tetrahydrofuran to thediastereomeric mixture of compounds of Formula (4-2). Using the methodspreviously described in Scheme 3, the mixture of compounds of Formula(4-2) can be converted to the compounds of Formula (4-3) and then tocompounds of Formula (4-4) and Formula (4-5). Diastereomeric compoundsof Formula (4-4) and Formula (4-5) can be chromatographically separated.Each diastereomer can then be carried forward independently. Forexample, a compound of Formula (4-5) can be transformed by hydrogenationin the presence of di-tert-butyl dicarbonate to remove both benzylgroups and introduce the tert-butoxycarbonyl moiety selectively to givea compound of Formula (4-6). The stereochemistry of the hydroxy groupcan be inverted in a two-step process. Introduction of a 4-nitrobenzoylgroup under Mitsunobu conditions results in inversion of the hydroxygroup stereocenter. Subsequent hydrolysis of the intermediate4-nitrobenzoyl group provides a compound of Formula (4-7). A compound ofFormula (4-7) can be converted to compounds of Formula (4-8) usingmethodologies described in the above and below Schemes.

As shown in Scheme 5, compounds of Formula (5-1) and Formula (5-2)wherein R¹ and R² are as described in the various embodiments of theinvention can be prepared from a compound of Formula (1-6). Compounds ofFormula (1-6) can be reacted with a carboxylic acid chloride, R²C(O)Cl,in the presence of a base (such as a tertiary amine) to give compoundsof Formula (5-1). Compounds of Formula (1-6) can also be transformed tocompounds of Formula (5-1) by coupling with a carboxylic acid, R²CO₂H.Examples of conditions known to generate amides from a mixture of acarboxylic acid and an amine include but are not limited to adding acoupling reagent such as but not limited toN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, EDAC or EDCI),1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)phosphinicchloride (BOPCl),O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), and2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouroniumhexafluorophosphate(V) (HBTU). The coupling reagents may be added as asolid, a solution, or as the reagent bound to a solid support resin. Inaddition to the coupling reagents, auxiliary-coupling reagents mayfacilitate the coupling reaction. Auxiliary coupling reagents that areoften used in the coupling reactions include but are not limited to(dimethylamino)pyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAT) and1-hydroxybenzotriazole (HOBT). The reaction may be carried outoptionally in the presence of a base such as triethylamine ordiisopropylethylamine. The coupling reaction may be carried out insolvents such as but not limited to tetrahydrofuran,N,N-dimethylformamide, dichloromethane, and ethyl acetate. The reactionmay be conducted at ambient or elevated temperatures. Compounds ofFormula (5-1) are representative of compounds of Formula (I).

Compounds of Formula (1-6) can be reacted with a Het²-Hal² (wherein Het²is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl optionallysubstituted as described for R²; and Hal² is halogen selected fromfluorine, chlorine, bromine or iodine) to give compounds of Formula(5-2). The reaction is performed in the presence of a base, such assodium carbonate, in an optionally heated solvent, such as dimethylsulfoxide. Compounds of Formula (5-2) are representative of compounds ofFormula (I), including compounds of Formula (I-A).

As shown in Scheme 6, compounds of Formula (6-2) wherein R¹ and R² areas described in the various embodiments of the invention can be preparedfrom compounds of Formula (2-8). Compounds of Formula (2-8) can bedeprotected to give compounds of Formula (6-1) upon treatment with acid.For example, treatment with trifluoroacetic acid in dichloromethane,hydrochloric acid in dioxane, or acetyl chloride in methanol willconvert compounds of Formula (2-8) to compounds of Formula (6-1).Reaction of compounds of Formula (6-1) with a sulfonyl chloride,R²SO₂Cl, in the presence of a base such as a tertiary amine givescompounds of Formula (6-2). Compounds of Formula (6-2) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-C-2).

As shown in Scheme 7, compounds of Formula (7-3) wherein R¹ and R² areas described in the various embodiments of the invention can be preparedfrom compounds of Formula (1-3). The hydroxy moiety of compounds ofFormula (1-3) can be protected to give compounds of Formula (7-1),wherein PG² is a hydroxy protecting group such as triethylsilyl ort-butyldimethylsilyl. To install the triethyl silyl protecting group,for examples, compounds of Formula (1-3) can be treated withtriethylsilyl chloride in the presence of imidazole inN,N-dimethylformamide. Compounds of Formula (7-1) can be reacted withR²CH₂-Hal¹ (wherein Hal¹ is a halogen such as chlorine, bromine oriodine) and a base (such as sodium hydride) in a solvent (such asN,N-dimethylformamide) to give compounds of Formula (7-2). Compounds ofFormula (7-2) can be converted to compounds of Formula (7-3) in atwo-step process. In the first step, the protecting group, PG², can beremoved under conditions known to one of skill in the art. In the casewhere PG² is triethylsilyl, treatment with acetic acid in water removesthe protecting group. In the second step, reaction with R¹-Hal¹ (whereinHal¹ is a halogen such as chlorine, bromine or iodine) and a base (suchas potassium tert-butoxide) under nucleophilic heteroaromaticsubstitution reaction conditions known to one of skill in the art givescompounds of Formula (7-3). Compounds of Formula (7-3) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-B-2).

As shown in Scheme 8, compounds of Formula (8-2) wherein R¹ and R² areas described in the various embodiments of the invention can be preparedfrom compounds of Formula (7-1). Compounds of Formula (7-1) can becross-coupled with R²-LG¹ (wherein LG¹ is a leaving group such as asulfonate, chlorine, bromine or iodine) to give compounds of Formula(8-1). One set of cross-coupling conditions is treatment withtris(dibenzylideneacetone)dipalladium(0),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANTPHOS), and cesiumcarbonate in deoxygenated and heated dioxane. Compounds of Formula (8-1)can be converted to compounds of Formula (8-2) in a two-step process. Inthe first step, the protecting group, PG², can be removed underconditions known to one of skill in the art. In the case where PG² istriethylsilyl, treatment with acetic acid in water removes theprotecting group. In the second step, reaction with R¹-Hal¹ (whereinHal¹ is a halogen such as chlorine, bromine or iodine) and a base (suchas potassium tert-butoxide) under nucleophilic heteroaromaticsubstitution reaction conditions known to one of skill in the art givescompounds of Formula (8-2). Compounds of Formula (8-2) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-B-2).

As shown in Scheme 9, compounds of Formula (9-3) wherein R¹ and R² areas described in the various embodiments of the invention can be preparedfrom compounds of Formula (3-5). Compounds of Formula (3-5) can bedeprotected to give compounds of Formula (9-1) upon treatment with acid.For example, treatment with trifluoroacetic acid in dichloromethane,hydrochloric acid in dioxane, or acetyl chloride in methanol willconvert compounds of Formula (3-5) to compounds of Formula (9-1).Compounds of Formula (9-1) can be reacted with a Het²-Hal² (wherein Het²is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl optionallysubstituted as described for R²; and Hal² is halogen selected fromfluorine, chlorine, bromine or iodine) to give compounds of Formula(9-2). The reaction is performed in the presence of a base, such assodium carbonate, in an optionally heated solvent, such as dimethylsulfoxide. The stereochemistry of the hydroxy group of compounds ofFormula (9-2) can optionally be inverted using the Mitsunobu reactionsequence described in Scheme 4 to convert compounds of Formula (4-6) tocompound of Formula (4-7). Reaction of compounds of Formula (9-2) withR¹-Hal¹ (wherein Hal¹ is a halogen such as chlorine, bromine or iodine)with a base (such as potassium tert-butoxide) under nucleophilicheteroaromatic substitution reaction conditions known to one of skill inthe art gives compounds of Formula (9-3). Compounds of Formula (9-3) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-C-1).

As illustrated in Scheme 10, compounds of Formula (3-6) can be convertedto compounds of Formulas (10-1), (10-2), (10-3) and (10-4), wherein R¹and R² are as described in the various embodiments of the invention.Compounds of Formula (3-6) can be reacted with a carboxylic acidchloride (R²C(O)Cl) in the presence of a base (such as a tertiary amine)to give compounds of Formula (10-1). Compounds of Formula (3-6) also canbe transformed to compounds of Formula (10-1) by coupling with acarboxylic acid (R²CO₂H). Examples of conditions known to generateamides from a mixture of a carboxylic acid and an amine include but arenot limited to adding a coupling reagent such as but not limited toN-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, EDAC or EDCI),1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)phosphinicchloride (BOPCl),O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), and2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouroniumhexafluorophosphate(V) (HBTU). The coupling reagents may be added as asolid, a solution, or as the reagent bound to a solid support resin. Inaddition to the coupling reagents, auxiliary-coupling reagents mayfacilitate the coupling reaction. Auxiliary coupling reagents that areoften used in the coupling reactions include but are not limited to(dimethylamino)pyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAT) and1-hydroxybenzotriazole (HOBT). The reaction may be carried outoptionally in the presence of a base such as triethylamine ordiisopropylethylamine. The coupling reaction may be carried out insolvents such as but not limited to tetrahydrofuran,N,N-dimethylformamide, dichloromethane, and ethyl acetate. The reactionmay be conducted at ambient or elevated temperatures. Compounds ofFormula (10-1) are representative of compounds of Formula (I), includingcompounds of Formula (I-C-1).

Compounds of Formula (3-6) can be reacted with R²CH₂C(O)Cl or R²CH₂CO₂Husing the methodology described above to give compounds of Formula(10-2). Compounds of Formula (10-2) are representative of compounds ofFormula (I).

Compounds of Formula (3-6) can be reacted with R²CH(OH)CO₂H using thecoupling methodology described above for joining a carboxylic acid andamine to give compounds of Formula (10-3). Compounds of Formula (10-3)are representative of compounds of Formula (I), including compounds ofFormula (I-C-1).

Compounds of Formula (10-3) can be converted to compounds of Formula(10-4) in a two-step process. In the first step, the hydroxy moiety canbe converted to the corresponding sulfonate by treatment withmethanesulfonyl chloride in the presence of a tertiary amine. In thesecond step, treatment of the intermediate sulfonate withHNR^(a1)R^(a2), wherein R^(a1) and R^(a2) are each independently eitherhydrogen or independently selected C₁-C₆-alkyl, with optional heatinggives compounds of Formula (10-4). Compounds of Formula (10-4) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-C-1).

As shown in Scheme 11, compounds of Formula (3-6) can be converted tocompounds of Formulas (11-1) and (11-2), wherein R¹ and R² are asdescribed in the various embodiments of the invention. Compounds ofFormula (3-6) can be reductively aminated with aldehydes, R²CHO, to givecompounds of Formula (11-1). The reductive amination can be achieved inthe presence of acetic acid and sodium cyanoborohydride or resin-boundcyanoborohydride. Alternatively, sodium triacetoxyborohydride can beused as the reductant. Compounds of Formula (11-1) are representative ofcompounds of Formula (I), including compounds of Formula (I-C-1).

Compounds of Formula (3-6) can also be reacted with a Het²-Hal² (whereinHet² is pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl optionallysubstituted as described for R²; and Hal² is halogen selected fromfluorine, chlorine, bromine or iodine) to give compounds of Formula(11-2). The reaction is performed in the presence of a base (such assodium carbonate) in an optionally heated solvent (such as dimethylsulfoxide). Compounds of Formula (11-2) are representative of compoundsof Formula (I), including compounds of Formula (I-C-1).

As shown in Scheme 12, compounds of Formula (12-5), Formula (12-6),Formula (12-7), and Formula (12-8) wherein R¹ and R² are as described inthe various embodiments of the invention can be prepared from a compoundof Formula (12-1). Compounds of Formula (12-1) wherein PG³ is a suitablehydroxy protecting group can be converted to compounds of Formula (12-2)in a two-step process. Initially, the primary hydroxy group can beconverted to a leaving group such as a sulfonate, chlorine, bromine oriodine using methodology known to one of skill in the art. For example,treatment with methanesulfonyl chloride in the presence of a tertiaryamine yields the corresponding sulfonate. Then, displacement of theleaving group upon treatment with sodium azide gives compounds ofFormula (12-2). The tert-butoxycarbonyl moiety can be removed bytreatment with an acid, and then reaction with ethyl acrylate givescompounds of Formula (12-3). Reduction of the azide of compounds ofFormula (12-3) gives the corresponding amines that cyclize upon warmingto give compounds of Formula (12-4). Compounds of Formula (12-4) can bereacted using the methodology described in Scheme 7 to convert compoundsof Formula (7-1) to compounds of Formula (7-3) to give compounds ofFormula (12-5). The conditions for the removal of PG³ are dependent uponthe particular protecting group employed and are known to one of skillin the art. Compounds of Formula (12-5) are representative of compoundsof Formula (I), including compounds of Formula (I-B-1).

Compounds of Formula (12-4) can also be transformed to compounds ofFormula (12-6). This transformation is accomplished using themethodology described in Scheme 8 for the conversion of compounds ofFormula (7-1) to compounds of Formula (8-2). Compounds of Formula (12-6)are representative of compounds of Formula (I), including compounds ofFormula (I-B-1).

Compounds of Formula (12-7) and Formula (12-8) can also be obtained fromcompounds of Formula (12-4). Compounds of Formula (12-4) can be acylatedwith R²C(O)Cl or R²CH(R⁴)C(O)Cl in the presence of a base. Subsequentremoval of PG³ and introduction of R¹ with a nucleophilic heteroaromaticsubstitution reaction give compounds of Formula (12-7) and Formula(12-8). A protecting group may be required for the acylation step whenR⁴ is hydroxy or amino, wherein amino is optionally substituted with oneC₁-C₆-alkyl. The protecting group can be removed after the introductionof R¹ to give compounds of Formula (12-7) and Formula (12-8).Alternatively, R⁴ can be converted from a hydroxy group to an aminomoiety, —NR^(a1)R^(a2), using the methodology described in theconversion of compounds of Formula (10-3) to compounds of Formula(10-4). Compounds of Formula (12-7) and Formula (12-8) arerepresentative of compounds of Formula (I), including compounds ofFormula (I-B-1).

As shown in Scheme 13, compounds of Formula (12-4) and Formula (12-5)wherein R¹ and R² are as described in the various embodiments of theinvention can be prepared from a compound of Formula (13-1). Compoundsof Formula (13-1), wherein PG³ is a suitable hydroxy protecting groupcan be converted to compounds of Formula (13-2) by reductive aminationwith H₂NCH₂R². Compounds of Formula (13-2) can be reacted with acryloylchloride to give compounds of Formula (13-3). Upon acidic treatment toremove the ten-butoxycarbonyl moiety and subsequent heating, compoundsof Formula 13-3 are transformed to compounds of Formula (13-4). Removalof the protecting group, PG³, of Formula (13-4) followed by reactionwith R¹-Hal¹ in the presence of base delivers compounds of Formula(12-5). The conditions for the removal of PG³ are dependent upon theparticular protecting group employed and are known to one of skill inthe art. Hal¹ is a halogen such as chlorine, bromine or iodine.Compounds of Formula (12-5) are representative of compounds of Formula(I), including compounds of Formula (I-B-1).

When R² is phenyl in compounds of Formula (13-4), catalytic reduction orreaction with sodium in ammonia converts compounds of Formula (13-4) tocompounds of Formula (12-4). Compounds of Formula (12-4) can be furtherreacted as described in Scheme 12.

Optimum reaction conditions and reaction times for each individual stepcan vary depending on the particular reactants employed and substituentspresent in the reactants used. Unless otherwise specified, solvents,temperatures and other reaction conditions can be readily selected byone of ordinary skill in the art. Specific procedures are provided inthe Examples section. Reactions can be worked up in the conventionalmanner, e.g., by eliminating the solvent from the residue and furtherpurified according to methodologies generally known in the art such as,but not limited to, crystallization, distillation, extraction,trituration and chromatography. Unless otherwise described, the startingmaterials and reagents are either commercially available or can beprepared by one skilled in the art from commercially available materialsusing methods described in the chemical literature.

Routine experimentations, including appropriate manipulation of thereaction conditions, reagents and sequence of the synthetic route,protection of any chemical functionality that cannot be compatible withthe reaction conditions, and deprotection at a suitable point in thereaction sequence of the method are included in the scope of theinvention. Suitable protecting groups and the methods for protecting anddeprotecting different substituents using such suitable protectinggroups are well known to those skilled in the art; examples of which canbe found in T. Greene and P. Wuts, Protective Groups in OrganicSynthesis (3^(rd) ed.), John Wiley & Sons, NY (1999), which isincorporated herein by reference in its entirety. Synthesis of thecompounds of the invention can be accomplished by methods analogous tothose described in the synthetic schemes described hereinabove and inspecific examples.

Starting materials, if not commercially available, can be prepared byprocedures selected from standard organic chemical techniques,techniques that are analogous to the synthesis of known, structurallysimilar compounds, or techniques that are analogous to the abovedescribed schemes or the procedures described in the synthetic examplessection.

When an optically active form of a compound of the invention isrequired, it can be obtained by carrying out one of the proceduresdescribed herein using an optically active starting material (prepared,for example, by asymmetric induction of a suitable reaction step), or byresolution of a mixture of the stereoisomers of the compound orintermediates using a standard procedure (such as chromatographicseparation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound of the inventionis required, it can be obtained by carrying out one of the aboveprocedures using a pure geometric isomer as a starting material, or byresolution of a mixture of the geometric isomers of the compound orintermediates using a standard procedure such as chromatographicseparation.

It can be appreciated that the synthetic schemes and specific examplesas illustrated in the Examples section are illustrative and are not tobe read as limiting the scope of the invention as it is defined in theappended claims. All alternatives, modifications, and equivalents of thesynthetic methods and specific examples are included within the scope ofthe claims.

H. Examples

The following examples are merely illustrative, and not limiting to thisdisclosure in any way.

Example 1 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepane

Part A. Preparation of methyl(4R)-1-(2-cyanoethyl)-4-hydroxy-L-prolinate

To a solution of methyl (4R)-4-hydroxy-L-prolinate hydrochloride (4.53g, 25 mmol) in water (10 mL) was added acrylonitrile (6.63 g, 125 mmol).The mixture was stirred while heating at 50° C., and a solution ofpotassium hydroxide (1.403 g, 25 mmol) in water (15 mL) was addeddropwise. The resulting mixture was heated to 70° C. and stirred for twohours. The cooled mixture was extracted with diethyl ether (4×25 mL).The combined ether extracts were dried with MgSO4, filtered, andconcentrated in vacuo. The residue was purified by column chromatographyon silica gel using a solvent gradient of 2-5% methanol indichloromethane to obtain desired the title compound as colorless oil(2.3 g, 46%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 4.95-4.87 (m, 1H),4.26-4.17 (m, 1H), 3.62 (s, 3H), 3.50 (t, J=7.6, 1H), 3.27-3.15 (m, 1H),2.98-2.87 (m, 1H), 2.76-2.66 (m, 1H), 2.67-2.56 (m, 2H), 2.41-2.33 (m,1H), 1.99 (ddd, J=12.8, 7.4, 6.4, 1H), 1.93-1.83 (m, 1H); MS (ESI) m/z199 (M+H)+.

Part B. Preparation of(8R,9aS)-8-hydroxyoctahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

A mixture of the product from Part A (1.3 g, 6.56 mmol), methanol (40mL), and Raney®-nickel 2800, water slurry (1.30 g, 22.2 mmol) in a 250mL stainless steel pressure bottle was stirred for six hours underhydrogen (60 psi) at 80° C. The mixture was filtered through a nylonmembrane and concentrated in vacuo to give the title compound as a waxysolid (1.05 g, 94%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.48 (bs, 1H), 4.79(bs, 1H), 4.03 (p, J=6.3, 1H), 3.29-3.10 (m, 3H), 3.12-2.84 (m, 2H),2.43 (dd, J=12.0, 3.0, 1H), 2.24 (dd, J=9.1, 6.6, 1H), 1.69-1.42 (m,3H); MS (ESI) m/z 171 (M+H)⁺.

Part C. Preparation of tert-butyl(8R,9aS)-8-hydroxyhexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a stirred solution of the product from Part B (0.60 g, 3.53 mmol) intetrahydrofuran (15 mL) at 10° C., was slowly added a 2.0 M solution oflithium aluminum hydride in tetrahydrofuran (5.29 mL, 10.58 mmol). Theresulting mixture was stirred at 65° C. for 48 hours. The mixture wascooled to 0-5° C., and quenched by the dropwise addition of ethylacetate (5 mL), water (1 mL), 10% aqueous NaOH solution (1 mL), andwater (1 mL). The resulting mixture was stirred at room temperature for30 minutes and filtered through diatomaceous earth. The filtrate wasconcentrated in vacuo, and the crude oily product was dissolved in a 1:1mixture of acetonitrile:water (30 mL). Triethylamine (0.606 g, 0.835 mL,5.99 mmol) was added, followed by di-tert-butyl dicarbonate (0.923 g,4.23 mmol). The resulting mixture was stirred at room temperature for 16hours, and then it was concentrated in vacuo to remove acetonitrile. Theresulting aqueous mixture was extracted with ethyl acetate, and theorganic extract was dried over MgSO₄, filtered, and concentrated invacuo. The residue was purified by column chromatography on silica gelusing a solvent gradient of 2-15% methanol in dichloromethane to givethe title compound as color less oil (0.235 g, 26%). ¹H NMR (400 MHz,pyridine-d₅) δ ppm 4.56-4.46 (m, 1H), 3.64-3.53 (m, 1H), 3.53-3.40 (m,3H), 3.00-2.83 (m, 3H), 2.58 (dd, J=9.3, 5.6, 1H), 2.41-2.30 (m, 1H),2.16-1.95 (m, 1H), 1.84-1.68 (m, 3H), 1.50 (s, 9H); MS (ESI) m/z 257(M+H)⁺.

Part D. Preparation of tert-butyl(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of the product from Part C (180 mg, 0.702 mmol) intetrahydrofuran (4 mL), was added a 1.0 M solution of potassiumtert-butoxide (0.983 mL, 0.983 mmol), followed by a solution of2-bromo-5-cyclopropylpyrazine (168 mg, 0.843 mmol) in tetrahydrofuran (2mL). The mixture was stirred at room temperature for 48 hours, and thenit was concentrated in vacuo. The residue was dissolved in ethyl acetate(20 mL), washed successively with water and brine, and dried over MgSO₄.The solution was filtered and concentrated in vacuo, and the crudeproduct was purified by column chromatography on silica gel using 30%hexanes in ethyl acetate. The title compound was obtained as a waxysolid (0.120 g, 45.6%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.11(d, J=1.5 Hz, 1H), 8.01 (d, J=1.5 Hz, 1H), 5.32-5.43 (m, 1H), 3.56-3.69(m, 1H), 3.40-3.51 (m, 1H), 2.76-2.99 (m, 3H), 2.56 (dd, J=10.1, 5.5 Hz,1H), 2.29-2.38 (m, 1H), 1.86-2.08 (m, 3H), 1.72-1.83 (m, 2H), 1.51 (s,9H), 0.97-1.03 (m, 2H), 0.84-0.90 (m, 2H); MS (ESI) m/z 375 (M+H)⁺.

Part E. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepane

To a solution of the product from Part D (0.050 g, 0.134 mmol) inanhydrous methanol (2 mL) was added 4 M HCl in 1,4-dioxane (0.167 mL,0.668 mmol). The resulting mixture was stirred at room temperature for18 hours, and then it was concentrated in vacuo. To the residue wasadded dichloromethane (2 mL), 3-(trifluoromethyl)benzene-1-sulfonylchloride (0.033 g, 0.134 mmol), and triethylamine (0.093 mL, 0.668mmol). The resulting mixture was stirred at room temperature for 16hours, and then it was partitioned between water and ethyl acetate. Theorganic extract was washed successively with water and brine, dried withMgSO4, filtered, and concentrated in vacuo. The crude product waspurified by column chromatography on silica gel using a solvent gradientof 0-4% methanol in dichloromethane to give the title compound as acolorless solid (0.039 g, 60% yield). ¹H NMR (400 MHz, pyridine-d₅, 90°C.) δ ppm 8.46 (bs, 1H), 8.30-8.24 (m, 1H), 8.22 (d, J=1.4, 1H), 8.11(d, J=1.4, 1H), 7.93-7.87 (m, 1H), 7.72 (t, J=7.9, 1H), 5.37-5.29 (m,1H), 4.06 (d, J=11.8, 1H), 3.69-3.55 (m, 2H), 3.45 (dt, J=13.4, 5.7,1H), 2.98-2.82 (m, 3H), 2.53 (dd, J=10.2, 5.1, 1H), 2.42-2.33 (m, 1H),2.08-1.96 (m, 2H), 1.95-1.85 (m, 1H), 1.83-1.72 (m, 2H), 1.12-1.02 (m,2H), 0.98-0.87 (m, 2H); MS (ESI) m/z 483 (M+H)⁺.

Example 2 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepane

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 4-(trifluoromethyl) benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400MHz, pyridine-d₅, 90° C.) δ ppm 8.23 (d, J=1.2, 2H), 8.21 (s, 1H), 8.11(d, J=1.4, 1H), 7.91 (s, 1H), 7.90 (s, 1H), 5.38-5.30 (m, 1H), 4.10-3.98(m, 1H), 3.67-3.58 (m, 2H), 3.47-3.39 (m, 1H), 2.97-2.87 (m, 3H), 2.54(dd, J=10.2, 5.1, 1H), 2.41 (dd, J=13.1, 6.5, 1H), 2.10-1.97 (m, 2H),1.99-1.88 (m, 1H), 1.78 (p, J=5.8, 2H), 1.14-1.02 (m, 2H), 1.02-0.85 (m,2H); MS (ESI) m/z 483 (M+H)⁺.

Example 3 Preparation of(8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

Part A. Preparation of tert-butyl(9aS)-7-oxo-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}hexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of the product from Example 21, Part G (0.10 g, 0.370mmol) in anhydrous N,N-dimethylformamide (4 mL) at 0° C. under N₂ wasadded sodium hydride (60% suspension in mineral oil) (0.016 g, 0.407mmol), followed by 2-bromo-5-(trifluoromethyl)pyridine (0.125 g, 0.555mmol). The resulting mixture was stirred at room temperature for fourhours, and then it was partitioned between water and ethyl acetate. Theorganic extract were dried over Na₂SO₄, the drying agent was removed byfiltration, and the solution was concentrated in vacuo to give a crudeproduct that was purified by column chromatography on silica gel using asolvent gradient of 0-5% methanol in dichloromethane. The title compoundwas obtained as a colorless solid (0.113 g, 74%).

Part B. Preparation of(9aS)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-onehydrochloride

A solution of the product from Part A (0.109 g, 0.262 mmol) in1,4-dioxane (1.3 mL) was treated with hydrogen chloride (4 N in1,4-dioxane, 0.066 mL, 0.262 mmol). The resulting mixture was stirred atroom temperature for 90 minutes, and then it was concentrated and driedin vacuo to give the title compound.

Part C. Preparation of(8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

To a solution of the product from Part B (46.1 mg, 0.131 mmol) andtriethylamine (0.055 mL, 0.393 mmol) in dichloromethane (1.5 mL) wasadded 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.025 mL, 0.157mmol). The resulting mixture was stirred at room temperature for twohours, and then it was partitioned between water and dichloromethane(3×). The organic extracts were combined and dried over Na₂SO₄, thedrying agent was removed by filtration, and the solution wasconcentrated in vacuo to give a crude product that was purified bycolumn chromatography on silica gel using a solvent gradient of 0-5%methanol in dichloromethane. The title compound was the first of twostereoisomers to elute, and it was obtained as a colorless solid (6.5mg, 9%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.88-2.07 (m, 3H) 2.83-2.95 (m,1H) 2.97-3.11 (m, 1H) 3.22-3.34 (m, 2H) 3.35-3.46 (m, 1H) 3.53 (dd,J=14.80, 3.20 Hz, 1H) 3.82-3.92 (m, 1H) 4.12-4.23 (m, 1H) 5.73 (t,J=8.39 Hz, 1H) 6.95 (d, J=8.85 Hz, 1H) 7.71 (t, J=7.78 Hz, 1H) 7.81 (dd,J=8.70, 2.29 Hz, 1H) 7.88 (d, J=7.93 Hz, 1H) 7.99 (d, J=7.93 Hz, 1H)8.04 (s, 1H) 8.41 (s, 1H); MS (APCI) m/z 524 (M+H)⁺.

Example 4 Preparation of(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

The title compound was obtained from the procedure described for Example3, Part C, and was the second of two stereoisomers to elute duringchromatography (40 mg, 58%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.92-2.11 (m,2H) 2.23-2.36 (m, 1H) 2.37-2.48 (m, 1H) 3.01 (dd, J=14.19, 8.09 Hz, 1H)3.08-3.20 (m, 2H) 3.51-3.64 (m, 1H) 3.77 (dd, J=14.34, 3.36 Hz, 1H)3.98-4.08 (m, 1H) 4.13-4.24 (m, 1H) 5.69 (dd, J=7.93, 5.19 Hz, 1H) 6.91(d, J=8.85 Hz, 1H) 7.71 (t, J=7.93 Hz, 1H) 7.81 (dd, J=8.54, 2.44 Hz,1H) 7.88 (d, J=7.93 Hz, 1H) 7.99 (d, J=7.93 Hz, 1H) 8.06 (s, 1H) 8.41(s, 1H); MS (APCI) m/z 524 (M+H)⁺.

Example 5 Preparation of(8S,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

The title compound was obtained according to the procedures described inExample 3, Part C, substituting 4-(trifluoromethyl)benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride, and it wasthe first of two stereoisomers to elute during chromatography. ¹H NMR(400 MHz, CDCl₃) δ ppm 1.86-2.07 (m, 3H) 2.82-2.95 (m, 1H) 2.96-3.08 (m,1H) 3.22-3.34 (m, 2H) 3.35-3.45 (m, 1H) 3.52 (dd, J=14.80, 3.20 Hz, 1H)3.81-3.92 (m, 1H) 4.11-4.22 (m, 1H) 5.73 (t, J=8.39 Hz, 1H) 6.95 (d,J=8.85 Hz, 1H) 7.81 (d, J=8.24 Hz, 3H) 7.92 (d, J=8.24 Hz, 2H) 8.41 (s,1H); MS (APCI) m/z 524 (M+H)⁺.

Example 6 Preparation of(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

The title compound was obtained according to the procedures described inExample 3, Part C, substituting 4-(trifluoromethyl)benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride, and was thesecond of two stereoisomers to elute during chromatography. ¹H NMR (400MHz, CDCl₃) δ ppm 1.92-2.12 (m, 2H) 2.23-2.34 (m, 1H) 2.36-2.47 (m, 1H)3.00 (dd, J=14.19, 8.09 Hz, 1H) 3.07-3.20 (m, 2H) 3.51-3.63 (m, 1H) 3.76(dd, J=14.19, 3.20 Hz, 1H) 3.97-4.09 (m, 1H) 4.12-4.24 (m, 1H) 5.69 (dd,J=8.09, 5.34 Hz, 1H) 6.91 (d, J=8.54 Hz, 1H) 7.76-7.86 (m, 3H) 7.93 (d,J=8.24 Hz, 2H) 8.41 (s, 1H); MS (APCI) m/z 524 (M+H)⁺.

Example 7 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 3-(trifluoromethyl)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 8.12 (d, J=1.4, 1H), 8.00 (d, J=1.4, 1H),7.90 (bs, 1H), 7.74-7.67 (m, 1H), 7.68-7.61 (m, 1H), 7.47 (t, J=1.4,1H), 5.41-5.34 (m, 1H), 3.75-3.43 (m, 4H), 3.12 (dd, J=13.7, 9.7, 1H),3.07-2.84 (m, 3H), 2.60 (dd, J=10.2, 5.1, 1H), 2.46-2.35 (m, 1H),2.29-1.18 (m, 4H), 1.14-0.93 (m, 2H), 0.95-0.74 (m, 2H); MS (ESI) m/z447 (M+H)⁺.

Example 8 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl](4-fluorophenyl)methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 4-fluorobenzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 8.23 (d, J=1.2, 2H), 8.21 (s, 1H), 8.11 (d,J=1.4, 1H), 7.91 (s, 1H), 7.90 (s, 1H), 5.38-5.30 (m, 1H), 4.10-3.98 (m,1H), 3.67-3.58 (m, 2H), 3.47-3.39 (m, 1H), 2.97-2.87 (m, 3H), 2.54 (dd,J=10.2, 5.1, 1H), 2.41 (dd, J=13.1, 6.5, 1H), 2.10-1.97 (m, 2H),1.99-1.88 (m, 1H), 1.78 (p, J=5.8, 2H), 1.14-1.02 (m, 2H), 1.02-0.85 (m,2H); MS (ESI) m/z 397 (M+H)⁺.

Example 9 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethoxy)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 3-(trifluoromethoxy)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.27-8.19 (m, 1H), 8.15-8.07 (m, 1H), 7.63-7.54 (m,2H), 7.49 (dd, J=15.1, 7.5 Hz, 1H), 7.41-7.30 (m, 1H), 5.46-5.29 (m,1H), 3.99-3.84 (m, 1H), 3.79-3.65 (m, 2H), 3.54-3.34 (m, 1H), 3.16 (dt,J=13.7, 10.1 Hz, 1H), 3.08-2.92 (m, 2H), 2.63-2.52 (m, 1H), 2.45-2.29(m, 1H), 2.19-1.70 (m, 4H), 1.62-1.21 (m, 1H), 1.12-1.03 (m, 2H),1.00-0.84 (m, 2H); MS (ESI) m/z 463 (M+H)⁺.

Example 10 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-3-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 2-fluoro-3-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400MHz, pyridine-d₅) δ ppm 8.22 (dd, J=26.1, 1.4 Hz, 1H), 8.10 (dd, J=22.0,1.4 Hz, 1H), 7.91-7.79 (m, 1H), 7.68 (dt, J=22.5, 7.0 Hz, 1H), 7.42-7.30(m, 1H), 5.45-5.29 (m, 1H), 4.57 (dd, J=13.7, 2.0 Hz, 1H), 3.98-3.89 (m,1H), 3.76-3.59 (m, 2H), 3.54-3.32 (m, 1H), 3.26-3.11 (m, 1H), 3.08-2.77(m, 2H), 2.63-2.51 (m, 1H), 2.45-2.31 (m, 1H), 2.16-1.75 (m, 4H),1.13-0.98 (m, 2H), 1.00-0.86 (m, 2H); MS (ESI) m/z 465 (M+H)⁺.

Example 11 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][5-(trifluoromethyl)pyridin-2-yl]methanone

To a solution of the product from Example 1, Part D (50 mg, 0.134 mmol)in anhydrous methanol (2 mL) was added 4 M HCl in 1,4-dioxane (0.334 mL,1.335 mmol), and the resulting mixture was stirred at room temperaturefor 18 hours and concentrated in vacuo. The residue was dissolved in amixture of dichloromethane (8 mL) and triethylamine (0.093 mL, 0.668mmol), and then 5-(trifluoromethyl)picolinic acid (0.026 g, 0.134 mmol),1-hydroxybenzotriazole hydrate (0.025 g, 0.160 mmol) andN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (0.031 g,0.160 mmol) were added. The resulting mixture was stirred at roomtemperature for 16 hours, and then it was partitioned between water andethyl acetate. The organic extract was washed successively with waterand brine, dried over MgSO₄, and filtered. The filtrate was concentratedin vacuo. The crude product was purified by column chromatography onsilica gel using a solvent gradient of 0-4% methanol in dichloromethaneto give the title compound as a waxy solid (0.042 g, 70%). ¹H NMR (400MHz, pyridine-d₅) δ ppm 9.05-8.97 (m, 1H), 8.28-8.13 (m, 2H), 8.11 (dd,J=19.6, 1.4 Hz, 1H), 8.00 (dd, J=18.4, 8.2 Hz, 1H), 5.45-5.32 (m, 1H),4.59 (dd, J=13.5, 2.2 Hz, 1H), 4.14-3.95 (m, 1H), 3.85-3.68 (m, 1H),3.59 (dd, J=12.1, 6.0 Hz, 2H), 3.18 (ddd, J=17.4, 13.7, 9.8 Hz, 1H),3.10-2.94 (m, 2H), 2.64-2.53 (m, 1H), 2.51-2.38 (m, 1H), 2.16-1.70 (m,4H), 1.14-0.98 (m, 2H), 0.99-0.84 (m, 2H); MS (ESI) m/z 448 (M+H)⁺.

Example 12 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][6-(trifluoromethyl)pyridin-2-yl]methanone

The title compound was prepared according to the procedure described inExample 11, substituting 6-(trifluoromethyl)picolinic acid for5-(trifluoromethyl)picolinic acid. ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.24 (dd, J=6.2, 1.4 Hz, 1H), 8.15-7.97 (m, 3H), 7.83-7.72 (m, 1H),5.44-5.34 (m, 1H), 4.17-3.95 (m, 1H), 3.77-3.67 (m, 2H), 3.63-3.55 (m,2H), 3.20-3.08 (m, 1H), 3.05-2.92 (m, 2H), 2.59 (dd, J=10.4, 5.2 Hz,1H), 2.50-2.35 (m, 1H), 2.16-1.72 (m, 4H), 1.15-0.98 (m, 2H), 1.00-0.81(m, 2H); MS (ESI) m/z 448 (M+H)⁺.

Example 13 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 4-(trifluoromethyl)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.23 (d, J=24.4 Hz, 1H), 8.11 (dd, J=27.2, 0.8 Hz,1H), 7.81-7.75 (m, 2H), 7.77-7.71 (m, 2H), 5.46-5.29 (m, 1H), 4.56 (dd,J=13.6, 1.6 Hz, 1H), 4.00-3.85 (m, 1H), 3.78-3.66 (m, 2H), 3.61 (s, 1H),3.54-3.32 (m, 1H), 3.17 (dt, J=13.6, 10.0 Hz, 1H), 3.02 (ddt, J=26.2,12.5, 4.3 Hz, 2H), 2.82 (q, J=7.2 Hz, 1H), 2.59 (ddd, J=18.3, 10.2, 5.3Hz, 1H), 2.44-2.29 (m, 1H), 2.18-1.72 (m, 3H), 1.15-1.01 (m, 2H),0.98-0.88 (m, 2H); MS (ESI) m/z 447 (M+H)⁺.

Example 14 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 4-fluoro-3-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl) benzene-1-sulfonyl chloride. ¹H NMR(500 MHz, pyridine-d₅) δ ppm 8.28-8.19 (m, 1H), 8.15-8.01 (m, 2H),7.91-7.80 (m, 1H), 7.46-7.29 (m, 1H), 5.45-5.30 (m, 1H), 4.55 (d, J=13.6Hz, 1H), 4.00-3.81 (m, 1H), 3.76-3.67 (m, 2H), 3.62 (d, J=5.0 Hz, 1H),3.58-3.37 (m, 1H), 3.27-3.11 (m, 1H), 3.09-2.88 (m, 1H), 2.63-2.53 (m,1H), 2.50-2.29 (m, 1H), 2.10-1.76 (m, 3H), 1.12-1.04 (m, 2H), 0.96-0.88(m, 2H); MS (ESI) m/z 465 (M+H)⁺.

Example 15 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-fluoro-4-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 3-fluoro-4-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.28-8.19 (m, 1H), 8.15-8.05 (m, 1H), 7.79-7.60(m, 2H), 7.52 (dd, J=19.8, 7.9 Hz, 1H), 5.45-5.29 (m, 1H), 4.55 (d,J=13.6 Hz, 1H), 3.89 (t, J=5.9 Hz, 1H), 3.76-3.68 (m, 1H), 3.62 (d,J=5.2 Hz, 1H), 3.55-3.33 (m, 1H), 3.16 (ddd, J=26.6, 13.7, 9.9 Hz, 1H),3.08-2.92 (m, 2H), 2.63-2.53 (m, 1H), 2.49-2.30 (m, 1H), 2.19-1.74 (m,4H), 1.14-1.01 (m, 2H), 1.03-0.85 (m, 2H); MS (ESI) m/z 465 (M+H)⁺.

Example 16 Preparation of(3-chloro-4-fluorophenyl)[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 3-chloro-4-fluorobenzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.22 (dd, J=22.2, 11.5 Hz, 1H), 8.16-8.04 (m, 1H),7.86-7.70 (m, 1H), 7.56-7.46 (m, 1H), 7.34-7.23 (m, 1H), 5.66 (q, J=5.3Hz, 0.5H), 5.50-5.29 (m, 1H), 4.60-4.46 (m, 0.5H), 3.96-3.82 (m, 1H),3.79-3.67 (m, 2H), 3.55-3.33 (m, 1H), 3.25-3.06 (m, 1H), 3.06-2.92 (m,2H), 2.89-2.75 (m, 1H), 2.66-2.51 (m, 1H), 2.45-2.26 (m, 1H), 2.20-1.76(m, 3H), 1.17-1.01 (m, 2H), 0.99-0.86 (m, 2H); MS (ESI) m/z 431 (M+H)⁺.

Example 17 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-5-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 2-fluoro-5-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.23 (dd, J=28.8, 1.3 Hz, 1H), 8.17-8.00 (m,2H), 7.78-7.65 (m, 1H), 7.35 (dt, J=28.4, 8.8 Hz, 1H), 5.66 (q, J=5.3Hz, 0.5H), 5.44-5.27 (m, 1H), 4.59 (dd, J=13.7, 1.9 Hz, 0.5H), 3.95 (t,J=5.9 Hz, 1H), 3.79-3.54 (m, 3H), 3.52-3.32 (m, 1H), 3.25-3.09 (m, 1H),3.08-2.88 (m, 2H), 2.61-2.51 (m, 1H), 2.44-2.31 (m, 1H), 2.15-1.73 (m,3H), 1.15-0.98 (m, 2H), 0.99-0.79 (m, 2H); MS (ESI) m/z 465 (M+H)⁺.

Example 18 Preparation of[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-4-(trifluoromethyl)phenyl]methanone

The title compound was prepared according to the procedure described inExample 1, Part E, substituting 2-fluoro-4-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.23 (dd, J=30.2, 1.4 Hz, 1H), 8.09 (dd, J=31.0,1.4 Hz, 1H), 7.81-7.70 (m, 1H), 7.63 (t, J=9.8 Hz, 1H), 7.54 (d, J=7.9Hz, 1H), 5.67 (d, J=5.2 Hz, 0.5H), 5.44-5.28 (m, 1H), 4.58 (dd, J=13.6,1.9 Hz, 0.5H), 4.03-3.84 (m, 1H), 3.75-3.67 (m, 1H), 3.69-3.59 (m, 1H),3.51-3.32 (m, 1H), 3.17 (ddd, J=23.6, 13.8, 9.9 Hz, 1H), 3.07-2.92 (m,1H), 2.82 (s, 1H), 2.63-2.53 (m, 1H), 2.50-2.33 (m, 1H), 2.18-1.73 (m,4H), 1.38-0.98 (m, 2H), 1.00-0.83 (m, 2H); MS (ESI) m/z 465 (M+H)⁺.

Example 19 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepane

To a solution of the product from Example 1, Part D (60 mg, 0.160 mmol)in anhydrous methanol (2 mL) was added 4 M HCl in 1,4-dioxane (0.40 mL,1.60 mmol), and the resulting mixture was stirred at room temperaturefor 18 hours and then concentrated in vacuo. The residue was dissolvedin dimethyl sulfoxide (1 mL), and sodium carbonate (0.085 g, 0.801 mmol)and 2-chloro-5-(trifluoromethyl)pyridine (0.038 g, 0.208 mmol) wereadded. The resulting mixture was stirred at 115° C. for 16 hours. Thecooled mixture was partitioned between water and ethyl acetate. Theorganic extract was washed successively with water and brine, dried overMgSO₄, filtered, and concentrated in vacuo. The crude product waspurified by column chromatography on silica gel using a solvent gradientof 0-4% methanol in dichloromethane to give the title compound as a waxysolid (0.046 g, 68.4% yield). ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.69-8.57 (m, 1H), 8.24 (d, J=1.4 Hz, 1H), 8.13 (d, J=1.4 Hz, 1H), 7.76(dd, J=9.0, 2.6 Hz, 1H), 6.66 (d, J=9.0 Hz, 1H), 5.50-5.33 (m, 1H),3.80-3.59 (m, 3H), 3.05 (dd, J=13.7, 9.9 Hz, 1H), 2.96 (dt, J=12.8, 4.3Hz, 1H), 2.91-2.80 (m, 1H), 2.55 (dd, J=10.1, 5.5 Hz, 1H), 2.30-1.96 (m,5H), 1.98-1.83 (m, 2H), 1.13-1.01 (m, 2H), 1.00-0.82 (m, 2H); MS (ESI)m/z 420 (M+H)⁺.

Example 20 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepane

The title compound was prepared according to the procedure described inExample 19, substituting 2-chloro-6-(trifluoromethyl)pyridine for2-chloro-5-(trifluoromethyl)pyridine. ¹H NMR (400 MHz, pyridine-d₅) δppm 8.23 (d, J=1.4 Hz, 1H), 8.12 (d, J=1.4 Hz, 1H), 7.65-7.56 (m, 1H),6.99 (d, J=7.2 Hz, 1H), 6.76 (d, J=8.7 Hz, 1H), 5.45-5.29 (m, 1H),4.50-4.38 (m, 1H), 3.78-3.59 (m, 4H), 3.05 (dd, J=13.8, 9.9 Hz, 1H),2.93 (dt, J=12.7, 4.2 Hz, 1H), 2.82 (tdd, J=9.6, 7.0, 2.6 Hz, 1H), 2.52(dd, J=10.0, 5.6 Hz, 1H), 2.18 (ddd, J=12.8, 9.1, 5.7 Hz, 1H), 2.10-1.99(m, 1H), 1.97-1.79 (m, 2H), 1.13-1.00 (m, 3H), 1.00-0.85 (m, 2H); MS(ESI) m/z 420 (M+H)⁺.

Example 21 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

Part A. Preparation of 3-(benzylamino)propan-1-ol

A solution of 3-aminopropan-1-ol (3 g, 39.9 mmol) and benzaldehyde (4.05mL, 39.9 mmol) in methanol (200 mL) was stirred at room temperatureovernight. The solution was cooled to 0° C., and sodium borohydride(1.813 g, 47.9 mmol) was added slowly in several portions. The resultingmixture was stirred at room temperature for three hours, and then it waspartitioned between water and dichloromethane (3×). The organic extractswere combined and dried over Na₂SO₄, the drying agent was removed byfiltration, and the solution was concentrated in vacuo to give the titlecompound as an oil (6.5 g, 98%).

Part B. Preparation of [(2S)-5-oxopyrrolidin-2-yl]methylmethanesulfonate

To a solution of (5S)-5-(hydroxymethyl)pyrrolidin-2-one (1.0 g, 8.69mmol) in dichloromethane (40 mL) at 0° C. was added triethylamine (1.816mL, 13.03 mmol) followed by dropwise addition of methanesulfonylchloride (0.812 mL, 10.42 mmol). The resulting mixture was stirred atroom temperature for two hours, and then it was partitioned betweenwater and dichloromethane (3×). The organic extracts were combined anddried over Na₂SO₄, the drying agent was removed by filtration, and thesolution was concentrated in vacuo to give the title compound as acolorless, waxy solid (1.68 g, quantitative).

Part C. Preparation of(5S)-5-{[benzyl(3-hydroxypropyl)amino]methyl}pyrrolidin-2-one

A mixture of the product from Part B (0.5 g, 2.59 mmol) and the productfrom Part A (1.5 g, 9.08 mmol) was heated at 50° C. for 2 days. Thecooled mixture was partitioned between water and ethyl acetate (3×). Theorganic extracts were combined and dried over Na₂SO₄, the drying agentwas removed by filtration, and the solution was concentrated in vacuo togive a crude product that was purified by column chromatography onsilica gel using a solvent gradient of 0-5% methanol in dichloromethane.The title compound was obtained as a colorless solid (0.468 g, 69%).

Part D. Preparation of 3-(benzyl{[(2S)-5-oxopyrrolidin-2-yl]methyl}amino)propyl methanesulfonate

To a solution of the product from Part C (0.45 g, 1.715 mmol) indichloromethane (17 mL) at 0° C. was added triethylamine (0.359 mL, 2.57mmol) followed by the dropwise addition of methanesulfonyl chloride(0.160 mL, 2.058 mmol). The resulting mixture was stirred at 0° C. fortwo hours, and then it was partitioned between water and ethyl acetate(3×). The organic extracts were combined and dried over Na₂SO₄, thedrying agent was removed by filtration, and the solution wasconcentrated in vacuo to give the title compound (0.58 g, quantitative).

Part E. Preparation of(9aS)-2-benzyloctahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

To a solution of the product from Part D (0.47 g, 1.38 mmol) inanhydrous 1,4-dioxane (47 mL) under N₂ was added sodium hydride (60%suspension in mineral oil) (66 mg, 1.65 mmol), and the resulting mixturewas stirred at room temperature for three hours. The mixture was pouredinto water and extracted with ethyl acetate (3×). The organic extractswere combined and dried over Na₂SO₄, the drying agent was removed byfiltration, and the solution was concentrated in vacuo to give a crudeproduct that was purified by column chromatography on silica gel using asolvent gradient of 0-5% methanol in dichloromethane. The title compoundwas obtained as a colorless solid (0.223 g, 74%).

Part F. Preparation of tert-butyl(9aS)-7-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

A mixture of the product from Part E (0.219 g, 0.896 mmol), ethanol (3mL), 20% palladium hydroxide on carbon, wet (22.4 mg, 0.160 mmol), anddi-tert-butyl dicarbonate (0.224 g, 1.025 mmol) in a 4 mL pressurebottle was stirred under 60 psi of H₂ at 50° C. for 3.5 hours. Thecooled mixture was filtered and concentrated in vacuo, and the crudeproduct was purified by column chromatography on silica gel using asolvent gradient of 0-5% methanol in dichloromethane. The title compoundwas obtained as a colorless solid (0.21 g, 91%).

Part G. Preparation of tert-butyl(8R,9aS)-8-hydroxy-7-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylateand tert-butyl(8S,9aS)-8-hydroxy-7-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of the product from Part F (0.21 g, 0.826 mmol) inanhydrous tetrahydrofuran (6 mL) under N₂ at −78° C. was added lithiumbis(trimethylsilyl)amide (1.0 M solution in tetrahydrofuran) (1.239 mL,1.239 mmol) dropwise over two to three minutes. The resulting mixturewas stirred at −78° C. for 15 minutes, and a solution of3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (0.432 g, 1.651 mmol) inanhydrous tetrahydrofuran (3 mL) was added dropwise via canula over fiveminutes. The resulting mixture was stirred at −40° C. for two hours. Asolution of 10% NH₄Cl in water was added, the resulting mixture wasallowed to warm to room temperature, and then it was partitioned betweenwater and ethyl acetate (5×). The organic extracts were combined anddried over Na₂SO₄, the drying agent was removed by filtration, and thesolution was concentrated in vacuo to give a crude product that waspurified by column chromatography on silica gel using a solvent gradientof 0-10% methanol in dichloromethane. The title compound was obtained asa colorless solid (0.10 g, 45%), and was approximately a 5:1 mixture oftrans:cis isomers according to ¹H NMR.

Part H. Preparation of tert-butyl(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-7-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of the product from Part G (98 mg, 0.363 mmol) inanhydrous N,N-dimethylformamide (3.6 mL) under N₂ at 0° C. was addedsodium hydride (60% dispersion in mineral oil) (16 mg, 0.40 mmol). Theresulting mixture was stirred at 0° C. for 20 minutes, and then2-bromo-5-cyclopropylpyrazine (108 mg, 0.544 mmol) was added. Theresulting mixture was allowed to warm to room temperature and stirredunder N₂ for 16 hours. The mixture was partitioned between water andethyl acetate, and the organic extract was dried over Na₂SO₄. The dryingagent was removed by filtration, and the filtrate was concentrated invacuo to give a crude product that was purified by column chromatographyon silica gel using a solvent gradient of 0-5% methanol indichloromethane. The resulting product was resubjected to silica gelchromatography using a solvent gradient of 0-100% ethyl acetate inhexanes to separate the trans isomer from the cis isomer. The titlecompound was first to elute, and was obtained as a colorless solid (62mg, 44%).

Part I. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-onehydrochloride

To a solution of the product from Part H (60 mg, 0.154 mmol) in1,4-dioxane (0.2 mL) was added hydrogen chloride solution (4 N solutionin dioxane) (0.2 mL, 0.800 mmol), and the resulting mixture was stirredat room temperature for 90 minutes. The mixture was concentrated anddried in vacuo to give the title compound (50 mg, quantitative).

Part J. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one

To a solution of the product from Part I (83 mg, 0.257 mmol) and2-bromo-5-(trifluoromethyl)pyridine (87 mg, 0.386 mmol) in anhydrous1,4-dioxane (3 mL) was added triethylamine (0.107 mL, 0.771 mmol), andthe resulting mixture was stirred at 80° C. for 16 hours. The mixturewas partitioned between water and ethyl acetate (3×), and the organicextracts were combined and dried over Na₂SO₄. The drying agent wasremoved by filtration, and the solution was concentrated in vacuo togive a crude product that was purified by column chromatography onsilica gel using a solvent gradient of 0-5% methanol in dichloromethane.The title compound was obtained as a colorless solid (55 mg, 49%). ¹HNMR (300 MHz, CDCl₃) δ ppm 0.90-1.01 (m, 4H) 1.94-2.16 (m, 3H) 2.20-2.32(m, 1H) 2.36-2.48 (m, 1H) 2.69-2.83 (m, 1H) 3.24 (dd, J=14.24, 9.83 Hz,1H) 3.40-3.54 (m, 1H) 3.85-4.00 (m, 2H) 4.20-4.32 (m, 1H) 4.62 (dd,J=14.24, 3.73 Hz, 1H) 5.64 (dd, J=8.14, 6.44 Hz, 1H) 6.56 (d, J=9.16 Hz,1H) 7.65 (dd, J=8.82, 2.37 Hz, 1H) 7.95 (d, J=1.36 Hz, 1H) 8.14 (d,J=1.36 Hz, 1H) 8.39 (d, J=2.37 Hz, 1H); MS (APCI) m/z 434 (M+H)⁺.

Example 22 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

Part A. Preparation of(8R,9aS)-8-[(triethylsilyl)oxy]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Example 1, Part B (0.33 g, 1.94 mmol)in anhydrous N,N-dimethylformamide (10 mL) was added imidazole (0.264 g,3.88 mmol) and triethylsilyl chloride (0.488 mL, 2.91 mmol). Theresulting solution was stirred at room temperature for 16 hours. Themixture was partitioned between ethyl acetate (50 mL) and water (2×50mL), and the organic extract was dried over Na₂SO₄. The drying agent wasremoved by filtration, and the filtrate was concentrated in vacuo togive a crude product that was purified by column chromatography onsilica gel using a solvent gradient of 0-10% methanol indichloromethane. The title compound was obtained as a colorless solid(0.28 g, 51%).

Part B. Preparation of(8R,9aS)-8-[(triethylsilyl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Part A (50 mg, 0.176 mmol) inanhydrous N,N-dimethylformamide (1.5 mL) under N₂ was added sodiumhydride (60% weight suspension in mineral oil) (8.4 mg, 0.21 mmol). Theresulting mixture was stirred at room temperature for 10 minutes, and1-(bromomethyl)-3-(trifluoromethyl)benzene (0.032 mL, 0.211 mmol) wasadded. The resulting mixture was stirred at room temperature for twohours. The mixture was partitioned between water and ethyl acetate (3×),and the organic extracts were combined and dried over Na₂SO₄. The dryingagent was removed by filtration, and the filtrate was concentrated invacuo to give a crude product that was purified by column chromatographyon silica gel using a solvent gradient of 0-10% methanol indichloromethane. The title compound was obtained as a colorless solid(35 mg, 45%).

Part C. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

A solution of the product from Part B (33 mg, 0.075 mmol) in acetic acid(0.9 mL) and water (0.3 mL) was stirred at room temperature for 36 hoursand concentrated and dried in vacuo. The residue was dissolved intetrahydrofuran (0.7 mL) and 2-bromo-5-cyclopropylpyrazine (22.4 mg,0.113 mmol) was added, followed by a 1.0 M solution of potassiumtert-butoxide in tetrahydrofuran (0.090 mL, 0.090 mmol). The resultingmixture was stirred at room temperature for two hours. The mixture waspartitioned between water and ethyl acetate (3×), and the organicextracts were combined and dried over Na₂SO₄. The drying agent wasremoved by filtration, and the filtrate was concentrated in vacuo togive a crude product that was purified by column chromatography onsilica gel using a solvent gradient of 0-5% methanol in dichloromethane.The title compound was obtained as a colorless solid (16 mg, 48%). ¹HNMR (300 MHz, CDCl₃) δ ppm 0.86-1.01 (m, 4H), 1.65-1.80 (m, 2H),1.90-2.06 (m, 1H), 2.14-2.83 (m, 3H), 2.93-3.12 (m, 1H), 3.14-3.91 (m,5H), 4.28-4.56 (m, 1H), 4.81-5.02 (m, 1H), 5.29-5.47 (m, 1H), 7.39-7.58(m, 4H), 7.90-8.17 (m, 2H); MS (ESI) m/z 447 (M+H)⁺.

Example 23 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

Part A. Preparation of(8R,9aS)-8-[(triethylsilyl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Example 22, Part A (0.10 g, 0.352mmol) in anhydrous N,N-dimethylformamide (3.0 mL) under N₂ was addedsodium hydride (60% weight suspension in mineral oil) (17 mg, 0.42mmol). The resulting mixture was stirred at room temperature for 10minutes, and 1-(bromomethyl)-4-(trifluoromethyl)benzene (0.065 mL, 0.422mmol) was added. The resulting mixture was stirred at room temperaturefor two hours. The mixture was partitioned between water and ethylacetate (3×), and the organic extracts were combined and dried overNa₂SO₄. The drying agent was removed by filtration, and the filtrate wasconcentrated in vacuo to give the title compound as a solid (0.16 g,quantitative).

Part B. Preparation of(8R,9aS)-8-hydroxy-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

A solution of the product from Part A (0.16 g, 0.36 mmol) in acetic acid(1.5 mL) and water (0.5 mL) was stirred at room temperature for 24 hoursand concentrated in vacuo. The crude product was purified by columnchromatography on silica gel using a solvent gradient of 0-10% methanolin dichloromethane. The title compound eluted at 8-10% methanol (72 mg,62%).

Part C. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Part B (0.065 g, 0.198 mmol) and2-bromo-5-cyclopropylpyrazine (0.059 g, 0.297 mmol) in anhydroustetrahydrofuran (2.0 mL) at 0° C. under N₂ was added a 1.0 M solution ofpotassium tert-butoxide in tetrahydrofuran (0.238 mL, 0.238 mmol). Theresulting mixture was stirred at room temperature for 90 minutes. Themixture was partitioned between water and ethyl acetate (3×), and theorganic extracts were combined and dried over Na₂SO₄. The drying agentwas removed by filtration, the filtrate was concentrated in vacuo, andthe crude product was purified by column chromatography on silica gelusing a solvent gradient of 0-5% methanol in dichloromethane. The titlecompound was the second of two stereoisomers to elute (21 mg, 24%). ¹HNMR (500 MHz, CDCl₃) δ ppm 0.89-1.00 (m, 4H) 1.66-1.74 (m, 2H) 1.95-2.04(m, 1H) 2.16-2.25 (m, 1H) 2.58-2.66 (m, 1H) 2.68 (dd, J=10.99, 3.97 Hz,1H) 2.95-3.06 (m, 1H) 3.16-3.28 (m, 2H) 3.56-3.66 (m, 1H) 3.69-3.77 (m,2H) 4.55 (d, J=14.95 Hz, 1H) 4.79 (d, J=14.95 Hz, 1H) 5.33-5.41 (m, 1H)7.39 (d, J=8.24 Hz, 2H) 7.58 (d, J=7.93 Hz, 2H) 7.96 (s, 1H) 8.03 (s,1H); MS (APCI) m/z 447 (M+H)⁺.

Example 24 Preparation of(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

The title compound was obtained from the procedure described in Example23, Part C and was the first of two stereoisomers to elute duringchromatography (9 mg, 10%). ¹H NMR (500 MHz, CDCl₃) δ ppm 0.90-0.98 (m,4H) 1.68-1.76 (m, 1H) 1.83-1.94 (m, 1H) 1.94-2.02 (m, 1H) 2.35-2.43 (m,1H) 2.46-2.55 (m, 1H) 2.74 (dd, J=10.99, 4.88 Hz, 1H) 3.05 (dd, J=15.26,6.10 Hz, 1H) 3.22-3.35 (m, 2H) 3.38 (dd, J=10.07, 6.10 Hz, 1H) 3.43 (d,J=11.29 Hz, 1H) 3.55 (dd, J=15.11, 11.44 Hz, 1H) 4.41 (d, J=15.26 Hz,1H) 4.90 (d, J=14.95 Hz, 1H) 5.36 (t, J=5.04 Hz, 1H) 7.38 (d, J=7.93 Hz,2H) 7.56 (d, J=8.24 Hz, 2H) 7.93 (s, 1H) 8.15 (s, 1H); MS (APCI) m/z 447(M+H)⁺.

Example 25 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

Part A. Preparation of(8R,9aS)-2-[3-fluoro-4-(trifluoromethyl)benzyl]-8-hydroxyoctahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Example 22, Part A (75 mg, 0.264 mmol)in tetrahydrofuran (2.0 mL) under N₂ was added sodium hydride (60%weight suspension in mineral oil) (11.6 mg, 0.290 mmol). The resultingmixture was stirred at room temperature for five minutes, and4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene (0.050 mL, 0.290mmol) was added. The resulting mixture was stirred at room temperaturefor two hours. The mixture was partitioned between water and ethylacetate (3×), and the organic extracts were combined and dried overNa₂SO₄. The drying agent was removed by filtration, and the filtrate wasconcentrated in vacuo. The residue was stirred in a mixture of aceticacid (1.5 mL) and water (0.500 mL) for 24 hours. The mixture wasconcentrated in vacuo and purified by column chromatography on silicagel using a solvent gradient of 0-10% methanol in dichloromethane. Thetitle compound eluted at 8-10% methanol (70 mg, 77%).

Part B. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

To a solution of the product from Part A (66 mg, 0.191 mmol) and2-bromo-5-cyclopropylpyrazine (57 mg, 0.286 mmol) in anhydroustetrahydrofuran (2.0 mL) at 0° C. under N₂ was added a 1.0 M solution ofpotassium tert-butoxide in tetrahydrofuran (0.20 mL, 0.200 mmol). Theresulting mixture was stirred at room temperature for 90 minutes. Themixture was partitioned between water and ethyl acetate (3×), and theorganic extracts were combined and dried over Na₂SO₄. The drying agentwas removed by filtration, the filtrate was concentrated in vacuo, andthe crude product was purified by column chromatography on silica gelusing a solvent gradient of 0-5% methanol in dichloromethane. The titlecompound was obtained as a colorless solid (16 mg, 18%). ¹H NMR (300MHz, CDCl₃) δ ppm 0.89-1.04 (m, 4H) 1.65-1.84 (m, 2H) 1.92-2.11 (m, 1H)2.14-2.36 (m, 2H) 2.55-2.82 (m, 2H) 2.92-3.09 (m, 1H) 3.14-3.36 (m, 2H)3.52-3.87 (m, 2H) 4.47-4.63 (m, 1H) 4.82 (d, J=14.24 Hz, 1H) 5.33-5.51(m, 1H) 7.10-7.33 (m, 2H) 7.53-7.61 (m, 1H) 7.97 (s, 1H) 8.04 (s, 1H);MS (APCI) m/z 465 (M+H)⁺.

Example 26 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

The title compound was obtained according to the procedure described forExample 25, substituting4-(bromomethyl)-1-fluoro-2-(trifluoromethyl)benzene for4-(bromomethyl)-2-fluoro-1-(trifluoromethyl)benzene. ¹H NMR (300 MHz,CDCl₃) δ ppm 0.89-1.01 (m, 4H) 1.64-1.82 (m, 2H) 1.92-2.07 (m, 1H)2.14-2.33 (m, 2H) 2.56-2.80 (m, 2H) 2.92-3.09 (m, 1H) 3.14-3.37 (m, 2H)3.53-3.86 (m, 2H) 4.47 (d, J=14.58 Hz, 1H) 4.78 (d, J=14.92 Hz, 1H)5.32-5.44 (m, 1H) 7.12-7.21 (m, 1H) 7.45-7.58 (m, 2H) 7.96 (s, 1H) 8.03(s, 1H); MS (APCI) m/z 465 (M+H)⁺.

Example 27 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

Part A. Preparation of(8R,9aS)-8-[(triethylsilyl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

A mixture of the product from Example 22, Part A (100 mg, 0.352 mmol),1-iodo-3-(trifluoromethyl)benzene (0.061 mL, 0.422 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANTPHOS, 6.10 mg,10.55 μmol), and cesium carbonate (172 mg, 0.527 mmol) in 1,4-dioxane(2.0 mL) was deoxygenated by bubbling with N₂ for 20 minutes.Tris(dibenzylideneacetone)dipalladium(0) (57.9 mg, 0.063 mmol) wasadded, and N₂ bubbling was continued for five minutes. The reactioncontainer was sealed, and the stirred mixture was heated at 90° C. for16 hours. The cooled mixture was partitioned between water and ethylacetate (3×), and the organic extracts were combined and dried overNa₂SO₄. The drying agent was removed by filtration, the filtrate wasconcentrated in vacuo, and the crude product was purified by columnchromatography on silica gel using a solvent gradient of 0-10% methanolin dichloromethane. The title compound was obtained as a colorless solid(96 mg, 64%).

Part B. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

The title compound was obtained according to the procedure described inExample 22, Part C, substituting the product from Part A for the productfrom Example 22, Part B. ¹H NMR (300 MHz, CDCl₃) δ ppm 0.88-0.99 (m, 4H)1.83-2.30 (m, 4H) 2.70-2.86 (m, 2H) 2.91-3.06 (m, 1H) 3.24-3.38 (m, 1H)3.64-3.82 (m, 2H) 3.81-3.94 (m, 1H) 4.00-4.14 (m, 1H) 5.34-5.44 (m, 1H)7.42-7.52 (m, 4H) 7.96 (d, J=1.36 Hz, 1H) 8.05 (d, J=1.36 Hz, 1H); MS(APCI) m/z 433 (M+H)⁺.

Example 28 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of tert-butyl(2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate

To a solution of(2S,4R)-4-(benzyloxy)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylicacid (5.00 g, 15.56 mmol) in tetrahydrofuran (50 mL) at −10° C. wasadded N-methylmorpholine (1.882 mL, 17.11 mmol). To this solution wasadded slowly isobutyl chloroformate (2.34 g, 2.25 mL, 17.11 mmol). Theresulting mixture was stirred for 30 minutes and filtered, and thefiltrate was added to a solution of sodium borohydride (1.18 g, 31.1mmol) in water (1.5 mL) at 0° C. The resulting mixture was stirred at 0°C. for 30 minutes, and the reaction was quenched by the addition of asaturated solution of NH₄Cl. The mixture was extracted with ethylacetate, and the organic extract was washed with brine, dried withMgSO₄, filtered, and concentrated in vacuo. The crude product waspurified by column chromatography on silica gel using a solvent gradientof 0-2% methanol in dichloromethane to give the title compound as acolorless oil (3.93 g, 82%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm7.36 (d, J=7.4 Hz, 2H), 7.30 (t, J=7.3 Hz, 2H), 7.23 (t, J=7.2 Hz, 1H),4.50 (s, 2H), 4.20-4.29 (m, 2H), 3.92-4.00 (m, 1H), 3.80-3.87 (m, 2H),3.50-3.59 (m, 1H), 2.16-2.30 (m, 2H), 1.47 (s, 9H).

Part B. Preparation of tert-butyl(2S,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate

To a stirred solution of oxalyl chloride (2.21 mL, 25.4 mmol) indichloromethane (120 mL) at −78° C. was added dimethyl sulfoxide (3.6mL, 50.8 mmol) dropwise via syringe. The mixture was stirred at −78° C.for 10 minutes, and a solution of tert-butyl(2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (3.9 g,12.69 mmol, Part A) in dichloromethane (30 mL) was added. The mixturewas stirred at −78° C. for 15 minutes, and triethylamine (7.07 mL, 50.8mol) was added. After 15 minutes, the reaction mixture was allowed towarm to 0° C. and stirred at that temperature for 30 minutes. Themixture was washed successively with water and brine, dried with MgSO₄,filtered, and concentrated in vacuo. The crude product was purified bycolumn chromatography on silica gel using a solvent gradient of 20-50%ethyl acetate in hexanes to give the title compound as a colorless oil(3.25 g, 84%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 9.62 (s, 1H),7.18-7.41 (m, 5H), 4.37-4.56 (m, 3H), 4.08-4.14 (m, 1H), 3.88-3.74 (m,1H), 3.56 (dd, J=11.7, 4.7 Hz, 1H) 2.19-2.29 (m, 1H) 1.95-2.05 (m, 1H)1.45 (s, 9H).

To a solution of tert-butyl(2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (20 g,0.065 mol, Part A) and triethylamine (27 ml, 0.195 mol) indichloromethane (200 mL) was added a solution of sulfur trioxidepyridine complex (31 g, 0.195 mol) in dimethyl sulfoxide (200 mL) at−15° C. The reaction mixture was stirred at that temperature for onehour and then another lot of sulfur trioxide pyridine complex (5.1 g,0.033 mol) in dimethyl sulfoxide (35 mL) was added. The reaction mixturewas allowed to stir at 20-25° C. for 18 hours, and then it was pouredinto cold water (400 mL) and extracted with ten-butyl methyl ether (200mL×2). The combined organic layers were washed with 10% citric acidsolution (200 mL), saturated sodium bicarbonate solution (200 mL), water(100 mL) and brine solution (100 mL). The organic layer was dried overanhydrous sodium sulfate, filtered and concentrated to give tert-butyl(2S,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate (17 g, 85%) aspale yellow oil which was used without further purification.

Part C. Preparation of tert-butyl(2S,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylate

To a solution of the product from Part B (3.2 g, 10.48 mmol) and ethyl3-(benzylamino)propanoate (2.17, 10.48 mmol) in dichloromethane (40 mL)was added acetic acid (1.8 mL) and polymer-supported cyanoborohydride(4.57 g, 47.2 mmol). The resulting mixture was stirred at roomtemperature for 18 hours, filtered and concentrated in vacuo. The crudeproduct was purified by column chromatography on silica gel using asolvent gradient of 20-50% ethyl acetate in hexanes to give the titlecompound as a colorless oil (4.25 g, 82%). ¹H NMR (500 MHz, pyridine-d₅,90° C.) δ ppm 7.40 (d, J=7.5 Hz, 2H), 7.34-7.38 (m, 2H), 7.28-7.34 (m,4H), 7.21-7.27 (m, 2H), 4.47 (s, 2H), 4.26-3.70 (m, 5H), 3.81 (t, J=13.2Hz, 1H), 3.52 (d, J=13.8 Hz, 1H), 3.42 (dd, J=11.6, 5.3 Hz, 1H),3.06-3.13 (m, 1H), 2.82-2.98 (m, 2H), 2.50-2.62 (m, 2H), 2.45 (dd,J=12.5, 9.3 Hz, 1H), 2.05-2.18 (m, 2H), 1.52 (s, 9H), 1.14 (t, J=7.1 Hz,3H).

Part D. Preparation of(8R,9aS)-2-benzyl-8-(benzyloxy)octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Part C (4.2 g, 8.46 mmol) in anhydrousmethanol (15 mL) was added 4 M HCl in 1,4-dioxane (10.57 mL, 42.3 mmol).The resulting mixture was stirred at room temperature for 18 hours andconcentrated in vacuo. The residue was suspended in ethanol (75 mL),triethylamine was added (5.8 mL, 41.8 mmol), and the mixture wasrefluxed for 48 hours. The mixture was concentrated in vacuo. Theresidue was dissolved in ethyl acetate (100 mL), washed successivelywith water and brine, dried over MgSO₄, filtered, and concentrated invacuo. The crude product was purified by column chromatography on silicagel using a solvent gradient of 20-70% ethyl acetate in hexanes to givethe title compound as a colorless oil (2.25 g, 76% yield).

Part E. Preparation of tert-butyl(8R,9aS)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

A mixture of the product from Part D (2.07 g, 5.91 mmol), ethanol (25mL), 20% palladium hydroxide on carbon, wet (2.15 g, 15.31 mmol), anddi-tert-butyl dicarbonate (1.418 g, 6.50 mmol) was placed in a 250 mLstainless steel pressure bottle. The mixture was shaken under H₂ at 30psi and 50° C. for 15 hours. The mixture was filtered through a nylonmembrane, and concentrated in vacuo to give a colorless solid which wasslurried in 5% ethyl acetate in hexanes (20 mL) and filtered. The titlecompound was obtained as a colorless solid (1.4 g, 84%). ¹H NMR (400MHz, pyridine-d₅, 90° C.) δ ppm 4.40-4.47 (m, 1H), 4.04-4.31 (m, 3H),3.54-3.66 (m, 2H), 2.97-3.08 (m, 1H), 2.55-2.81 (m, 3H), 2.20-2.30 (m,1H), 1.67-1.77 (m, 1H), 1.47 (s, 9H).

Part F. Preparation of tert-butyl(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of the product from Part E (1.4 g, 5.18 mmol) intetrahydrofuran (40 mL) was added a 1.0 M solution of potassiumtert-butoxide in tetrahydrofuran (7.25 mL, 7.25 mmol), followed by thedropwise addition of a solution of 2-bromo-5-cyclopropylpyrazine (1.237g, 6.21 mmol) in tetrahydrofuran (10 mL). The resulting mixture wasstirred at room temperature for 48 hours and concentrated in vacuo. Theresidue was dissolved in ethyl acetate (60 mL), washed successively withwater and brine, dried over MgSO₄, filtered, and concentrated in vacuo.The crude product was purified by column chromatography on silica gelusing a solvent gradient of 0-2% methanol in dichloromethane to give thetitle compound as a waxy solid (1.62 g, 81%). ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 8.05 (d, J=1.2 Hz, 1H), 7.98 (d, J=1.2 Hz,1H), 5.42-5.50 (m, 1H), 4.30 (d, J=14.3 Hz, 1H), 4.10-4.24 (m, 3H), 3.80(dd, J=13.6, 4.4 Hz, 1H), 2.98-3.12 (m, 1H), 2.80 (dd, J=14.3, 9.5 Hz,1H), 2.63-2.74 (m, 2H), 2.41 (dd, J=14.0, 6.7 Hz, 1H), 1.85-2.03 (m,2H), 1.48 (s, 9H), 0.96-1.02 (m, 2H), 0.84-0.91 (m, 2H).

Part G. Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The product from Part F (60 mg, 0.134 mmol) in anhydrous methanol (2 mL)was added to 4 M HCl in 1,4-dioxane (0.386 mL, 1.545 mmol). Theresulting mixture was stirred at room temperature for 18 hours, and thenit was concentrated in vacuo. To the residue was added dichloromethane(4 mL), 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.042 g, 0.17mmol), and triethylamine (0.108 mL, 0.772 mmol). The resulting mixturewas stirred at room temperature for 16 hours, and then it waspartitioned between water and ethyl acetate. The organic extract waswashed successively with water and brine, dried with MgSO4, filtered,and concentrated in vacuo. The crude product was purified by columnchromatography on silica gel using a solvent gradient of 0-4% methanolin dichloromethane to give the title compound as a colorless solid (51mg, 66.5%). ¹H NMR (500 MHz, pyridine-d₅, 90° C.) δ ppm 8.42 (bs, 1H),8.22 (d, J=7.9 Hz, 1H), 8.16 (d, J=1.1 Hz, 1H), 8.06 (d, J=1.4 Hz, 1H),7.95 (d, J=7.9 Hz, 1H), 7.79-7.64 (m, 1H), 5.43 (t, J=4.1 Hz, 1H),4.41-4.15 (m, 3H), 4.02-3.69 (m, 1H), 3.64-3.55 (m, 1H), 3.11-2.70 (m,3H), 2.62 (dd, J=13.2, 9.2 Hz, 1H), 2.54-2.40 (m, 1H), 2.11-1.98 (m,1H), 1.92 (ddd, J=14.2, 10.0, 4.3 Hz, 1H), 1.14-0.99 (m, 2H), 1.01-0.86(m, 2H). MS (ESI) m/z 497 (M+H)⁺.

Example 29 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 4-(trifluoromethyl)benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅, 90° C.) δ ppm 8.19-8.13 (m, 3H), 8.07 (d, J=1.4 Hz,1H), 7.95-7.90 (m, 2H), 5.45 (t, J=4.1 Hz, 1H), 4.39-4.25 (m, 3H),4.25-4.15 (m, 1H), 4.06-3.69 (m, 1H), 3.21-2.88 (m, 1H), 2.84 (dd,J=15.0, 6.4 Hz, 1H), 2.76 (d, J=12.4 Hz, 1H), 2.62 (dd, J=13.4, 9.4 Hz,1H), 2.51-2.42 (m, 1H), 2.27-1.90 (m, 2H), 1.24-1.00 (m, 2H), 1.02-0.82(m, 2H); MS (ESI) m/z 497 (M+H)⁺.

Example 30 Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of(8R,9aS)-8-hydroxyoctahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride

To tert-butyl(8R,9aS)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(122 mg, 0.451 mmol, Example 28, Part E) in methanol (0.2 mL) was addedHCl solution (5.42 mmol, 1.35 ml, 4 N in dioxane). The mixture wasstirred at room temperature for two hours and then concentrated. Theresidue was used without purification. MS (APCI) m/z 171 (M+H)⁺.

Part B. Preparation of(8R,9aS)-8-hydroxy-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

A mixture of(8R,9aS)-8-hydroxyoctahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (90 mg, 0.435 mmol, Part A),2-bromo-5-(trifluoromethyl)pyridine (148 mg, 0.635 mmol) and sodiumcarbonate (138 mg, 1.306 mmol) in dimethyl sulfoxide (0.4 mL) wasstirred at 100° C. overnight. The mixture was purified by chromatographyon silica gel (ethyl acetate/methanol=15:1) to give 135 mg (98% yield)of the titled compound. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.77 (m, 1H),2.09 (m, 1H), 2.50-2.66 (m, 2H), 3.08 (m, 1H), 3.35 (m, 2H), 3.50 (m,1H), 3.98 (m, 2H), 4.20 (m, 1H), 4.44 (m, 1H), 4.55 (m, 1H), 4.88 (br s,1H), 7.01 (d, J=8 Hz, 1H), 7.81 (d, J=8 Hz, 1H), 8.43 (s, 1H); MS (ESI)m/z 316.0 (M+H)⁺.

Part C. Preparation of(8S,9aS)-5-oxo-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-8-yl4-nitrobenzoate

(8R,9aS)-8-Hydroxy-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one(100 mg, 0.317 mmol, Part B), triphenylphosphine (104 mg, 0.396 mmol),and 4-nitrobenzoic acid (80 mg, 0.476 mmol) were dissolved intetrahydrofuran (2 mL), and the resulting solution was cooled to −78° C.Diisopropyl azodicarboxylate (77 mg, 0.381 mmol) in tetrahydrofuran (0.5mL) was added. The mixture was warmed to room temperature and stirredfor two hours. Then 1 drop of water was added. The mixture was purifiedby chromatography on silica gel (ethyl acetate/heptanes=1:1 then 100%ethyl acetate) to give 138 mg (94% yield) of the titled compound as asolid. ¹H NMR (400 MHz, CDCl₃) δ ppm 2.20 (m, 1H), 2.77 (m, 3H), 3.33(m, 1H), 3.47 (m, 1H), 3.88 (m, 1H), 4.00 (m, 1H), 4.12 (m, 1H), 4.37(m, 1H), 4.77 (dd, J=14, 4 Hz, 1H), 5.54 (m, 1H), 6.67 (d, J=8 Hz, 1H),7.69 (d, J=8 Hz, 1H), 8.20 (d, J=8 Hz, 2H), 8.35 (d, J=8 Hz, 2H), 8.42(s, 1H); MS (ESI) m/z 465.0 (M+H)⁺.

Part D. Preparation of(8S,9aS)-8-hydroxy-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To(8S,9aS)-5-oxo-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-8-yl-4-nitrobenzoate(135 mg, 0.291 mmol, Part C) in methanol (2.5 mL) was added potassiumcarbonate (24 mg, 0.174 mmol). The mixture was stirred at roomtemperature for 1.5 hours and then concentrated. The residue waspurified by chromatography on silica gel (ethyl acetate, then ethylacetate/methanol=10:1) to give 78 mg (85% yield) of the titled compoundas a solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.72 (m, 1H), 2.28 (m, 1H),2.45 (m, 1H), 2.63 (m, 1H), 3.35 (m, 3H), 3.44 (m, 1H), 3.92 (m, 1H),4.17 (m, 1H), 4.42 (m, 2H), 5.09 (br s, 1H), 7.00 (d, J=8 Hz, 1H), 7.80(d, J=8 Hz, 1H), 8.43 (s, 1H); MS (ESI) m/z 316.0 (M+H)⁺.

Part E. Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To(8S,9aS)-8-hydroxy-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one(74 mg, 0.235 mmol, Part D), 2-bromo-5-cyclopropylpyrazine (79 mg, 0.4mmol) in tetrahydrofuran (1.2 mL) was added potassium tert-butoxide(0.47 ml, 0.47 mmol, 1 M in tetrahydrofuran). The mixture was stirred atroom temperature overnight. The mixture was purified by chromatographyon silica gel (ethyl acetate) to give 48 mg (47%) of the titled compoundas a solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.88-1.04 (m, 4H), 2.00 (m,1H), 2.15 (br d, J=14 Hz, 1H), 2.66 (m, 1H), 2.72 (m, 2H), 3.36 (dd,J=14, 10 Hz, 1H), 3.48 (m, 1H), 3.83 (dd, J=12, 8 Hz, 1H), 3.90 (br d,J=12 Hz, 1H), 4.03 (m, 1H), 4.34 (br d, J=15 Hz, 1H), 4.63 (d, J=14 Hz,1H), 5.44 (m, 1H), 6.65 (d, J=9 Hz, 1H), 7.66 (dd, J=9, 2 Hz, 1H), 7.95(s, 1H), 8.06 (s, 1H), 8.41 (s, 1H); MS (ESI) m/z 434.0 (M+H)⁺.

Example 31 Preparation of(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of tert-butyl(8R,9aS)-5-oxo-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}hexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

The title compound was prepared according to the procedure described forExample 28, Part F, substituting 2-chloro-5-(trifluoromethyl)pyridinefor 2-bromo-5-cyclopropylpyrazine.

Part B. Preparation of(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described forExample 28, Part G, substituting the product from Part A for the productfrom Example 28, Part F. ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm8.47 (d, J=3.1 Hz, 1H), 8.29 (bs, 1H), 8.16-8.10 (m, 1H), 7.90-7.83 (m,1H), 7.79 (dd, J=8.7, 2.6 Hz, 1H), 7.66 (t, J=7.8 Hz, 1H), 6.79 (d,J=8.6 Hz, 1H), 5.59-5.53 (m, 1H), 4.31-4.21 (m, 2H), 4.19 (d, J=14.6 Hz,1H), 4.16-4.05 (m, 1H), 3.73 (dd, J=13.5, 4.3 Hz, 1H), 2.93-2.83 (m,1H), 2.82 (d, J=12.0 Hz, 1H), 2.80-2.73 (m, 1H), 2.73 (d, J=4.1 Hz, 1H),2.46 (ddt, J=14.0, 6.8, 1.9 Hz, 1H), 1.94 (ddd, J=14.1, 9.6, 4.6 Hz,1H); MS (ESI) m/z 524 (M+H)⁺.

Example 32 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 3-(trifluoromethyl)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.20-7.87 (m, 3H), 7.86-7.68 (m, 2H), 7.56-7.46 (m,1H), 5.48 (bs, 1H), 4.41-4.15 (m, 3H), 4.02-3.69 (m, 1H), 3.64-3.55 (m,1H), 3.11-2.70 (m, 3H), 2.62 (dd, J=13.2, 9.2 Hz, 1H), 2.54-2.40 (m,1H), 2.11-1.98 (m, 1H), 1.92 (ddd, J=14.2, 10.0, 4.3 Hz, 1H), 1.14-0.99(m, 2H), 1.01-0.86 (m, 2H); MS (ESI) m/z 461 (M+H)⁺.

Example 33 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 4-(trifluoromethyl)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.19-7.98 (m, 2H), 7.76 (bs, 4H), 5.48 (bs, 1H),4.60-4.29 (m, 2H), 4.15-3.71 (m, 2H), 3.62 (s, 2H), 3.45-2.64 (m, 3H),2.52-2.39 (m, 1H), 2.18-1.75 (m, 3H), 1.13-1.04 (m, 2H), 1.01-0.85 (m,2H); MS (ESI) m/z 461 (M+H)⁺.

Example 34 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[2-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 2-fluoro-3-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.25-8.14 (m, 0.5H), 8.10 (d, J=6.8, 1H),8.04-7.99 (m, 0.5H), 7.98-7.75 (m, 1H), 7.72-7.61 (m, 1H), 7.42-7.24 (m,1H), 5.53-5.41 (m, 1H), 5.19-4.99 (m, 1H), 4.55-4.26 (m, 2H), 3.98-3.69(m, 2H), 3.50-3.09 (m, 1H), 3.02-2.80 (m, 2H), 2.79-2.69 (m, 1H),2.54-2.36 (m, 1H), 2.11-1.83 (m, 2H), 1.15-0.99 (m, 2H), 0.99-0.85 (m,2H); MS (ESI) m/z 479 (M+H)⁺.

Example 35 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 3-fluoro-4-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.14 (bs, 1H), 7.93 (m, 2H), 7.78-7.63 (m, 2H),5.52-5.41 (m, 1H), 4.63-4.27 (m, 2H), 4.15-3.77 (m, 2H), 3.56-2.72 (m,4H), 2.53-2.40 (m, 2H), 2.09-1.87 (m, 2H), 1.19-0.98 (m, 2H), 1.00-0.86(m, 2H); MS (ESI) m/z 479 (M+H)⁺.

Example 36 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 4-fluoro-3-(trifluoromethyl)benzoylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.14 (bs, 1H), 8.09-8.02 (m, 2H), 7.89 (bs, 1H),7.40-7.31 (m, 1H), 5.48 (bs, 1H), 4.42-4.34 (m, 2H), 4.30-3.68 (m, 2H),3.62-2.67 (m, 4H), 2.52-2.43 (m, 2H), 2.05-1.97 (m, 2H), 1.13-1.05 (m,2H), 0.96-0.90 (m, 2H); MS (ESI) m/z 479 (M+H)⁺.

Example 37 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 3-(trifluoromethoxy)benzoyl chloridefor 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.14 (bs, 1H), 8.07 (bs, 1H), 7.66 (m, 1H), 7.49-7.32(m, 2H), 5.47 (bs, 1H), 4.41-4.34 (m, 2H), 3.88-3.80 (m, 2H), 3.61-2.58(m, 4H), 2.51-2.34 (m, 2H), 2.16-1.61 (m, 2H), 1.10-1.05 (m, 2H),0.96-0.89 (m, 2H); MS (ESI) m/z 477 (M+H)⁺.

Example 38 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28, Part G, substituting 4-(trifluoromethoxy)benzoyl chloridefor 3-(trifluoromethyl)benzene-1-sulfonyl chloride. ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 8.07 (d, J=1.3 Hz, 1H), 7.98 (d, J=1.3 Hz,1H), 7.66-7.56 (m, 2H), 7.28 (d, J=8.0 Hz, 2H), 5.50-5.43 (m, 1H), 4.50(d, J=12.3 Hz, 1H), 4.37-4.15 (m, 2H), 3.82 (dd, J=13.6, 4.4 Hz, 2H),3.24 (ddd, J=14.4, 10.8, 1.9 Hz, 1H), 3.01 (dd, J=14.1, 9.4 Hz, 1H),2.82 (dd, J=15.2, 2.6 Hz, 1H), 2.79-2.64 (m, 1H), 2.46-2.37 (m, 1H),2.04-1.88 (m, 2H), 1.30-0.92 (m, 2H), 0.93-0.78 (m, 2H); MS (ESI) m/z477 (M+H)⁺.

Example 39 Preparation of(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Example 28, Part F (95 mg, 0.245 mmol)in anhydrous methanol (3 mL) was added 4 M HCl in 1,4-dioxane (0.611 mL,2.446 mmol). The resulting mixture was stirred at room temperature for18 hours, and the solvent was removed in vacuo. The resulting solid wasdissolved in dichloromethane (3 mL) and triethylamine (0.112 mL, 0.807mmol). To the solution was added 2-(3-(trifluoromethyl)phenyl)aceticacid (0.055 g, 0.269 mmol), 1-hydroxybenzotriazole hydrate (0.041 g, 269mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride(0.052 g, 0.269 mmol), and the resulting mixture was stirred at roomtemperature for 16 hours. The mixture was partitioned between water anddichloromethane. The organic extract was washed with brine, dried overMgSO₄, filtered, and concentrated in vacuo. The crude product waspurified by column chromatography on silica gel using a solvent gradientof 0-2% methanol in dichloromethane. The resulting oil was trituratedwith ethyl acetate and hexanes to give a solid that was collected byfiltration and dried to give the title compound as a colorless solid(0.085 g, 73%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.06-7.96(m, 2H), 7.73 (bs, 1H), 7.56 (d, J=1.3 Hz, 1H), 7.49 (d, J=1.3 Hz, 1H),7.38 (t, J=7.8 Hz, 1H), 5.44 (t, J=4.5 Hz, 1H), 5.14-4.23 (m, 2H),4.20-4.13 (m, 1H), 4.05 (t, J=7.1 Hz, 1H), 3.94 (bs, 2H), 5.84-3.75 (m,1H), 3.68-2.67 (m, 3H), 2.68-2.57 (m, 1H), 2.37 (ddt, J=13.9, 6.6, 1.9Hz, 1H), 2.04-1.86 (m, 2H), 1.07-0.94 (m, 2H), 0.95-0.78 (m, 2H); MS(ESI) m/z 475 (M+H)⁺.

Example 40 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{hydroxy[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Example 28, Part F (90 mg, 0.232 mmol)in anhydrous methanol (3 mL) was added 4 M HCl in 1,4-dioxane (0.579 mL,2.317 mmol). The resulting mixture was stirred at room temperature for18 hours, and the volatiles were removed in vacuo. The residue wassuspended in N,N-dimethylformamide (3 mL),2-hydroxy-2-(3-(trifluoromethyl)phenyl)acetic acid (0.056 g, 0.255mmol), O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU, 0.106 g, 0.278 mmol), and N-methyl morpholine(0.117 g, 1.158 mmol) were added, and the resulting solution was stirredat room temperature for 16 hours. The mixture was partitioned betweenwater and ethyl acetate. The organic extract was washed with brine,dried over MgSO₄, filtered, and concentrated in vacuo. The crude productwas purified by column chromatography on silica gel using a solventgradient of 0-7% methanol in dichloromethane. The title compound wasobtained as a colorless solid (0.065 g, 57% yield). ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 8.09-7.99 (m, 2H), 7.98 (d, J=1.4 Hz, 1H),7.87-7.79 (m, 1H), 7.56 (d, J=1.3 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H),5.94-5.85 (m, 1H), 5.40 (t, J=4.1 Hz, 1H), 4.90-4.15 (m, 3H), 4.12 (d,J=13.5 Hz, 1H), 3.73 (dd, J=13.5, 4.3 Hz, 1H), 3.50-2.15 (m, 6H),2.07-1.79 (m, 2H), 1.05-0.93 (m, 2H), 0.95-0.83 (m, 2H).); MS (ESI) m/z491 (M+H)⁺.

Example 41 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{(methylamino)[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Example 40 (50 mg, 0.102 mmol) indichloromethane (2 mL), was added methanesulfonyl chloride (0.009 mL,0.112 mmol) followed by diisopropylethylamine (0.027 mL, 153 mmol), andthe resulting mixture was stirred at room temperature for 16 hours. Themixture was partitioned between water and dichloromethane, and theorganic extract was washed with brine and dried over MgSO₄. The dryingagent was removed by filtration, and the filtrate was concentrated invacuo. The oily residue was dissolved in tetrahydrofuran (2.0 mL), a 2.0M solution of methylamine in tetrahydrofuran (0.242 mL, 0.484 mmol) wasadded, and the resulting mixture was stirred at 45° C. for 16 hours. Themixture was concentrated in vacuo, and the residue was partitionedbetween ethyl acetate and water. The organic extract was washed withbrine, dried over MgSO₄, filtered, and concentrated in vacuo. The crudeproduct was purified by column chromatography on silica gel using asolvent gradient of 0-10% methanol in dichloromethane. The titlecompound was obtained as a waxy solid (0.011 g, 23%). ¹H NMR (501 MHz,pyridine-d₅, 90° C.) δ ppm 8.06-7.90 (m, 3H), 7.73 (t, J=6.9 Hz, 1H),7.55 (d, J=7.5 Hz, 1H), 7.46-7.28 (m, 1H), 5.42 (m, 1H), 4.89 (d, J=24.0Hz, 1H), 4.14 (d, J=13.8 Hz, 1H), 3.76 (dd, J=13.4, 4.4 Hz, 1H),3.32-2.44 (m, 4H), 2.39 (d, J=4.9 Hz, 3H), 2.28-1.79 (m, 2H), 1.69-1.10(m, 5H), 1.07-0.78 (m, 4H); MS (ESI) m/z 504 (M+H)⁺.

Example 42 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Example 28, Part F (65 mg, 0.167 mmol)in anhydrous methanol (3 mL) was added 4 M HCl in 1,4-dioxane (0.418 mL,1.673 mmol). The resulting mixture was stirred at room temperature for18 hours, and the volatiles were removed in vacuo. The resulting solidwas dissolved in dichloromethane (3 mL) and triethylamine (0.117 mL,0.837 mmol). To the solution was added 3-(trifluoromethyl)benzaldehyde(29 mg, 0.167 mmol), acetic acid (0.029 mL, 0.507 mmol), andpolymer-supported cyanoborohydride (73 mg, 0.753 mmol). The resultingmixture was stirred at room temperature for 18 hours; then the mixturewas filtered and concentrated in vacuo. The crude product was purifiedby column chromatography on silica gel using a solvent gradient of 0-10%methanol in dichloromethane. The title compound was obtained as a waxysolid (0.048 g, 64%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.08(d, J=1.3 Hz, 1H), 7.98 (d, J=1.4 Hz, 1H), 7.74 (bs, 1H), 7.56 (t, J=7.7Hz, 2H), 7.42 (t, J=7.7 Hz, 1H), 5.47-5.41 (m, 1H), 4.29-4.17 (m, 2H),3.75 (dd, J=13.4, 4.4 Hz, 1H), 3.62 (s, 2H), 3.51 (s, 1H), 2.98-2.90 (m,1H), 2.91-2.75 (m, 2H), 2.59 (dd, J=14.8, 6.8 Hz, 1H), 2.46-2.28 (m,2H), 2.20 (dd, J=12.7, 9.2 Hz, 1H), 2.03-1.93 (m, 1H), 1.82 (ddd,J=14.1, 9.6, 4.6 Hz, 1H), 1.03-0.93 (m, 2H), 0.94-0.83 (m, 2H); MS (ESI)m/z 447 (M+H)⁺.

Example 43 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 42 substituting 3-(trifluoromethoxy)benzaldehyde for3-(trifluoromethyl)benzaldehyde. ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δppm 8.08 (d, J=1.4 Hz, 1H), 7.98 (d, J=1.4 Hz, 1H), 7.44-7.37 (m, 2H),7.23 (d, J=1.4 Hz, 2H), 5.47-5.41 (m, 1H), 4.27-4.17 (m, 2H), 3.75 (dd,J=13.4, 4.4 Hz, 1H), 3.56 (s, 2H), 2.97-2.89 (m, 1H), 2.91-2.76 (m, 2H),2.64-2.55 (m, 1H), 2.40 (d, J=12.2 Hz, 1H), 2.37-2.27 (m, 1H), 2.17 (dd,J=12.7, 9.2 Hz, 1H), 2.03-1.93 (m, 1H), 1.82 (ddd, J=14.0, 9.6, 4.5 Hz,1H), 1.03-0.92 (m, 2H), 0.92-0.84 (m, 2H); MS (ESI) m/z 463 (M+H)⁺.

Example 44 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 42 substituting 4-(trifluoromethoxy)benzaldehyde for3-(trifluoromethyl)benzaldehyde. ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δppm 8.09 (d, J=1.4 Hz, 1H), 7.98 (d, J=1.4 Hz, 1H), 7.36 (d, J=2.9 Hz,1H), 7.36-7.27 (m, 2H), 7.17 (d, J=2.9 Hz, 1H), 5.44 (t, J=4.6 Hz, 1H),4.29-4.17 (m, 2H), 3.75 (dd, J=13.4, 4.3 Hz, 1H), 3.59 (s, 2H),2.97-2.75 (m, 3H), 2.64-2.55 (m, 1H), 2.45-2.28 (m, 2H), 2.19 (dd,J=12.7, 9.2 Hz, 1H), 2.03-1.93 (m, 1H), 1.82 (ddd, J=14.1, 9.6, 4.5 Hz,1H), 1.06-0.92 (m, 2H), 0.94-0.78 (m, 2H); MS (ESI) m/z 463 (M+H)⁺.

Example 45 Preparation of(8R,9aS)-2-[3-(trifluoromethyl)benzyl]-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 42 substituting the product from Example 31, Part A for theproduct from Example 28, Part F. ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δppm 8.50-8.45 (m, 1H), 7.81-7.73 (m, 2H), 7.62-7.52 (m, 2H) 7.42 (t,J=7.7 Hz, 1H), 6.79 (d, J=8.7 Hz, 1H), 5.58 (t, J=4.6 Hz, 1H), 4.30-4.18(m, 2H), 3.78 (dd, J=13.4, 4.3 Hz, 1H), 3.63 (s, 2H), 2.99-2.92 (m, 1H),2.92-2.75 (m, 2H), 2.65-2.55 (m, 1H), 2.47-2.30 (m, 2H), 2.22 (dd,J=12.7, 9.2 Hz, 1H), 1.85 (ddd, J=14.1, 9.7, 4.6 Hz, 1H); MS (ESI) m/z474 (M+H)⁺.

Example 46 Preparation of(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of tert-butyl(2R,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate and tert-butyl(2S,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate

To a solution of tert-butyl(2S,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate (17 g, 0.055mol, Example 28, Part B) in tetrahydrofuran (180 mL) was added1,8-diazabicyclo[5.4.0]undec-7-ene (4.25 g, 0.0276 mol) at 10° C., andthe reaction mixture was stirred at 20-25° C. for 16 hours. The reactionmixture was concentrated, diluted with dichloromethane (200 mL) andwashed with water (200 mL×2). The organic layer was dried over anhydroussodium sulfate and concentrated to give a mixture of tert-butyl(2R,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate and tert-butyl(2S,4R)-4-(benzyloxy)-2-formylpyrrolidine-1-carboxylate, (17 g, 100%) aspale brown oil which was taken as such for the next step without anypurification.

Part B. Preparation of tert-butyl(2R,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylateand tert-butyl(2S,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylate

Sodium triacetoxyborohydride (17.7 g, 0.083 mol) was added to a solutionof ethyl 3-(benzylamino)propanoate (11.5 g, 0.055 mol) and Part A (17 g,0.055 mol) in dichloromethane (200 mL) at 10° C. The resultant mixturewas stirred at 25° C. for 30 minutes. The reaction mixture was quenchedwith saturated sodium bicarbonate solution (150 mL) and extracted withdichloromethane (100 mL). The organic layer was separated, washed withwater (100 mL) and brine (50 mL), dried over anhydrous sodium sulfate,filtered and concentrated to supply tert-butyl(2R,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylateand tert-butyl(2S,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylate(20.3 g, 73.8%) as pale yellow oil in a ratio of 2:3 determined by HPLC(column: Agilent ZORBAX® Eclipse XDB C18, 150 mm×4.6 mm, 3.5 μm;gradient: 5-90% acetonitrile in 20 mM ammonium acetate/water over nineminutes with a hold at 90% for an additional seven minutes; flow rate:1.0 mL/minute; temperature: 25° C.). Retention time for the (2R,4R)isomer was 13.293 minutes and for the (2S,4R) isomer, 13.626 minutes. ¹HNMR (300 MHz, CDCl₃) δ ppm 7.41-7.20 (m, 10H), 4.45-3.79 (m, 6H),3.64-3.28 (m, 3H), 3.10-1.90 (m, 9H), 1.56-1.42 (m, 9H), 1.32-1.20 (m,3H).

Part C. Preparation of(8R,9aR)-2-benzyl-8-(benzyloxy)octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a 2:3 mixture of tert-butyl(2R,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylateand tert-butyl(2S,4R)-2-{[benzyl(3-ethoxy-3-oxopropyl)amino]methyl}-4-(benzyloxy)pyrrolidine-1-carboxylate(25 g, 0.050 mol, Part B) in methanol (125 mL) was added a solution of4.0 M HCl/dioxane (125 mL) while maintaining the internal temperaturebelow 5° C. The reaction mixture was allowed to stir at 20-25° C. for 22hours and was then concentrated. The residue was stirred with toluene(250 mL) and 1 M sodium carbonate solution (250 mL). The organic layerwas separated, washed with water (100 mL) and brine (100 mL), dried overanhydrous sodium sulfate and filtered. The toluene filtrate was heatedto reflux at 115° C. for four hours and was then concentrated. Theisomers were separated by silica gel column chromatography eluted withethyl acetate/hexane (60:40) to give(8R,9aR)-2-benzyl-8-(benzyloxy)octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one(6.2 g, 35%) as dark brown oil. HPLC (column: Agilent ZORBAX® RX-C8, 150mm×4.6 mm, 5 μm; gradient: 10-80% acetonitrile in 0.1% phosphoricacid/water over 13 minutes with a hold at 80% for an additional fiveminutes; flow rate: 1.0 mL/minute; temperature: 30° C.). Retention timefor the titled isomer was 7.147 minutes and for the (8R,9aS) isomer,6.704 minutes. ¹H NMR (300 MHz, CDCl₃) δ ppm 7.41-7.23 (m, 10H),4.62-4.47 (m, 2H), 4.11-3.96 (m, 2H), 3.83-3.75 (m, 1H), 3.64-3.56 (m,3H), 3.02-2.74 (m, 3H), 2.61-2.53 (m, 1H), 2.47-2.36 (m, 3H), 1.88-1.79(m, 1H).

Part D. Preparation of tert-butyl(8R,9aR)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To a solution of(8R,9aR)-2-benzyl-8-(benzyloxy)octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one(6 g, 0.017 mol, Part C) in ethanol (60 mL) was added 20% Pd(OH)₂/C (3.5g) and di-tert-butyl dicarbonate (7.5 g, 0.034 mol) in an autoclave. Thereaction mixture was hydrogenated (30 psi) at 50° C. for four hours andthen filtered through a bed of diatomaceous earth. The filter bed waswashed with ethanol (30 mL), and the combined filtrates wereconcentrated. The residue was dissolved in water (10 ml) and extractedwith dichloromethane (25 mL×3). The combined organic layers were driedover anhydrous sodium sulfate and concentrated. The solid obtained waswashed with tert-butyl methyl ether (25 mL) to give the titled compound(3 g, 65%) as white solid. HPLC (column: Agilent ZORBAX® RX-C8, 150mm×4.6 mm, 5 μm; gradient: 40-80% acetonitrile in 0.1% phosphoricacid/water over 13 minutes with a hold at 80% for an additional fiveminutes; flow rate: 1.5 mL/minute; temperature: 30° C.). Retention timefor the titled isomer was 1.389 minutes. Chiral HPLC (column: ChiralTechnologies Chiralpak® IC™, 250 mm×4.6 mm, 5 μm; eluent: 15% (1:1)methanol/ethanol in 0.1% triethylamine/heptane; flow rate: 1.0mL/minute; temperature: 30° C.). Retention time for the titled isomerwas 17.355 minutes. ¹H NMR (300 MHz, CDCl₃) δ ppm 4.36-4.46 (m, 1H)4.04-4.26 (m, 2H) 3.81-3.94 (m, 1H) 3.56-3.71 (m, 2H) 3.09 (dd, J=14.1,10.0 Hz, 1H) 2.52-2.70 (m, 2H) 2.35-2.48 (m, 1H) 1.77-1.89 (m, J=9.8,3.7 Hz, 1H) 1.47 (s, 9H); MS (ESI+) m/z 541.6 (2M+H)⁺.

Part E. Preparation of tert-butyl(8S,9aR)-8-[(4-nitrobenzoyl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

tert-Butyl(8R,9aR)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(50 mg, 0.185 mmol, 1.0 equivalent, Part D), triphenylphosphine (60.6mg, 0.231 mmol, 1.25 equivalents), and 4-nitrobenzoic acid (46.4 mg,0.277 mmol, 1.5 equivalents) were dissolved in tetrahydrofuran (1.0 mL),and the resulting solution was cooled to −78° C. Diisopropylazodicarboxylate (0.043 mL, 0.222 mmol, 1.2 equivalents) was dissolvedin tetrahydrofuran (0.5 mL), and the resultant solution was added to thereaction mixture. The reaction mixture was removed from the cooling bathand warmed to room temperature for 0.5 hour. After the addition of 1drop of saturated sodium bicarbonate, the tetrahydrofuran solution wasloaded directly onto 2 sequentially linked 4 g silica gel cartridges,eluted with 50-100% ethyl acetate/heptanes over 20 minutes. The titledcompound co-eluted with triphenylphosphine oxide and was used withoutadditional purification (225 mg combined material). ¹H NMR (400 MHz,CDCl₃) δ ppm 8.28 (d, J=8.9 Hz, 2H), 8.15 (d, J=8.9 Hz, 2H), 5.52 (t,J=4.0 Hz, 1H), 4.53-3.94 (m, 4H), 3.73 (dd, J=14.1, 4.2 Hz, 1H), 3.02(br s, 1H), 2.78-2.59 (m, 3H), 2.55 (dt, J=13.7, 7.0 Hz, 1H), 2.03-1.91(m, 1H), 1.47 (s, 9H); MS (ESI+) m/z 419.8 (M+H)⁺.

Part F. Preparation of tert-butyl(8S,9aR)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

tert-Butyl(8S,9aR)-8-[(4-nitrobenzoyl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(156 mg, 0.372 mmol, 1.0 equivalent, Part E) was dissolved in methanol(3 mL). Potassium carbonate (20 mg, 0.145 mmol, 0.39 equivalent) wasadded and stirring was continued at room temperature for 30 minutes. Thesolvent was removed in vacuo, and the crude material was loaded onto a12-g silica column with dichloromethane and eluted with 0-5%methanol:dichloromethane over 15 minutes, held at 5%methanol:dichloromethane for five minutes, then eluted with 10%methanol:dichloromethane for 10 minutes to afford the titled compound(65 mg, 0.240 mmol, 64.6% yield over two steps) as a white solid. ¹H NMR(300 MHz, CDCl₃) δ ppm 4.44 (t, J=3.7 Hz, 1H), 4.39-3.86 (m, J=79.8 Hz,2H), 4.06 (dt, J=17.5, 8.9 Hz, 1H), 3.83 (dd, J=13.2, 2.3 Hz, 1H), 3.51(dd, J=13.2, 3.7 Hz, 1H), 3.35-2.96 (br s, 1H), 2.74-2.46 (m, 3H), 2.24(dd, J=13.2, 6.0 Hz, 1H), 1.74 (ddd, J=12.0, 9.0, 3.0 Hz, 1H), 1.48 (s,9H); MS (ESI+) m/z 270.9 (M+H)⁺.

Part G. Preparation of tert-butyl(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

tert-Butyl(8S,9aR)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(55 mg, 0.203 mmol, Part F) was dissolved in tetrahydrofuran (1.2 mL).Potassium tert-butoxide (0.400 mL, 0.400 mmol, 1.0 M in tetrahydrofuran,2.0 equivalents) was added at room temperature, and the resultingsolution was stirred for five minutes. Then2-bromo-5-cyclopropylpyrazine (81 mg, 0.407 mmol, 2.0 equivalents) wasadded as a solution in tetrahydrofuran (0.5 mL). The reaction wasallowed to stir at room temperature for 16 hours, at which point it wasquenched with 3 drops of saturated sodium bicarbonate. The mixture wasconcentrated in vacuo, and the residue was loaded onto a 12 g silicacolumn eluted with 100:0 to 95:5 dichloromethane:methanol over 20minutes to give the titled compound (41 mg, 52% yield) as a white solid.¹H NMR (300 MHz, CDCl₃) δ ppm 8.02 (d, J=1.0 Hz, 1H), 7.93 (d, J=1.4 Hz,1H), 5.44 (t, J=4.0 Hz, 1H), 4.45-4.17 (br s, 2H), 4.07-3.98 (m, 2H),3.67 (dd, J=13.8, 4.1 Hz, 1H), 3.00 (br s, 1H), 2.73-2.66 (m, 3H), 2.49(dd, J=12.0, 7.6 Hz, 1H), 2.01-1.82 (m, 2H), 1.48 (s, 9H), 1.02-0.89 (m,4H); MS (ESI+) m/z 333.0 (M-tBu+H)⁺.

Part H. Preparation of(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

tert-Butyl(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(40 mg, 0.103 mmol, 1.0 equivalent, Part G) was dissolved in methanol(1.0 mL) in a 20-mL scintillation vial. In a separate 4-mL vial, acetylchloride (0.073 ml, 1.030 mmol, 10.0 equivalents) was added to methanol(0.5 mL) at 0° C., and the resulting acidic solution was added to thereaction mixture. The reaction vial was capped, and the reaction mixturewas heated to 60° C. for 0.5 hour. The reaction mixture was cooled toroom temperature and concentrated, and(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride was used without additional purification in the next step.

(8S,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride was dissolved in dimethyl sulfoxide (1.0 mL).2-Chloro-5-(trifluoromethyl)pyridine (28.0 mg, 0.154 mmol, 1.5equivalents) and sodium carbonate (65.5 mg, 0.618 mmol, 6.0 equivalents)were added, and the resulting suspension was heated to 115° C. for 14hours. The reaction was cooled to room temperature, diluted with ethylacetate, and washed with water and brine, and then dried over sodiumsulfate. The solvent was removed in vacuo, and the residue was purifiedvia silica chromatography on 2 sequentially linked 4 g silicacartridges, eluting with 25:75 to 0:100 heptanes:ethyl acetate to givethe titled compound (16 mg, 40% yield) as a white solid. ¹H NMR (300MHz, CDCl₃) δ ppm 8.42 (s, 1H), 7.96 (dd, J=14.0, 1.2 Hz, 2H), 7.67 (dd,J=9.0, 2.4 Hz, 1H), 6.66 (d, J=9.0 Hz, 1H), 5.48 (t, J=4.0 Hz, 1H), 4.81(d, J=14.6 Hz, 1H), 4.37-4.32 (m, 1H), 4.19-4.10 (m, 1H), 4.04 (dd,J=13.9, 2.2 Hz, 1H), 3.73 (dd, J=13.8, 4.1 Hz, 1H), 3.54-3.36 (m, 1H),3.04 (dd, J=14.5, 9.4 Hz, 1H), 2.75 (dd, J=6.6, 3.6 Hz, 2H), 2.55 (dd,J=13.8, 5.1 Hz, 1H), 2.05-1.95 (m, 2H), 0.98-0.91 (m, 4H); ¹H NMR (400MHz, pyridine-d₅) δ ppm 8.63 (s, 1H), 8.16 (d, J=1.1 Hz, 1H), 8.08 (d,J=1.2 Hz, 1H), 7.79 (dd, J=9.0, 2.4 Hz, 1H), 6.90 (d, J=9.1 Hz, 1H),5.52 (t, J=4.0 Hz, 1H), 4.82 (d, J=14.5 Hz, 1H), 4.53-4.24 (m, 3H), 3.92(dd, J=13.6, 4.1 Hz, 1H), 3.40 (ddd, J=14.7, 10.2, 1.9 Hz, 1H), 3.07(dd, J=14.5, 9.4 Hz, 1H), 2.89-2.72 (m, 2H), 2.65-2.47 (m, 1H),2.11-1.91 (m, 2H), 1.10-0.97 (m, 2H), 0.97-0.81 (m, 2H); MS (ESI+) m/z434.1 (M+H)⁺; [α]_(D) ^(24.8)=−3.2 (c=0.41, CH₃OH).

Example 47 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To a solution of the product from Example 28, Part F (60 mg, 0.160 mmol)in anhydrous methanol (2 mL) was added 4 M HCl in 1,4-dioxane (0.386 mL,1.545 mmol), and the resulting mixture was stirred at room temperaturefor 18 hours and concentrated in vacuo. The residue was dissolved indimethyl sulfoxide (1 mL), and sodium carbonate (0.082 g, 0.772 mmol)and 2-chloro-5-(trifluoromethyl)pyridine (0.036 g, 0.201 mmol) wereadded. The resulting mixture was stirred at 115° C. for 16 hours. Thecooled mixture was partitioned between water and ethyl acetate. Theorganic extract was washed successively with water and brine, dried overMgSO₄, filtered, and concentrated in vacuo. The crude product waspurified by column chromatography on silica gel using a solvent gradientof 0-2% methanol in dichloromethane to give the title compound as acolorless, crystalline solid (0.033 g, 49%). ¹H NMR (500 MHz,pyridine-d₅, 90° C.) δ ppm 8.65-8.60 (m, 1H), 8.16 (d, J=1.3 Hz, 1H),8.07 (d, J=1.4 Hz, 1H), 7.79 (dd, J=9.0, 2.5 Hz, 1H), 6.89 (d, J=9.0 Hz,1H), 5.51 (t, J=4.2 Hz, 1H), 4.85-4.78 (m, 1H), 4.48-4.37 (m, 1H),4.39-4.27 (m, 1H), 3.91 (dd, J=13.6, 4.2 Hz, 1H), 3.62 (d, J=4.8 Hz,1H), 3.57-3.35 (m, 1H), 3.06 (dd, J=14.4, 9.4 Hz, 1H), 3.01-2.68 (m,2H), 2.54 (ddd, J=13.9, 6.4, 2.1 Hz, 1H), 2.18-1.83 (m, 2H), 1.11-0.97(m, 2H), 0.99-0.80 (m, 2H); MS (ESI) m/z 434 (M+H)⁺.

Example 48 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 47, substituting 2-chloro-6-(trifluoromethyl)pyridine for2-chloro-5-(trifluoromethyl)pyridine. ¹H NMR (500 MHz, pyridine-d₅, 90°C.) δ ppm 8.19-8.14 (m, 1H), 8.06 (d, J=1.4 Hz, 1H), 7.66-7.59 (m, 1H),7.08-6.96 (m, 2H), 5.52-5.45 (m, 1H), 4.74-4.62 (m, 1H), 4.47-4.22 (m,1H), 4.11-3.86 (m, 1H), 3.60 (d, J=12.5 Hz, 1H), 3.39-3.27 (m, 1H), 3.04(dd, J=14.5, 9.3 Hz, 1H), 2.87-2.58 (m, 2H), 2.50 (s, 1H), 2.19-1.92 (m,2H), 1.18-0.99 (m, 2H), 0.99-0.83 (m, 2H); MS (ESI) m/z 434 (M+H)⁺.

Example 49 Preparation of(8R,9aS)-2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 47, substituting 3-chloro-2-fluoro-5-(trifluoromethyl)pyridinefor 2-chloro-5-(trifluoromethyl)pyridine. ¹H NMR (400 MHz, pyridine-d₅,90° C.) δ ppm 8.43 (d, J=2.0 Hz, 1H), 8.05 (dd, J=37.6, 1.4 Hz, 2H),7.89 (d, J=2.2 Hz, 1H), 5.52 (t, J=4.6 Hz, 1H), 4.65-4.36 (m, 1H),4.34-4.18 (m, 3H), 3.51 (s, 1H), 3.29 (ddd, J=14.4, 10.7, 1.5 Hz, 1H),3.07 (dd, J=14.2, 9.3 Hz, 1H), 2.98 (ddd, J=15.4, 10.6, 2.3 Hz, 1H),2.83 (ddd, J=15.4, 6.7, 1.5 Hz, 1H), 2.53 (ddt, J=13.9, 6.8, 1.9 Hz,1H), 2.06-1.94 (m, 2H), 1.04-0.93 (m, 2H), 0.94-0.82 (m, 2H); MS (ESI)m/z 468 (M+H)⁺.

Example 50 Preparation of(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 47, substituting 2,3-difluoro-5-(trifluoromethyl)pyridine for2-chloro-5-(trifluoromethyl)pyridine. ¹H NMR (400 MHz, pyridine-d₅, 90°C.) δ ppm 8.30 (bs, 1H), 8.04 (dd, J=30.4, 1.4 Hz, 2H), 7.55 (d, J=2.2Hz, 1H), 5.51 (t, J=4.6 Hz, 1H), 4.57-4.49 (m, 1H), 4.47-4.30 (m, 2H),4.28-4.20 (m, 1H), 3.51 (s, 1H), 3.41-3.31 (m, 1H), 3.13 (dd, J=14.5,9.2 Hz, 1H), 2.94-2.76 (m, 2H), 2.51 (ddt, J=13.9, 6.7, 1.9 Hz, 1H),2.05-1.94 (m, 2H), 1.03-0.92 (m, 2H), 0.93-0.82 (m, 2H); MS (ESI) m/z452 (M+H)⁺.

Example 51 Preparation of(8R,9aS)-2-(5-cyclopropylpyrazin-2-yl)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 47 substituting the product from Example 31, Part A for theproduct from Example 28, Part F, and substituting2-bromo-5-cyclopropylpyrazine for 2-chloro-5-(trifluoromethyl)pyridine.¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.49 (s, 1H), 8.13 (dd,J=36.6, 1.5 Hz, 2H), 7.76 (dd, J=8.7, 2.6 Hz, 1H), 6.77 (d, J=8.7 Hz,1H), 5.62 (t, J=4.6 Hz, 1H), 4.60-4.52 (m, 1H), 4.22-4.32 (m, 1H),3.96-3.55 (m, 2H), 3.51 (s, 1H), 3.34 (ddd, J=14.7, 9.7, 2.6 Hz, 1H),3.04 (dd, J=14.4, 9.3 Hz, 1H), 2.84-2.68 (m, 2H), 2.49 (ddt, J=13.9,6.6, 1.8 Hz, 1H), 2.17-1.93 (m, 2H), 1.14-0.92 (m, 2H), 0.94-0.81 (m,2H); MS (ESI) m/z 434 (M+H)⁺.

Example 52 Preparation of(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28 substituting 2-chloro-5-(trifluoromethyl)pyridine for2-bromo-5-cyclopropylpyrazine in Example 28, Part F and substituting4-(trifluoromethyl) benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in Example 28, Part G. ¹HNMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.50-8.45 (m, 1H), 8.10-8.03(m, 2H), 7.84 (s, 1H), 7.83-7.76 (m, 2H), 6.79 (d, J=8.7 Hz, 1H), 5.58(t, J=4.6 Hz, 1H), 4.32-4.22 (m, 2H), 4.23-4.19 (m, 2H), 4.20-4.02 (m,1H), 3.75 (dd, J=13.5, 4.3 Hz, 1H), 2.92-2.61 (m, 3H), 2.48 (ddt,J=14.0, 7.0, 1.9 Hz, 1H), 2.02-1.90 (m, 1H); MS (ESI) m/z 524 (M+H)⁺.

Example 53 Preparation of(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28 substituting 5-chloro-2-(trifluoromethyl)pyridine for2-bromo-5-cyclopropylpyrazine in Example 28, Part F. ¹H NMR (400 MHz,pyridine-d₅, 90° C.) δ ppm 1.94 (ddd, J=14.3, 10.0, 4.4 Hz, 1H), 2.45(dd, J=14.0, 6.7 Hz, 1H), 2.64-2.99 (m, 4H), 3.71 (dd, J=13.5, 4.1 Hz,1H), 4.05-4.37 (m, 4H), 4.98 (t, J=4.1 Hz, 1H), 7.34 (dd, J=8.6, 2.7 Hz,1H), 7.64 (dd, J=18.4, 8.3 Hz, 2H), 7.86 (d, J=7.8 Hz, 1H), 8.13 (d,J=7.9 Hz, 1H), 8.29 (s, 1H), 8.42 (d, J=2.7 Hz, 1H); MS (ESI) m/z 524(M+H)⁺.

Example 54 Preparation of(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

The title compound was prepared according to the procedure described inExample 28 substituting 5-chloro-2-(trifluoromethyl)pyridine for2-bromo-5-cyclopropylpyrazine in Example 28, Part F and substituting4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in Example 28, Part G. ¹HNMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 1.96 (ddd, J=14.2, 9.9, 4.4 Hz,1H), 2.47 (dd, J=14.0, 6.7 Hz, 1H), 2.67-2.94 (m, 4H), 3.72 (dd, J=13.5,4.1 Hz, 1H), 4.04-4.38 (m, 4H), 5.00 (t, J=4.1 Hz, 1H), 7.35 (dd, J=8.7,2.8 Hz, 1H), 7.62 (d, J=8.7 Hz, 1H), 7.82 (d, J=8.3 Hz, 2H), 8.06 (d,J=8.2 Hz, 2H), 8.42 (d, J=2.8 Hz, 1H); MS (ESI) m/z 524 (M+H)⁺.

Example 55 Preparation of(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of tert-butyl(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

tert-Butyl(8R,9aR)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(60 mg, 0.222 mmol, 1.0 equivalent, Example 46, Part D) was dissolved intetrahydrofuran (1.0 mL). Potassium tert-butoxide (0.311 mL, 0.311 mmol,1 M in tetrahydrofuran, 1.4 equivalents) was added at room temperature,and the resulting yellow solution was stirred for five minutes. Then2-bromo-5-cyclopropylpyrazine (57.4 mg, 0.289 mmol, 1.3 equivalents) wasadded as a solution in tetrahydrofuran (0.5 mL), and the reactionmixture was stirred for 16 hours at the same temperature. The reactionmixture was quenched with 1 drop of saturated sodium bicarbonate, thesolvent was removed in vacuo, and the crude material was loaded onto a12 g silica column with 5% methanol/dichloromethane and eluted with100:0 to 95:5 dichloromethane:methanol over 20 minutes to give thetitled compound (50 mg, 0.129 mmol, 58.0% yield) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.02 (s, 1H), 7.94 (d, J=1.1 Hz, 1H), 5.38(br s, 1H), 4.23 (br s, 2H), 3.95 (t, J=7.2 Hz, 1H), 3.90-3.73 (m, 2H),3.00 (br s, 2H), 2.71-2.45 (m, 3H), 2.18-1.86 (m, 2H), 1.47 (s, 9H),1.05-0.85 (m, 4H); MS (ESI+) m/z 333.0 (M-tBu+H)⁺.

Part B. Preparation of(8R,9aR)-8-[5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

tert-Butyl(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(50 mg, 0.103 mmol, Part A) was dissolved in methanol (1.0 mL) in a20-mL scintillation vial. In a separate 4-mL vial, acetyl chloride(0.090 ml, 1.29 mmol) was added to methanol (0.5 mL) at 0° C., and theresulting acidic solution was added to the reaction vial. The vial wascapped, and the reaction mixture was heated to 60° C. for 0.5 hour. Thereaction mixture was then cooled to room temperature and concentrated toprovide(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride that was used in the next step without additionalpurification.

(8R,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride was dissolved in dimethyl sulfoxide (1.0 mL).2-Chloro-5-(trifluoromethyl)pyridine (36.0 mg, 0.198 mmol, 1.9equivalents) and sodium carbonate (82.0 mg, 0.774 mmol, 7.5 equivalents)were added, and the resulting suspension was heated to 115° C. for 14hours. The reaction mixture was cooled to room temperature, diluted withethyl acetate, washed with water and brine, and then dried over sodiumsulfate. The solvent was removed in vacuo, and the residue was purifiedvia silica chromatography on 2 sequentially linked 4 g silicacartridges, eluted with 25:75 to 0:100 heptanes:ethyl acetate to givethe titled compound (26 mg, 0.055 mmol, 47% yield) as a white solid. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.41 (s, 1H), 8.06 (s, 1H), 7.95 (s, 1H),7.66 (dd, J=9.0, 2.2 Hz, 1H), 6.65 (d, J=9.0 Hz, 1H), 5.56-5.20 (m, 1H),4.63 (d, J=14.4 Hz, 1H), 4.34 (d, J=15.2 Hz, 1H), 4.03 (td, J=9.3, 3.7Hz, 1H), 3.90 (d, J=12.0 Hz, 1H), 3.83 (dd, J=16.0, 8.0 Hz, 1H),3.56-3.41 (m, 1H), 3.36 (dd, J=14.4, 9.7 Hz, 1H), 2.72 (dd, J=12.1, 7.3Hz, 2H), 2.66 (ddd, J=14.2, 9.1, 5.1 Hz, 1H), 2.15 (d, J=14.0 Hz, 1H),2.06-1.91 (m, 1H), 1.04-0.88 (m, 4H); ¹H NMR (400 MHz, pyridine-d₅) δppm 8.64 (s, 1H), 8.25 (d, J=1.2 Hz, 1H), 8.09 (d, J=1.2 Hz, 1H), 7.79(dd, J=9.1, 2.4 Hz, 1H), 6.90 (d, J=9.1 Hz, 1H), 5.53-5.38 (m, 1H), 4.67(d, J=14.3 Hz, 1H), 4.46 (d, J=15.4 Hz, 1H), 4.14 (d, J=13.2 Hz, 1H),4.04 (ddd, J=18.1, 11.2, 4.4 Hz, 2H), 3.57-3.40 (m, 2H), 2.96-2.80 (m,2H), 2.62 (ddd, J=14.1, 9.0, 5.3 Hz, 1H), 2.16 (dd, J=14.0, 3.3 Hz, 1H),2.04 (td, J=8.2, 4.1 Hz, 1H), 1.15-1.04 (m, 2H), 1.04-0.83 (m, 2H); MS(ESI+) m/z 434.1 (M+H)⁺; [α]_(D) ^(24.6)=+37.3 (c=0.85, CH₃OH).

Example 56 Preparation of(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8R,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (60 mg, 0.185 mmol, prepared as described in Example 55,Part B) was suspended in dichloromethane (1.0 mL) in a 4-mLscintillation vial. 4-(Trifluoromethoxy)benzaldehyde (45.7 mg, 0.240mmol, 1.3 equivalents) was added followed by triethylamine (0.051 mL,0.369 mmol, 2.0 equiv). After stirring for 10 minutes, sodiumtriacetoxyborohydride (94 mg, 0.443 mmol, 2.4 equivalents) was added,and the reaction was stirred at room temperature for an additional fourhours. The suspension was loaded directly onto a 4 g silica gel columnand eluted with ethyl acetate (flow rate=18 mL/minute) over 20 minutesto give the title compound as a light yellow oil (42 mg, 50%). ¹H NMR(400 MHz, CDCl₃) δ ppm 8.03 (d, J=1.2 Hz, 1H), 7.93 (d, J=1.3 Hz, 1H),7.35 (d, J=8.6 Hz, 2H), 7.17 (d, J=8.0 Hz, 2H), 5.44-5.24 (m, 1H), 4.10(td, J=9.3, 4.5 Hz, 1H), 3.88 (dd, J=13.2, 5.2 Hz, 1H), 3.74 (dd,J=13.2, 2.0 Hz, 1H), 3.59 (s, 2H), 2.91 (dd, J=12.6, 6.8 Hz, 1H),2.86-2.71 (m, 2H), 2.71-2.50 (m, 2H), 2.50-2.31 (m, 2H), 2.08-1.82 (m,2H), 1.00-0.88 (m, 4H); MS (ESI+) m/z 463.1 (M+H)⁺; [α]_(D) ^(23.6)=0.08(c=0.17, CH₃OH).

Example 57 Preparation of(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8R,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (27.6 mg, 0.085 mmol, 1 equivalent, prepared as describedin Example 55, Part B) was suspended in dichloromethane (1.0 mL) in a4-mL scintillation vial. 3-(Trifluoromethyl)benzoyl chloride (23.05 mg,0.111 mmol, 1.3 equivalents) was added as a solution in dichloromethane(0.1 mL) followed by the addition of triethylamine (0.059 mL, 0.425mmol, 5.0 equiv) and 4-(dimethylamino)pyridine (1.0 mg, 0.0085 mmol, 0.1equivalent). The resulting solution was stirred at room temperature foran additional 30 minutes. The reaction was loaded directly onto a 4 gsilica gel column eluted with 50:50 to 100:0 ethyl acetate:heptanes(flow rate=18 mL/minute) over 20 minutes to give the title compound as awhite solid (25 mg, 64%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm8.06 (s, 1H), 7.97 (d, J=1.3 Hz, 1H), 7.89 (s, 1H), 7.68 (dd, J=18.2,7.8 Hz, 2H), 7.47 (t, J=7.8 Hz, 1H), 5.40 (dq, J=8.0, 4.0 Hz, 1H),4.53-4.10 (m, 1H), 4.13 (td, J=8.8, 3.6 Hz, 2H), 3.96 (d, J=4.1 Hz, 2H),3.41 (dd, J=13.9, 10.0 Hz, 1H), 3.32-3.17 (m, 1H), 2.90-2.67 (m, 2H),2.55 (ddd, J=14.2, 8.8, 5.5 Hz, 1H), 2.07-1.91 (m, 2H), 1.06-0.97 (m,2H), 0.92-0.79 (m, 2H); MS (ESI+) m/z 461.1 (M+H)⁺; [α]_(D) ^(23.7)=0.10(c=0.12, CH₃OH).

Example 58 Preparation of(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8R,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (27.6 mg, 0.085 mmol, 1.0 equivalent, prepared asdescribed in Example 55, Part B) was suspended in dichloromethane (1.0mL) in a 4-mL scintillation vial. Triethylamine (43 mg, 0.425 mmol, 5.0equivalents) was added followed by 4-(trifluoromethyl)benzene-1-sulfonylchloride (27 mg, 0.11 mmol, 1.3 equivalents) as a solution indichloromethane (0.1 mL). The reaction was stirred for 15 minutes. Themixture was loaded directly onto a 4 g silica gel column and with 0:100to 50:50 ethyl acetate:heptanes (flow rate=18 mL/minute) over 20 minutesto give the title compound as a white solid (25 mg, 62%). ¹H NMR (400MHz, CDCl₃) δ ppm 7.95 (d, J=1.4 Hz, 1H), 7.92 (d, J=1.4 Hz, 1H), 7.89(d, J=8.4 Hz, 2H), 7.82 (d, J=8.4 Hz, 2H), 5.53-5.25 (m, 1H), 4.17 (td,J=9.4, 3.0 Hz, 1H), 4.12-4.00 (m, 1H), 3.97 (d, J=13.4 Hz, 1H), 3.79 (d,J=3.5 Hz, 2H), 2.99-2.55 (m, 5H), 2.14-1.92 (m, 2H), 0.95 (ddt, J=12.1,7.0, 2.0 Hz, 4H); MS (ESI+) m/z expected 497.1; found: 497.0 (M+H)⁺;[α]_(D) ^(24.1)=0.19 (c=0.12, CH₃OH).

Example 59 Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

Part A. Preparation of tert-butyl(8S,9aS)-8-[(4-nitrobenzoyl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

tert-Butyl(8R,9aS)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(370 mg, 1.369 mmol, prepared as described in Example 28, Part E),triphenylphosphine (449 mg, 1.711 mmol), and 4-nitrobenzoic acid (343mg, 2.053 mmol) were dissolved in tetrahydrofuran (6.0 mL), and theresulting solution was cooled to −78° C. Diisopropyl azodicarboxylate(332 mg, 1.642 mmol) in tetrahydrofuran (1.5 mL) was added. The mixturewas warmed to room temperature, and stirred for two hours. Then one dropof water was added. The mixture was concentrated. The residue waspurified by chromatography on silica gel (ethyl acetate/heptanes=1:1then ethyl acetate) to give 500 mg (87% yield) of the title compound asan oil. ¹H NMR (500 MHz, CDCl₃) δ ppm 1.50 (s, 9H), 2.10 (m, 1H), 2.70(m, 3H), 3.00 (m, 2H), 3.82 (m, 1H), 3.96-4.40 (m, 4H), 5.52 (t, J=4 Hz,1H), 8.18 (d, J=8 Hz, 2H), 8.32 (d, J=8 Hz, 2H); MS (ESI) m/z 420.0(M+H)⁺.

Part B. Preparation of tert-butyl(8S,9aS)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To tert-butyl(8S,9aS)-8-[(4-nitrobenzoyl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(495 mg, 0.291 mmol, Part A) in methanol (8 ml) was added potassiumcarbonate (98 mg, 0.708 mmol). The mixture was stirred at roomtemperature for one hour, and then concentrated. The residue waspurified by chromatography on silica gel (ethyl acetate, then ethylacetate/methanol=10:1) to give 280 mg (88% yield) of the title compoundas a solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40 (s, 9H), 1.61 (m, 1H),2.24 (m, 1H), 2.38 (m, 1H), 2.58 (m, 1H), 2.80-3.15 (m, 2H), 3.23 (dd,J=13, 4 Hz, 1H), 3.42 (dd, J=13, 4 Hz, 1H), 3.81 (m, 1H), 3.98 (m, 2H),4.18 (m, 1H), 5.02 (t, J=4 Hz, 1H); MS (ESI) m/z 271.0 (M+H)⁺.

Part C. Preparation of tert-butyl(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate

To tert-butyl(8S,9aS)-8-hydroxy-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(270 mg, 1 mmol, Part B) and 2-bromo-5-cyclopropylpyrazine (299 mg, 1.5mmol) in tetrahydrofuran (3 mL) and dichloromethane (1 mL) was addedpotassium t-butoxide (3 mL, 3 mmol, 1 M in tetrahydrofuran). The mixturewas stirred at room temperature for three days, and then concentrated.The residue was purified by chromatography on silica gel (ethyl acetate)to give 255 mg (65.6% yield) of the title compound as a solid. ¹H NMR(400 MHz, CDCl₃) δ ppm 0.98 (m, 4H), 1.47 (s, 9H), 2.01 (m, 2H), 2.61(m, 3H), 3.01 (m, 2H), 3.80-3.98 (m, 3H), 4.22 (m, 2H), 5.40 (m, 1H),7.95 (d, J=1 Hz, 1H), 8.02 (d, J=1 Hz, 1H); MS (ESI) m/z 389.0 (M+H)⁺.

Part D. Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride

To tert-butyl(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-5-oxohexahydro-1H-pyrrolo[1,2-a][1,4]diazepine-2(3H)-carboxylate(254 mg, 0.654 mmol, Part C) in methanol/dichloromethane (1:1, 1 mL) wasadded 4 N HCl solution in dioxane (3 mL). The mixture was stirred atroom temperature for three hours and then concentrated to give 212 mg(100% yield) of the title compound as a solid which was used withoutpurification. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.82 (m, 2H), 0.96 (m,2H), 2.10 (m, 2H), 2.66 (m, 1H), 3.10 (m, 3H), 3.40 (m, 2H), 3.65 (m,2H), 4.22 (m, 1H), 4.40 (m, 1H), 5.38 (m, 1H), 8.15 (d, J=1 Hz, 1H),8.19 (d, J=1 Hz, 1H), 9.38 (br s, 1H), 9.50 (br s, 1H); MS (ESI) m/z289.0 (M+H)⁺.

Part E. Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (50 mg, 0.154 mmol, Part D) in anhydrous dichloroethane(0.7 mL) was added 4-(trifluoromethoxy)benzaldehyde (38 mg, 0.2 mmol),and N-ethyl-N-isopropylpropan-2-amine (39.8 mg, 0.308 mmol). After 10minutes, sodium triacetoxyborohydride (75 mg, 0.354 mmol) was added. Themixture was stirred at room temperature overnight and then concentrated.The residue was purified by chromatography on silica gel (ethyl acetate)to give 33 mg (46.4% yield) of the title compound as a solid. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 0.83 (m, 2H), 0.98 (m, 2H), 1.82 (m, 1H), 2.12(m, 1H), 2.20-2.32 (m, 2H), 2.42 (dd, J=12, 8 Hz, 1H), 2.61 (m, 1H),2.70-2.90 (m, 3H), 3.50 (br d, J=12 Hz, 1H), 3.57 (br d, J=12 Hz, 1H),3.62-3.72 (m, 2H), 4.12 (m, 1H), 5.29 (m, 1H), 7.31 (d, J=9 Hz, 2H),7.43 (d, J=9 Hz, 2H), 8.15 (s, 1H), 8.18 (s, 1H); MS (ESI) m/z 463.0(M+H)⁺.

Example 60 Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (50 mg, 0.154 mmol, prepared as described in Example 59,Part D) in dichloromethane (1 mL) was added triethylamine (62.3 mg,0.616 mmol) followed by 3-(trifluoromethyl)benzoyl chloride (38.5 mg,0.185 mmol) in dichloromethane (0.5 mL). The mixture was stirred at roomtemperature for 3 hours and then concentrated. The residue was purifiedby chromatography on silica gel (ethyl acetate) to give 34 mg (48%yield) of the title compound as a solid. ¹H NMR (400 MHz, CDCl₃) δ ppm0.87-1.02 (m, 4H), 2.00 (m, 1H), 2.23 (m 1H), 2.60-2.90 (m, 3H),3.10-3.40 (m, 2H), 3.70-3.96 (m, 3H), 4.09 (m, 1H), 4.80 (m, 1H), 5.42(m, 1H), 7.60 (m, 2H), 7.70 (br s, 1H), 7.76 (m, 1H), 8.00 (m, 2H); MS(ESI) m/z 461.0 (M+H)⁺.

Example 61 Preparation of(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

To(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (50 mg, 0.154 mmol, prepared as described in Example 59,Part D) in dichloromethane (1 mL) was added triethylamine (62.3 mg,0.616 mmol) followed by 4-(trifluoromethyl)benzene-1-sulfonyl chloride(45.2 mg, 0.185 mmol) in dichloromethane (0.5 mL). The mixture wasstirred at room temperature for 18 hours and then concentrated. Theresidue was purified by chromatography on silica gel (ethyl acetate) togive 37 mg (48.4% yield) of the title compound as a solid. ¹H NMR (400MHz, CDCl₃) δ ppm 0.86-1.02 (m, 4H), 2.00 (m, 1H), 2.08 (br d, J=14 Hz,1H), 2.66-2.92 (m, 5H), 3.78 (d, J=4 Hz, 2H), 3.99 (br d, J=12 Hz, 1H),4.03 (dd, J=12, 8 Hz, 1H), 4.18 (m, 1H), 5.40 (m, 1H), 7.81 (d, J=9 Hz,2H), 7.87 (m, 4H); MS (ESI) m/z 497.0 (M+H)⁺.

Example 62 Preparation of(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8S,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (45 mg, 0.139 mmol, prepared as described in Example 46,Part H) was suspended in dichloromethane (1.5 mL) in a 4-mLscintillation vial. Triethylamine (28.0 mg, 0.277 mmol) was addedfollowed by the addition of 4-(trifluoromethoxy)benzaldehyde (34.2 mg,0.180 mmol) as a solution in dichloromethane (0.2 mL). The resultingsolution was stirred at room temperature for 15 minutes, at which pointsodium triacetoxyborohydride (70.5 mg, 0.333 mmol) was added as a neatsolid in one portion, and the resulting suspension was stirred at roomtemperature for an additional 4 hours. The suspension was loadeddirectly onto a 4 g silica column and eluted with ethyl acetate (flowrate=18 mL/minute) over 15 minutes to give the title compound as acolorless oil (34 mg, 53%). ¹H NMR (400 MHz, CDCl₃) δ ppm 8.02 (d, J=1.2Hz, 1H), 7.92 (d, J=1.3 Hz, 1H), 7.35 (d, J=8.6 Hz, 2H), 7.17 (d, J=8.0Hz, 2H), 5.41 (t, J=3.9 Hz, 1H), 4.18 (dd, J=16.4, 9.4 Hz, 1H), 4.02(dd, J=13.7, 2.0 Hz, 1H), 3.69-3.45 (m, 3H), 2.94 (d, J=12.5 Hz, 2H),2.81 (d, J=12.0 Hz, 1H), 2.60 (dd, J=14.8, 6.9 Hz, 1H), 2.50-2.34 (m,2H), 2.15 (dd, J=12.8, 9.3 Hz, 1H), 1.98 (tt, J=7.9, 5.1 Hz, 1H), 1.86(ddd, J=14.4, 10.4, 4.4 Hz, 1H), 1.02-0.79 (m, 4H); MS (ESI+) m/z 463.1(M+H)⁺; [α]_(D) ^(24.1)=−0.04 (c=0.23, CH₃OH).

Example 63 Preparation of(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8S,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (40 mg, 0.123 mmol, 1.0 equivalent, prepared as describedin Example 46, Part H) was suspended in dichloromethane (1.0 mL) in a4-mL scintillation vial, and triethylamine (0.051 mL, 0.37 mmol, 3.0equivalents) was added. 3-(Trifluoromethyl)benzoyl chloride (33.4 mg,0.160 mmol, 1.3 equivalents) was added as a solution in 0.1 mL ofdichloromethane followed by 4-(dimethylamino)pyridine (1.50 mg, 0.012mmol, 0.1 equivalent). The reaction was stirred for 30 minutes. Thereaction solution was loaded directly onto a 4 g silica column andeluted with 50:50 to 100:0 ethyl acetate:heptanes (flow rate=18mL/minute) over 20 minutes to give the title compound as a white solid(31 mg, 54%). ¹H NMR (400 MHz, pyridine-d₅, 90° C.) δ ppm 8.07 (d, J=1.3Hz, 1H), 7.98 (d, J=1.3 Hz, 1H), 7.91 (s, 1H), 7.72 (d, J=7.7 Hz, 1H),7.66 (d, J=7.8 Hz, 1H), 7.48 (t, J=7.8 Hz, 1H), 5.47 (t, J=4.4 Hz, 1H),4.51 (s, 1H), 4.34 (dd, J=17.0, 9.1 Hz, 1H), 4.22 (d, J=13.6 Hz, 2H),3.84-3.75 (m, 1H), 3.26 (dd, J=12.7, 11.1 Hz, 1H), 3.04 (dd, J=14.2, 9.5Hz, 1H), 2.94-2.77 (m, 1H), 2.71 (dd, J=15.4, 4.9 Hz, 1H), 2.41 (dd,J=14.0, 6.7 Hz, 1H), 2.05-1.82 (m, 2H), 1.00 (dt, J=4.9, 2.9 Hz, 2H),0.93-0.80 (m, 2H); MS (ESI+) m/z 461.1 (M+H)⁺; [α]_(D) ^(23.6)=−0.09(c=0.13, CH₃OH).

Example 64 Preparation of(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one

(8S,9aR)-8-[(5-Cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-onehydrochloride (35 mg, 0.108 mmol, 1.0 equivalent, prepared as describedin Example 46, Part H) was suspended in dichloromethane (1.0 mL) in a4-mL scintillation vial. Triethylamine (32.7 mg, 0.323 mmol, 3.0equivalents) was added followed by the addition of4-(trifluoromethyl)benzene-1-sulfonyl chloride (34.3 mg, 0.140 mmol, 1.3equivalents). The resulting solution was allowed to stir for 30 minutesat room temperature. The reaction solution was loaded directly onto a 4g silica gel column and eluted with 0:100 to 50:50 ethylacetate:heptanes (flow rate=18 mL/minute) over 20 minutes to give thetitle compound as a white solid (30 mg, 56%). ¹H NMR (400 MHz, CDCl₃) δppm 8.03 (d, J=1.3 Hz, 1H), 7.91 (dd, J=9.0, 4.9 Hz, 3H), 7.82 (d, J=8.4Hz, 2H), 5.43 (t, J=3.9 Hz, 1H), 4.25 (dd, J=16.5, 9.6 Hz, 1H),4.16-3.95 (m, 3H), 3.57 (dd, J=13.7, 4.0 Hz, 1H), 2.96-2.83 (m, 1H),2.82-2.64 (m, 2H), 2.65-2.52 (m, 1H), 2.47 (dd, J=13.4, 9.3 Hz, 1H),2.04-1.84 (m, 2H), 1.08-0.77 (m, 4H); MS (ESI+) m/z 497.0 (M+H)⁺;[α]_(D) ^(23.8)=−0.15 (c=0.13, CH₃OH).

Additional examples of compounds of Formula (I) are listed below. Suchcompounds can be prepared using the general method-of-preparationdiscussion, specific synthesis examples above, and/or the discussionthroughout this application.

Example 65

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 66

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[{4-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 67

-   (8S,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 68

-   (8R,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 69

-   (8S,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 70

-   (8R,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 71

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethyl)phenyl]methanone;

Example 72

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl](4-fluorophenyl)methanone;

Example 73

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethoxy)phenyl]methanone;

Example 74

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 75

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][5-(trifluoromethyl)pyridin-2-yl]methanone;

Example 76

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][6-(trifluoromethyl)pyridin-2-yl]methanone;

Example 77

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-(trifluoromethyl)phenyl]methanone;

Example 78

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 79

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 80

-   (3-chloro-4-fluorophenyl)[(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl]methanone;

Example 81

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-5-(trifluoromethyl)phenyl]methanone;

Example 82

-   [(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 83

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 84

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 85

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 86

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 87

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 88

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 89

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 90

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 91

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 92

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 93

-   (8R,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 94

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 95

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[2-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 96

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 97

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 98

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 99

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 100

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 101

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{hydroxy[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 102

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{(methylamino)[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 103

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 104

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 105

-   (8R,9aR)-2-[3-(trifluoromethyl)benzyl]-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 106

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 107

-   (8R,9aR)-2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 108

-   (8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 109

-   (8R,9aR)-2-(5-cyclopropylpyrazin-2-yl)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 110

-   (8R,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 111

-   (8R,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 112

-   (8R,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 113

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 114

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 115

-   (8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 116

-   (8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 117

-   (8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 118

-   (8S,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 119

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethyl)phenyl]methanone;

Example 120

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl](4-fluorophenyl)methanone;

Example 121

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethoxy)phenyl]methanone;

Example 122

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 123

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][5-(trifluoromethyl)pyridin-2-yl]methanone;

Example 124

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][6-(trifluoromethyl)pyridin-2-yl]methanone;

Example 125

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-(trifluoromethyl)phenyl]methanone;

Example 126

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 127

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 128

-   (3-chloro-4-fluorophenyl)[(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl]methanone;

Example 129

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-5-(trifluoromethyl)phenyl]methanone;

Example 130

-   [(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 131

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 132

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 133

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 134

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 135

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 136

-   (8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 137

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 138

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 139

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 140

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 141

-   (8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 142

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 143

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[2-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 144

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 145

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 146

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 147

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 148

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 149

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{hydroxy[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 150

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{(methylamino)[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 151

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 152

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 153

-   (8S,9aS)-2-[3-(trifluoromethyl)benzyl]-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 154

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 155

-   (8S,9aS)-2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 156

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 157

-   (8S,9aS)-2-(5-cyclopropylpyrazin-2-yl)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 158

-   (8S,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 159

-   (8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 160

-   (8S,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 161

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 162

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 163

-   (8R,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 164

-   (8S,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 165

-   (8R,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 166

-   (8S,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 167

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethyl)phenyl]methanone;

Example 168

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl](4-fluorophenyl)methanone;

Example 169

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethoxy)phenyl]methanone;

Example 170

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 171

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][5-(trifluoromethyl)pyridin-2-yl]methanone;

Example 172

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][6-(trifluoromethyl)pyridin-2-yl]methanone;

Example 173

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-(trifluoromethyl)phenyl]methanone;

Example 174

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone;

Example 175

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 176

-   (3-chloro-4-fluorophenyl)[(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl]methanone;

Example 177

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-5-(trifluoromethyl)phenyl]methanone;

Example 178

-   [(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-4-(trifluoromethyl)phenyl]methanone;

Example 179

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 180

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;

Example 181

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;

Example 182

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 183

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 184

-   (8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 185

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 186

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 187

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;

Example 188

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 189

-   (8S,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 190

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 191

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[2-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 192

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 193

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 194

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 195

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 196

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 197

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{hydroxy[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 198

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{(methylamino)[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 199

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 200

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 201

-   (8S,9aR)-2-[3-(trifluoromethyl)benzyl]-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 202

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 203

-   (8S,9aR)-2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 204

-   (8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 205

-   (8S,9aR)-2-(5-cyclopropylpyrazin-2-yl)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 206

-   (8S,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;

Example 207

-   (8S,9aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;    and

Example 208

-   (8S,9aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one.

I. Biological Data

Abbreviations which have been used in the descriptions of BiologicalData that follow are: EDTA for ethylenediaminetetraacetic acid; FBS forfetal bovine serum; FLIPR for fluorometric imaging plate reader; HBSSfor Hank's balanced salt solution; HEPES for4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; i.p. forintraperitoneal; MEM for minimum essential medium; MEM NEAA for minimumessential medium non-essential amino acid; p.o. for per orem (by mouth).

(A) In Vitro Assessment of Calcium Channel Activity

Compounds were tested for effect on calcium flux in cells endogenouslyexpressing human Cav2.2. Specifically, IMR32 cells endogenouslyexpressing human Ca_(v)2.2 were assayed for Ca⁺ influx using a no-washcalcium indicator dye (Calcium 4 dye: Molecular Probes) and FLIPRtechnology (Lubin, M L; et al. Assay and Drug Development Technologies,2006, 4(6), 689-694). The IMR32 cells were maintained in MEM mediacontaining 10% (v/v) FBS, 1% (v/v) antibiotic/antimitotic, 1% (v/v)sodium pyruvate and 1% (v/v) MEM NEAA. Following dissociation in 0.05%(v/v) trypsin/EDTA, cells were seeded into black 1×96-well plates(Corning Cellbind) at a density of 1−1.2×10⁵ cells/well and incubated inthe maintenance media above for 48 hours at 37° C. Immediately prior toperforming the assay the media was removed and cells were loaded for 1.5hours with 1× Calcium 4 dye prepared in HBSS (137 mM NaCl, 5.4 mM KCl,0.25 mM Na₂HPO₄, 0.44 mM KH₂PO₄, 1.3 mM CaCl₂, 1 mM MgSO₄, 4.2 mMNaHCO₃) containing HEPES pH 7.4 at room temperature. After dye loadingand a subsequent 60 minute pre-incubation with compounds (full logdilutions from 10 μM to 0.1 nM) in the presence of 1.3 mM CaCl₂ and 2 μMnifedipine to block endogenous L-type channels, the external Ca²⁺concentration was increased to 5 mM CaCl₂ and the cells concomitantlydepolarized with 80 mM KCl to assay channel activity.

To determine the IC₅₀ values, the percent inhibition of the compound ateach concentration was determined relative to the activity in theabsence of inhibitor, and data was fitted using non-linear regressionsigmoidal dose response curve analysis with GraphPad Prism®. Unlessotherwise indicated (*), the reported values are average values from atleast two runs (i.e., n≧2). Results are reported in Table 3.

TABLE 3 EXAMPLE IC₅₀ (μM) 1 0.32 2 0.20 3 1.25 4 0.88 5 1.76 6 0.91 71.66 8 3.04* 9 1.35 10 0.92 11 9.27 12 6.22 13 0.88 14 1.45 15 1.33 162.30 17 1.58 18 1.19 19 1.21 20 0.75 21 3.47 22 1.72 23 0.98 24 2.94 251.19 26 1.10 27 10.0 28 1.83 29 0.49 30 6.34 31 0.60 32 1.72 33 3.73 341.01 35 1.03 36 1.78 37 1.14 38 2.81 39 2.08 40 4.70 41 3.45 42 0.92 431.11 44 1.65 45 0.62 46 5.07 47 2.52 48 1.54 49 2.13 50 2.46 51 7.35 521.26 53 4.02 54 1.29 55 3.43 56 2.50 57 11.2 58 3.75 59 3.17 60 18.8 611.20 62 3.23 63 22.5 64 2.20

(B) In Vivo Analgesic Effect (Neuropathic Pain Model)

Test compounds can be evaluated for analgesic effect in an in vivo modelof neuropathic pain. Specifically, animals were prepared for testing, byuse of a surgical procedure that induces neuropathic pain in one paw.IACUC guidelines for rodent survival surgery were followed. All surgicalprocedures were conducted on a clean, uncluttered surgical station. Thearea was wiped with a 70% ethanol solution before and after use. Allinstruments were sterilized by either autoclave or chemical sterilant(such as 2% glutaraldehyde >10 hours). Surgeons wore sterile gloves (forthe initial procedure), clean lab coat or scrubs, hairnet or cap, and ahalf-mask respirator (when not working under a hood). Surgeonsthoroughly washed their hands prior to donning sterile gloves. Gloveswere disinfected in-between animals by cleansing with povidone iodine,chlorhexidine or 70% alcohol for at least 30 seconds. If multiplesurgeries were performed, the instruments were cleaned and sterilizedbetween procedures with hot glass beads (>10 seconds). To preventthermal or chemical burns, the instruments were cooled by rinsing insterile saline before use.

Male, Sprague Dawley® rats, 175-200 g were used for surgeries. Tominimize post-operative dehydration/maintain blood volume during thesurgery, warmed sterile saline or Lactate Ringers solution at 10-15mL/kg was administered subcutaneously immediately before or aftersurgery. This facilitates better renal function and presumablyanesthesia product excretion post surgery. For all surgical procedures,anesthesia was induced with 4-5% isoflurane. Anesthesia was maintainedduring surgery with 1-3% isoflurane. Following induction, the surgicalsite was carefully shaved and the exposed area was aseptically preparedwith povidone-iodine scrub solution and 70% ethanol 2-3 times.

Chronic constriction injury (CCI), a model of neuropathic pain, wasproduced by following the method of Bennett and Xie (Bennett, G., et al.Pain, 1988, 33, 87-107). After site sterilization and anestheticprocedures outline above were completed, a 1.5 cm incision is made atthe mid-thigh level to expose the biceps femoris and gluteoussuperficialis (right side), which were then separated by bluntdissection. The common sciatic nerve was exposed, isolated, and looselyligated by four 5-0 chromic gut ligatures with <1 mm spacing betweeneach. The surgical site was closed in layers—muscle is closed with 6.0absorbable sutures, and the skin closed with wound clips. Animals wereallowed to recover on a warming plate and were returned to their homecages when fully ambulatory. Animals were not be used for testing untilat least 10 days following surgery.

To measure mechanical sensitivity, tactile allodynia was measured usingcalibrated von Frey filaments (Stoelting, Wood Dale, Ill.) as describedby Chaplan et al. (Chaplan S., et al. J of Neuroscience Methods 1994,53, 55-63). Filament strengths used were: 0.4, 0.6, 1.0, 2, 4, 6, 8, and15 g. Rats were placed into inverted individual plastic containers(20×12.5×20 cm) on top of a suspended wire mesh grid, and acclimated tothe test chambers for at least 20 minutes. Filaments were appliedperpendicular to the mid-plantar paw surface with enough force to causeslight buckling and held in place for 6-8 seconds. Positive responsesincluded an abrupt withdrawal of the paw from the stimulus or flinchingbehavior immediately following removal of the stimulus. The maximumforce applied was 15 g. The 50% paw withdrawal threshold (PWT) wascalculated in grams (g) using the up-down method of Dixon (Dixon W. AnnRev Pharmacol Toxicol 1980, 20, 441-462). Only rats exhibiting increasedmechanical sensitivity were used (threshold responses below 5 g). Allcompounds were orally administered at 10 mg/kg in 10% dimethylsulfoxide/polyethylene glycol at a volume of 2.0 mL/kg, and mechanicalallodynia was determined 60 minutes following compound administration

Results are reported in Table 4. The data are reported as log g valuesand the percentage of maximum possible effect (% MPE) is calculatedusing log g values with the Formula:

${\% \mspace{14mu} M\; P\; E} = \frac{\left( {{\log \left\lbrack {{observed}\mspace{14mu} P\; W\; T\mspace{14mu} {in}\mspace{14mu} {grams}} \right\rbrack} - {\log \left\lbrack {{mean}\mspace{14mu} P\; W\; T\mspace{14mu} {vehicle}} \right\rbrack}} \right)}{\left( {{\log \lbrack 15\rbrack} - {\log \left\lbrack {{mean}\mspace{14mu} P\; W\; T\mspace{14mu} {vehicle}} \right\rbrack}} \right)*100}$

All statistical procedures are run on log g values.

TABLE 4 EXAMPLE % MPE 7 44 13 40 19 36 32 46 42 27 44 48 47 73

The ability of the compounds of the present invention to reducenociceptive pain can be evaluated using conventional in vivo nociceptivepain models known in the art. Such models include, for example, thosedescribed in Pain (1996) 64:493-501; and Pain (2001) 93:69-76.

The ability of the compounds of the present invention to reduceinflammatory pain can be evaluated using conventional in vivonociceptive pain models known in the art. Such models include, forexample, those described in Pain (1999) 80:67-82.

Although specific embodiments and examples have been described above,these embodiments and examples are only illustrative and do not limitthe scope of the invention. Changes and modifications can be made inaccordance with ordinary skill in the art without departing from theinvention in its broader aspects as defined in the following claims. Forexample, any embodiment described herein can be combined with any othersuitable embodiment described herein to provide additional embodiments.

As will be understood by the skilled artisan, all numbers, includingthose expressing quantities of ingredients, properties such as molecularweight, reaction conditions, and so forth, are approximations andunderstood as being modified in all instances by the term “about.” Thesevalues can vary depending upon the desired properties sought to beobtained by those skilled in the art utilizing the present teachings ofthe present invention. It is also understood that such values inherentlycontain variability necessarily resulting from the standard deviationsfound in their respective testing measurements.

As will be understood by one skilled in the art, for any and allpurposes, particularly in terms of providing a written description, allranges disclosed herein also encompass any and all possible subrangesand combinations of subranges thereof as well as the individual valuesmaking up the range, particularly integer values. Any listed range canbe easily recognized as sufficiently describing and enabling the samerange being broken down into at least equal halves, thirds, quarters,fifths, tenths, etc. As will also be understood by one skilled in theart, all language such as “up to,” “at least,” “greater than,” “lessthan,” “more than,” “or more” and the like include the number recitedand refer to ranges which can be subsequently broken down into subrangesas discussed above. In the same manner, all ratios disclosed herein alsoinclude all subratios falling within the broader ratio.

One skilled in the art will also readily recognize that where membersare grouped together in a common manner, such as in a Markush group, thepresent invention encompasses not only the entire group listed as awhole, but each member of the group individually and all possiblesubgroups of the main group. Additionally, for all purposes, the presentinvention encompasses not only the main group, but also the main groupabsent one or more of the group members. The present invention alsoenvisages the explicit exclusion or disclaimer of one or more of any ofthe group members in the claimed invention.

All references (patent and non-patent) cited above are incorporated byreference into this patent application. The discussion of thosereferences is intended merely to summarize the assertions made by theirauthors. No admission is made that any reference (or a portion of anyreference) is relevant prior art (or prior art at all). Applicantsreserve the right to challenge the accuracy and pertinence of the citedreferences.

1. A compound or a salt thereof, wherein: the compound corresponds instructure to Formula (I):

R¹ is selected from the group consisting of pyridinyl, pyrimidinyl,pyrazinyl, and pyridazinyl, wherein each such substituent is optionallysubstituted with one, two, or three substituents independently selectedfrom the group consisting of halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, andC₃-C₆-cycloalkyl; R² is selected from the group consisting of phenyl,pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, wherein each suchsubstituent is optionally substituted with one, two, or threesubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl; as to X¹, X², X³, X⁴, and L: X¹is —CH₂—; X² is —CH₂—; X³ is —CH₂—; X⁴ is —CH₂—; and L is selected fromthe group consisting of a bond, —CH₂—, —C(O)—, —C(O)C(R³)(H)—, and—S(O)₂—; or X¹ is —CH₂—; one of X² and X³ is —C(O)— and the other one ofX² and X³ is —CH₂—; X⁴ is —CH₂—; and L is selected from the groupconsisting of a bond, —CH₂—, —C(O)—, and —C(O)C(R⁴)(H)—; or one of X¹and X⁴ is —C(O)— and the other one of X¹ and X⁴ is —CH₂—; X² is —CH₂—;X³ is —CH₂—; and L is selected from the group consisting of a bond,—CH₂—, —C(O)—, —C(O)C(R⁵)(H)—, and —S(O)₂—; and R³, R⁴, and R⁵ areindependently selected from the group consisting of hydrogen, hydroxy,C₁-C₆-alkyl, C₁-C₆-alkoxy, and amino, wherein such amino is optionallysubstituted with one or two independently selected C₁-C₆-alkyl.
 2. Thecompound or salt of claim 1, wherein the compound corresponds instructure to Formula (I-i):


3. The compound or salt of claim 1, wherein the compound corresponds instructure to Formula (I-ii):


4. The compound or salt of claim 1, wherein the compound corresponds instructure to Formula (I-iii):


5. The compound or salt of claim 1, wherein the compound corresponds instructure to Formula (I-iv):


6. The compound or salt of claim 1, wherein X¹ is —CH₂—; X² is —CH₂—; X³is —CH₂—; and X⁴ is —CH₂—.
 7. The compound or salt of claim 1, whereinX¹ is —CH₂—; X² is —C(O)—; X³ is —CH₂—; and X⁴ is —CH₂—.
 8. The compoundor salt of claim 1, wherein X¹ is —CH₂—; X² is —CH₂—; X³ is —C(O)—; andX⁴ is —CH₂—.
 9. The compound or salt of claim 1, wherein X¹—C(O)—; X² is—CH₂—; X³ is —CH₂—; and X⁴ is —CH₂.
 10. The compound or salt of claim 1,wherein X¹ is —CH₂—; X² is —CH₂—; X³ is —CH₂—; and X⁴ is —C(O)—.
 11. Thecompound or salt of claim 1, wherein L is —S(O)₂—.
 12. The compound orsalt of claim 1, wherein L is a bond.
 13. The compound or salt of claim1, wherein L is —CH₂—.
 14. The compound or salt of claim 1, wherein L is—C(O)—.
 15. The compound or salt of claim 1, wherein: R¹ is selectedfrom the group consisting of pyridinyl and pyrazinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and R² is selectedfrom the group consisting of phenyl and pyridinyl, wherein each suchsubstituent is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen, cyano,C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.
 16. The compoundor salt of claim 1, wherein: R¹ is selected from the group consisting ofpyridinyl and pyrazinyl, wherein each such substituent is optionallysubstituted with one substituent selected from the group consisting ofhalomethyl and cyclopropyl; and R² is selected from the group consistingof phenyl and pyridinyl, wherein each such substituent is optionallysubstituted with one or two substituents independently selected from thegroup consisting of fluoro, trifluoromethyl, and trifluoromethoxy. 17.The compound or salt of claim 1, wherein: R¹ is pyrazinyl, wherein suchpyrazinyl is optionally substituted with one or two substituentsindependently selected from the group consisting of halogen,C₁-C₆-alkyl, halo-C₁-C₆-alkyl, and C₃-C₆-cycloalkyl; and R² is phenyl,wherein such phenyl is optionally substituted with one or twosubstituents independently selected from the group consisting ofhalogen, cyano, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, C₁-C₆-alkoxy,halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.
 18. The compound or salt ofclaim 1, wherein: R¹ is pyrazinyl, wherein such pyrazinyl is optionallysubstituted with one or two substituents independently selected from thegroup consisting of halogen, C₁-C₆-alkyl, halo-C₁-C₆-alkyl, andC₃-C₆-cycloalkyl; and R² is pyridinyl, wherein such pyridinyl isoptionally substituted with one or two substituents independentlyselected from the group consisting of halogen, cyano, C₁-C₆-alkyl,halo-C₁-C₆-alkyl, C₁-C₆-alkoxy, halo-C₁-C₆-alkoxy, and C₃-C₆-cycloalkyl.19. The compound or salt of claim 1, wherein: R¹ is selected from thegroup consisting of:

and R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.
 20. The compound or salt of claim1, wherein: R¹ is selected from the group consisting of pyridinyl andpyrazinyl, wherein each such substituent is substituted with onesubstituent selected from the group consisting of halomethyl andcyclopropyl; and R² is selected from the group consisting of:


21. The compound or salt of claim 1, wherein: R¹ is selected from thegroup consisting of:

and R² is selected from the group consisting of:


22. The compound or salt of claim 1, wherein: R¹ is

and R² is selected from the group consisting of phenyl and pyridinyl,wherein each such substituent is substituted with one or twosubstituents independently selected from the group consisting of fluoro,trifluoromethyl, and trifluoromethoxy.
 23. The compound or salt of claim1, wherein the compound is selected from the group consisting of:(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;(8S,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;(8S,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethyl)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl](4-fluorophenyl)methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-(trifluoromethoxy)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-3-(trifluoromethyl)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][5-(trifluoromethyl)pyridin-2-yl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][6-(trifluoromethyl)pyridin-2-yl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-(trifluoromethyl)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][4-fluoro-3-(trifluoromethyl)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][3-fluoro-4-(trifluoromethyl)phenyl]methanone;(3-chloro-4-fluorophenyl)[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-5-(trifluoromethyl)phenyl]methanone;[(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]hexahydro-1H-pyrrolo[1,2-a][1,4]diazepin-2(3H)-yl][2-fluoro-4-(trifluoromethyl)phenyl]methanone;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepine;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-7H-pyrrolo[1,2-a][1,4]diazepin-7-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)phenyl]octahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[2-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-4-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-fluoro-3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{hydroxy[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{(methylamino)[3-(trifluoromethyl)phenyl]acetyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-[3-(trifluoromethyl)benzyl]-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[6-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]-8-[(5-cyclopropylpyrazin-2-yl)oxy]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-(5-cyclopropylpyrazin-2-yl)-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[5-(trifluoromethyl)pyridin-2-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-8-{[6-(trifluoromethyl)pyridin-3-yl]oxy}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[5-(trifluoromethyl)pyridin-2-yl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8R,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aS)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[4-(trifluoromethoxy)benzyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-[3-(trifluoromethyl)benzoyl]octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one;and(8S,9aR)-8-[(5-cyclopropylpyrazin-2-yl)oxy]-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydro-5H-pyrrolo[1,2-a][1,4]diazepin-5-one.24. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound of claim 1, or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable carrier.
 25. A method fortreating pain in a subject in need thereof, wherein the method comprisesadministering to the subject a therapeutically effective amount of acompound of claim 1 or pharmaceutically acceptable salt thereof.